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ABSTRACT OF DISSERTATION

DEVELOPMENT OF DIVERSE SIZE AND SHAPE RNA NANOPARTICLES AND
INVESTIGATION OF THEIR PHYSICOCHEMICAL PROPERTIES FOR
OPTIMIZED DRUG DELIVERY
RNA nanotechnology is an emerging field that holds great promise for advancing
drug delivery and materials science. Recently, RNA nanoparticles have seen increased use
as an in vivo delivery system. RNA was once thought to have little potential for in vivo use
due to biological and thermodynamic stability issues. However, these issues have been
solved by: (1) Finding of a thermodynamically stable three-way junction (3WJ) motif; (2)
Chemical modifications to RNA confer enzymatic stability in vivo; and (3) the finding that
RNA nanoparticles exhibit low immunogenicity in vivo.
In vivo biodistribution and pharmacokinetics are affected by the physicochemical
properties, such as size, shape, stability, and surface chemistry/properties, of the
nanoparticles being delivered. RNA has an inherent advantage for nanoparticle
construction as each of these properties can be finely tuned. The focus of this study is as
follows: (1) Construction of diverse size and shape RNA nanoparticles with tunable
physicochemical properties; (2) Investigation of the effect that size, shape, and nanoparticle
properties have on in vivo biodistribution; (3) Development of drug encapsulation and
release mechanism utilizing RNA nanotechnology; and (4) Establishment of large-scale
synthesis and purification methods of RNA nanoparticles.
In (1), RNA triangle, square, and pentagon shaped nanoparticles were constructed
using the phi29 pRNA-3WJ as a core motif. Square nanoparticles were constructed with
sizes of 5, 10, and 20 nanometers. The RNA polygons were characterized by AFM to
demonstrate formation of their predicted geometry per molecular models. Furthermore, the
properties of RNA polygons were tuned both thermodynamically and chemically by
substitution of nucleic acid type used during nanoparticle assembly.
In (2), the biodistribution of RNA nanosquares of diverse sizes and RNA polygons
of diverse shapes were investigated using tumor models in nude mice. It was found that
increasing the size of the nanosquares led to prolonged circulation time in vivo and higher
apparent accumulation in the tumor. However, it was observed that changing of shape had
little effect on biodistribution. Furthermore, the effect of the hydrophobicity on RNA

nanoparticles biodistribution was examined in mouse models. It was found that
incorporation of hydrophobic ligands into RNA nanoparticles causes non-specific
accumulation in healthy organs, while incorporation of hydrophilic ligands does not. Lower
accumulation in vital organs of hydrophobic chemicals was observed after conjugation to
RNA nanoparticles, suggesting RNA has the property to solubilize hydrophobic chemicals
and reduce accumulation and toxicity in vital organs.
In (3), a 3D RNA nanoprism was constructed to encapsulate a small molecule
fluorophore acting as a model drug. The fluorophore was held inside the nanoprism by
binding to an RNA aptamer. The ability of the stable frame of the nanoprism to protect the
fragile aptamer inside was evidenced by a doubling of the fluorescent half-life in a
degrading environment.
In (4), a method for large-scale in vitro synthesis and purification of RNA
nanoparticles was devised using rolling circle transcription (RCT). A novel method for
preparing circular double stranded DNA was developed, overcoming current challenges in
the RCT procedure. RCT produced more than 5 times more RNA nanoparticles than
traditional run-off transcription, as monitored by gel electrophoresis and fluorescence
monitoring. Finally, large-scale purification methods using rate-zonal and equilibrium
density gradient ultracentrifugation, as well as gel electrophoresis column, were developed.

KEYWORDS: RNA Nanotechnology, Bionanotechnology, Nanoparticle Properties, Drug
Encapsulation, Rolling Circle Transcription
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Chapter 1: Introduction and Literature Review

Chapter 1 was reproduced (with some modification) with permission from Jasinski,
D; Haque, F; Binzel, DW; and Guo, P. “Advancement of the Emerging Field of RNA
Nanotechnology.” ACS Nano, 2017. DOI: 10.1021/acsnano.6b05737. Copyright 2017
American Chemical Society.

SUMMARY:
Chapter 1 begins this thesis with an overview on nanotechnology and its application
to advancing the field of drug delivery. The creation of RNA nanotechnology is then
discussed, and previous and current RNA nanoparticle construction methods are
introduced. Next, ways in which RNA nanotechnology overcomes current challenges in
nanotechnology drug delivery are outlined. Finally, the importance of nanoparticle
physical properties, such as size, shape, stability, and surface chemistry/properties, for in
vivo drug delivery are discussed.
Chapter 2 introduces a method for the construction of RNA nanoparticles with
diverse size, shape, and thermodynamic and chemical stability. RNA triangles, squares,
and pentagons were constructed using the three-way junction (3WJ) motif from the
packaging RNA (pRNA) of bacteriophage phi29. It was found that the inner angle of the
3WJ could be tuned from its native angle of 60°, ideal for triangle geometry, to 90° and
108°, ideal for square and pentagon geometry, respectively. The resulting nanoparticles
display high thermodynamic stability despite stretching of the 3WJ from its ideal geometry.
1

RNA nanosquares with sizes of 5, 10, and 20 nm were constructed. Sizes were tuned by
simply increasing or decreasing the number of RNA duplex turns between each corner of
the square. Furthermore, nanosquare stability was tuned by chemically modifying one
RNA strand used during construction. Nanosquare thermodynamic and serum stability was
decreased and increased by modifying the structure with DNA and 2’-fluorine modified
(2’F) RNA, respectively, thus demonstrating the tunable nature of RNA nanoparticles.
Chapter 3 considers how physical properties of RNA nanoparticles affect in vivo
biodistribution. 2’F modified and fluorescently labeled nanosquares of different sizes were
injected into tumor bearing nude mice and analyzed for tumor accumulation and
nanoparticle clearance. A strong correlation between nanoparticle size, circulation time,
and tumor accumulation was found. An increase in both tumor accumulation and
circulation time is seen from the larger nanoparticles. However, the RNA nanosquares still
show little fluorescence in healthy organs such as the liver and kidneys, compared to
tumors, after 24 hours (h). Finally, the hydrophobic effects of externally conjugated
chemicals on biodistribution was examined. It was found that increased hydrophobicity of
conjugates caused accumulation of RNA nanoparticles in healthy tissue and organs, while
more hydrophilic ligands showed weaker accumulation signal in vital organs.
Chapter 4 demonstrates a novel method for the encapsulation and controlled release
of a model small molecule drug using RNA nanotechnology. Using previously designed
RNA triangles, a three-dimensional (3D) nanoprism was constructed and characterized. A
fluorogenic RNA aptamer was then encapsulated inside the nanoprism, allowing capture
of a small molecule fluorophore, acting as a model drug, by binding to the aptamer. It was
shown that the stable nanoprism frame protected the fragile RNA aptamer, which holds the
2

model drug, from degradation due to steric hindrance of degrading enzymes. Tuning the
amount of 2’F modified nucleotides in the frame led to a controlled degradation profile of
the nanoprism frame, allowing controlled release of the model fluorophore encapsulated
within the nanoprism.
Chapter 5 details the development of large-scale synthesis and purification of RNA
nanoparticles. A large-scale in vitro method for RNA nanoparticle synthesis was developed
using rolling circle transcription (RCT) of a fully double stranded (ds) DNA template. This
method overcomes current challenges associated with RCT to synthesize RNA
nanoparticles from a single stranded (ss) DNA template displaying stable secondary
structure, which hinders the progress of bacterial RNA polymerases. RNA nanoparticles
were then purified by two large-scale methods: 1) rate-zonal and equilibrium density
ultracentrifugation and 2) column gel electrophoresis. Both methods resulted in the
purification of large amounts of pure RNA nanoparticles, paving the way towards preclinical development.
Chapter 6 summarizes the major findings and advancements of the research
discussed in this thesis dissertation. Furthermore, the future direction of this work is
described providing a prospective on research that is still needed to fully prove the benefits
of RNA nanotechnology. Finally, the current state of RNA nanotechnology is discussed
looking at the major hurdles that have been overcome, and the challenges that still need to
be faced.
HYPOTHESIS:
The 3WJ motif from bacteriophage phi29 pRNA provides a stable RNA motif from
which to build diverse size and shape, yet physicochemically tunable, RNA nanoparticles.
3

Different physical properties of RNA nanoparticles will affect biodistribution and
pharmacokinetic profiles.
INTRODUCTION:
Nanotechnology and drug delivery
Nanotechnology can be defined as the science of engineering materials and
systems; the ultimate goal being control over specific functions and properties of
nanoparticles on a molecular scale. While the field of nanotechnology was conceived in
1959 by Richard Feynman’s lecture “There’s Plenty of Room at the Bottom” (1) it took
more than two decades before one of Feynman’s challenges, proposed during his lecture,
was completed. Tom Newman, then a graduate student at Stanford, successfully printed
the first paragraph of A Tale of Two Cities at 1/25000th scale (2). Nanotechnology was later
defined by the National Nanotechnology Initiative to be the manipulation of materials with
the size range of 1 – 100 nm in size. As imaging technology progressed, so did
nanotechnology, as the development of techniques such as atomic force microscopy
(AFM), transmission electron microscopy (TEM), and scanning tunneling microscopy
(STEM) allowed researches more detailed imaging and analysis of nanoparticles.
Nanoparticles have since been created from a wide variety of materials such as lipids (3);
polymers (4); proteins and peptides (5); viruses and viral components (6); carbons (7);
heavy metals, such as gold (8) and silver (9); iron oxide (10); deoxyribonucleic acid (DNA)
(11); and ribonucleic acid (RNA) (12).
One major focus for the implementation of nanotechnology has been the
advancement of drug delivery, and while nanoparticles are used in many applications,
nanoparticle drug delivery is among the most promising (13,14). In traditional drug
4

delivery, therapeutic agents, such as small molecule drugs, are cleared from the body rather
quickly. This results in low accumulation of the therapeutic agent at the target site,
requiring increased dosage, which increases toxicity. A key feature of nanoparticles is their
extended half-life in vivo compared to therapeutic agents, which increases the circulation
time and bioavailability of therapeutic agents conjugated to or encapsulated within the
nanoparticles (15,16). Many drugs currently under development are not soluble and cause
off-target toxicity issues, limiting their practical application for the treatment of disease
(17). Nanoparticles have previously shown the ability to conjugate or encapsulate
hydrophobic and toxic drugs, with hopes to increase therapeutic dose to the disease site
(18-23). Nanoparticles have shown to increase the solubility of highly hydrophobic drugs;
deliver a high dosage of therapeutic to the disease site using release mechanisms such as
pH sensitive linkages (24-28); and provide targeting to cells by use of cell specific peptides
(29-31) and aptamers, specific RNA sequences selected to bind chemical or protein
ligands, such as cell-surface receptors (32,33). As a result, the amount of therapeutic
getting to the diseased site is increased, allowing lower dosage and decreased toxicity.
Many different materials are used to construct nanoparticles, each offering their
own advantages and disadvantages, and nanotechnologists are continually searching for an
ideal candidate to improve the current state of drug delivery. Lipid based nanoparticles
allow for high therapeutic loading and delivery of payloads through membrane fusion with
cells while remaining nontoxic and non-immunogenic (34,35). However, lipids have
shown issues with thermodynamic stability, releasing their payload before reaching the
target site (36). Also, reproducibility during nanoparticle construction results in
inconsistent products (37). Similarly, polymer based nanoparticles allow for high levels of
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therapeutic encapsulation (38). Moreover, polymers display a significant increase in
thermodynamic stability and can easily be functionalized on the surface for targeting
capabilities (39). Yet, polymers have shown issues with batch reproducibility, water
solubility, and overall bioavailability. Biologically derived nanoparticles such as viruses,
viral components, and proteins or peptides, illicit immune responses and generate toxicity.
But, targeted delivery of these nanoparticles allows for a lower overall dose while having
a high accumulation in targeted tissues (40-43). Inorganic nanoparticles such as carbon
structures and metal ions can be created with high reproducibility at a lower cost than most
nanoparticles. Additionally, these particles can be functionalized through chemical
modifications. However, their accumulation in healthy organs such as kidneys, lungs, and
liver result in toxicity and limit their overall potential for therapeutic delivery. DNA
nanostructures are constructed with defined shape, size, and stoichiometry (44-46) and can
achieve targeted delivery with the functionalization of DNA aptamers (47,48). However,
relatively low thermodynamic stability limits DNA’s ability for in vivo applications.
Cationic nanoparticles, such as metal ions, some polymers, and proteins, display an overall
positive charge allowing for endosomal escape through the proton sponge effect (49).
However, positive charge also causes passive attraction with negatively charged cell
membranes, thus leading to non-specific binding and cell entry.
Conception of RNA nanotechnology
The idea of RNA nanotechnology was first conceived in 1998(12) when the pRNA
from bacteriophage phi29 was engineered to form a hexameric RNA nanoparticle from six
copies of pRNA. Each of the pRNA monomers interacts using loop-loop complementary
base-pairing, referred to as hand-in-hand interactions (50). The intermolecular connections
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between adjacent pRNA units was the first demonstration of specific arrangement of RNA
into an engineered nanoparticle. pRNA is a 120 nucleotide (nt) RNA that adopts a stable
secondary structure. Its function is to act as a connector between the portal proteins and
ATPase in the bacteriophage phi29 DNA packaging motor (51-54).
Within the pRNA is a unique three-way junction (3WJ) motif, which drives the
assembly of the pRNA structure (55). The 3WJ has been extracted from the pRNA and
used as a nanoparticle for drug delivery (56-61). It is thermodynamically stable (62,63),
enzymatically stable with chemical modification (64), assembles without metal ions from
its three component RNA oligomers (3WJ-a, 3WJ-b, 3WJ-c), and can accommodate the
addition of multiple functional groups while still retaining folding and stability (55).
RNA’s versatility in structure and function, propensity for bottom-up selfassembly, defined size and structure, favorable in vivo attributes, and large potential as a
therapeutic modality make it an attractive candidate as a biomaterial for nanoparticle drug
delivery. RNA’s ability to adopt complex quaternary structures (12,65-69), to base stack
(70,71), to form canonical Watson-Crick (A‒U; G‒C) and non-canonical (ex. G‒U
wobble) base pairing (72,73), leads to a variety of natural structural motifs (74,75). RNA
nanotechnology uses such properties to construct nanoparticles for use in nanomedicine
and bionanotechnology applications.
Beneficial properties of RNA for nanoparticle construction
Nanotechnology that revolves around the manipulation of biological materials is
referred to as bionanotechnology, which includes the field of nucleic acid nanotechnology.
First envisioned over 30 years ago (76), DNA self-assembly was exploited to form
nanoparticles using base-pairing mechanism (A‒T, G‒C)(77,78). DNA nanostructures
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including nano-capsules and other nano-carriers for drug delivery applications have since
been constructed (79-81). DNA origami was developed as a powerful tool to build large
2D (82) and 3D architectures including tetrahedrons (83), nano-robots (84), helix bundles
(85), and tensegrity-based shapes (86). Although DNA nanostructures have exemplified
the power of the base-pairing mechanism for structure design, DNA cannot match the
thermostability and structural and functional diversity of its nucleic acid counterpart, RNA.
Like DNA, RNA is a chain-like biopolymer composed of nucleotide subunits
joined by phosphodiester bonds. Each nucleotide is composed of a ribose sugar, phosphate
group, and nitrogenous base. The most common bases are cytosine (C), guanine (G),
adenine (A), and uracil (U). The basis of RNA secondary structure is hydrogen bonding
occurring between complementary nucleotides, G‒C and A‒U, analogous to that of
canonical base pairing found in DNA. Furthermore, the presence of the 2’‒OH in RNA has
dramatic effects on its properties. The C3’‒endo sugar conformation in RNA leads to Atype helical formation (11 bp/turn), offering improved thermostability over DNA B-type
helix.
RNA was first characterized as the link between genomic DNA and protein,
transferring the genomic code for proteins to the cell’s translation machinery. Investigation
of RNA structure revealed the catalytic nature of RNA with the discovery of ribozymes
(87). The revolutionary finding of catalytic RNA, an attribute thought only to belong to
proteins, led to a shift in the thought of the functions of RNA. In addition to functions
generated by elaborately structured RNA molecules, specific base-pairing interactions
mediated by single stranded regions of unstructured RNA have further expanded RNA's
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functional repertoire (88). Years of research found that RNA performs diverse functions in
biology, juggling tasks from catalysis to protein synthesis to gene regulation.
An emerging class of targeted therapeutic molecules has been developed based on
RNA aptamers (89); single-stranded RNA sequences that fold into specific 3D
configurations and bind with high selectivity and affinity to extracellular domains of cell
surface receptors. A combination of electrostatic interactions, hydrogen bonding, and van
der Waals forces mediates binding. Aptamers possess many advantages as targeting
reagents including low cost, fast selection and optimization, convenient synthesis and
modification with high batch fidelity, low immunogenicity, and long term stability (90,91).
The development of the systematic evolution of ligands by exponential enrichment
(SELEX) (92,93) process has made aptamer development possible for many proteins and
peptides. Currently, tens of RNA aptamers are available for targeting specific cell surface
receptors followed by subsequent internalization of RNA nanoparticles. RNA aptamers
offer unique advantages to RNA nanotechnology, as the aptamer can easily incorporated
into RNA nanoparticles by sequence fusion.
Ribozyme-based therapeutic strategies have emerged as powerful tools for the
treatment of cancer and viral infections. Ribozymes are RNA motifs that possess catalytic
properties much like those of proteins. Ribozymes targeting mRNA show promise for gene
therapy of breast cancer and hepatocellular carcinoma in animal models as they display
similar effectiveness as RNAi, while exhibiting less off-target effects (94).
Riboswitches offer therapeutic avenues for addressing a wide range of diseases by
regulating gene expression. Riboswitches are composed of two domains, a sensor portion
(a natural aptamer) for ligand recognition, and an expression platform that can adopt two
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mutually exclusive conformations based on ligand binding for controlling gene expression
(without the need for protein cofactors) (95). Based on simplistic design principles, RNA
nanotechnology can be applied not only to deliver the RNA switches in vivo but also to
rationally engineer synthetic riboswitches to repress or activate gene expression in a liganddependent fashion.
The discovery of the RNA interference (RNAi) pathway in 1998 (96) created an
avenue of treatments for many diseases, including cancer. RNAi is the process by which
the expression of a gene is modulated by short double stranded RNA sequences, typically
21-23 nucleotides in length. There are two central molecules to RNAi, miRNA and siRNA
(97). While miRNAs are endogenous to cells, and target multiple genes, siRNAs are mostly
artificial sequences (some endogenous siRNAs do exist in cells (98)) that are designed to
target a specific mRNA. Theoretically, any known mRNA sequence can be targeted using
siRNAs and miRNAs, making diseases previously thought to be undruggable susceptible
to RNAi therapy. RNA nanoparticles are designed such that endonuclease Dicer can access
the dsRNA sequences encoding for the siRNAs and miRNAs and cleave them to generate
functional miRNA and siRNA, which are then loaded into the RNA induced silencing
complex (RISC) and thereby regulate gene expression by selectively targeting mRNAs.
RNA’s negatively charged phosphate backbone renders RNA nanoparticles highly
anionic, disallowing non-specific targeting to all cells. Furthermore, the high
thermostability of RNA allows for the construction of stable RNA nanoparticles. While
RNA is quickly digested in vivo by numerous of RNA specific nucleases, modifications to
the 2’ of the ribose sugar render RNA more thermodynamically and enzymatically stable.
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One modification is substitution of fluorine for the hydroxyl at the 2’ sugar positons of the
pyrimidines, cytosine and uracil.
RNA’s anionic charge, versatile structure, myriad of functional RNA motifs
available for nanoparticle construction, and the availability of chemical modifications,
which endow stability, contribute towards the fact that RNA is a unique biomaterial that
can be utilized in nanotechnology and bionanotechnology.
RNA nanoparticles
While RNA nanoparticles were initially constructed to study RNA structure (99101), advancements in the technology, such as improvements in stability, have allowed
RNA nanotechnology to be developed with more biomedical applications in mind. There
are three major challenges associated with using RNA as a nanoparticle: (1)
Thermodynamic stability; (2) Enzymatic stability; and (3) immune response elicited by
dsRNA. However, these issues have been overcome by the finding of an unusually stable
3WJ motif suitable for nanoparticle construction (55), chemical modifications to RNA
allowing prolonged stability in serum (64,102), and studies showing the immunogenicity
of RNA nanoparticles are very low in vivo (103).
Because of the versatility of RNA structure, many different methods have been
developed over the years for RNA nanoparticle construction. Some of the most popular
methods for RNA nanoparticle construction are through intermolecular interactions,
computer aided design, RNA tectonics, rolling circle transcription (RCT), and modular
design approach, the last method of which this thesis will focus.
The use of intermolecular interactions to construct RNA nanoparticles was
pioneered by the Guo lab using pRNA as a monomer unit. The pRNA was engineered to
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contain complementary kissing loops, which interact to form dimers, trimers, tetramers,
pentamers, hexamers, and heptamers using “hand-in-hand” interactions (12,50,104,105).
Furthermore, pRNA monomers were functionalized with palindrome sticky ends
sequences to interact “foot-to-foot” to form nanoparticles (50,104,105).
RNA tectonics is a field pioneered by Neocles Leontis, Eric Westhof, and Luc
Jaeger. Tectonics is a RNA nanoparticle construction method by which different RNA
motifs, or tecto units, are arranged to interact and form nanoparticles. RNA nanoparticles
can be constructed using motifs such as kissing loops, dovetails, pseudoknots, kink turns,
and multi-way junctions (74,75,99,101,106). Increasing knowledge of RNA folding and
the availability of databases such as the Nucleic Acid Database (NAD) (107) and the
RNAjunction database (68) have increased the power of tectonics, as the number of motifs
that can be used as potential tectoRNAs is quite large. Examples include the tecto RNA
squares and cubes designed from tRNA and nanoprisms designed from pRNA
(100,101,104,108-117).
Computer based nanoparticle design has become extremely powerful due to the
predictive abilities of the software programs written specifically for RNA nanoparticle
design. Several software programs have been developed over the years such as Nanotiler
(118), Assemble2 (119), RNA2D3D (120), INFO-RNA (121), and NUPACK (122), which
are useful to design de novo RNA nanoparticles. Examples are a six-membered RNA
nanoring (123) and an RNA nanocube generated using Nanotiler (124). Long sequences as
well as individual monomer units that contain internal structures can be computationally
designed and experimentally assembled in a one-pot manner including co-transcriptional
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assembly. Computer aided design is especially useful as RNA folding is complicated and
engineering sequences for correct folding enhances stability for biomedical applications.
RCT produces large amounts of concatemeric RNA sequences from a circular DNA
template using in vitro transcription (125). A ssDNA oligomer anti-sense to the target
sequence is circularized through ligation, while a short splint ssDNA containing the RNA
polymerase promoter sequence is annealed to the circular DNA allowing RNA polymerase
initiation. After ligation, in vitro transcription occurs in a continuous fashion. RCT has
been used to synthesize RNA microsponges containing thousands of copies of siRNA,
which were then delivered to tumor bearing mice showing efficient tumor regression (38).
The focus of this thesis is a modular design approach using a natural 3WJ RNA
motif, derived from the pRNA of bacteriophage phi29, as the core for nanoparticle
construction (126). While similar to RNA tectonics, the modular design approach avoids
the use of sticky end, loop-loop, or other intramolecular interactions resulting in more
stable nanoparticles. Despite increased knowledge of RNA structure and folding, de novo
design of RNA remains difficult. Using a RNA motif, of which the crystal structure is
known, molecular modeling software can be used to design RNA nanoparticles. This
technique was first used to construct RNA triangles (126). To do this, three 3WJ motifs
were aligned in a planar configuration, and adjacent helices were attached using dsRNA.
To construct the nanoparticle, four strands were used: three external short strands and one
internal long core strand to tether all strands together. This method results in a fully double
stranded RNA nanoparticle, held together by hundreds of hydrogen bonds.
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Importance of nanoparticle physical properties
Nanoparticle properties such as size, shape, charge, surface chemistry/properties,
and construction material, govern how the nanoparticles interact with their in vivo
environment, mainly the mononuclear phagocytic system (MPS) (127), and largely control
uptake and elimination pathways. In turn, the behavior of the nanoparticles, such as
circulation time and biodistribution, are determined. The properties of nanoparticles are of
paramount importance, as in vivo behavior is a determining factor of success for a particular
nanoparticle.
One of the most important properties that determines how nanoparticles interact
once in circulation is their size. Importantly, the size of nanoparticles determines the
pathways in which they are taken into cells, such as pino- and phagocytosis (128), and
which parts of the MPS they interact with, such as the liver or the kidneys. Smaller
nanoparticles, less than 15 nm, are excreted quickly through the kidneys (129) while larger
particles, 15-100 nm, have more interaction with macrophages, and are excreted more
slowly through the liver (130). Interactions with the MPS dictate the circulation time of
nanoparticles, as well as how long they stay in organs once they have reached their
destination. For example, gold nanoparticles 50 nm in size accumulated in the liver and
spleens of beagles, and remained in said organs for more than six months (131). Circulation
time is extremely important for nanoparticles relying on the enhanced permeability and
retention (EPR) effect, as longer circulation times gives the nanoparticles a higher chance
to accumulate at the tumor site. In addition to circulation time, the size of nanoparticles
also affects their entry into the tumor. It has been shown that smaller nanoparticles, less
than 10 nm, have the highest penetration into the tumor tissue (132). Additionally, smaller
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nanoparticles are taken into the cells of tumors, not just the tumor site, more rapidly and in
higher amounts (133). Size also affects the composition and extent to which the protein
corona forms. The protein corona has drastic effects on the “stealthiness” of a nanoparticle,
and higher amounts of protein corona formation on a nanoparticle will results in faster
removal by the MPS (128).
Along with size, shape is also an important factor for nanoparticle behavior in vivo
(134). The geometry of a particle has a large effect on its interaction with macrophages.
Studies have shown that less angular nanoparticles, side angles less than 45˚, are
completely enveloped by macrophages, whereas particles with shaper angles, side angles
more than 45˚, are unable to be completely phagocytized (135,136). Shape also affects
where the particles accumulate as short rod particles have been shown to accumulate in the
liver while longer rods go to the spleen (137). Furthermore, particles that display a higher
aspect ratio, such as rods, are more efficient at accumulating in the tumor than spherical
particles and plate shaped particles (128,132). Yet, higher aspect ratio nanoparticles also
result in higher inflammation and stimulation of pro-inflammatory cytokines (128). As
with size, shape also affects the formation of a protein corona, affecting the stealth nature
of nanoparticles (138).
The surface charge of a nanoparticle can also affect its circulation, biodistribution,
and cellular uptake. Neutral particles circulate the longest, while anionic and cationic
particles see reduced circulation times (139). Particles that carry a charge have increased
protein corona and protein opsonization, causing higher macrophage recognition and faster
clearance (128). Cationic particles enter cells more rapidly and to a higher degree than
neutral and anionic particles due to fusion with the negatively charged cell membrane.
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However, cationic particles show high toxicity and significant immune reactions, thus,
negatively charged and neutral particles are generally preferred. The charge of particles
also affects the mechanism of uptake into cells, which has a large effect on their
intracellular fate and drug delivery efficacy (132).
Surface functionalization and surface properties also play a role in interaction with
the immune system. Generally, hydrophilic particles are preferred over hydrophobic, as
hydrophilic particles see an increase in circulation time over their hydrophobic counterparts
(140). Hydrophobicity of nanoparticles increases protein adsorption significantly, leading
to faster clearance (141). Protein adsorption can also increase non-specific accumulation
in vital organs. Increased hydrophobicity has also been linked to increased activation of
immune system cytokines, both in vitro and in vivo (142). Surface functionalization, such
as PEGylation, can drastically alter the way nanoparticles interact with their environment.
Increased PEG density leads to higher uptake by liver kupffer cells, while lower PEG
density increases uptake by kidney phagocytes (143,144). Also, albumin (BSA) coating
can lead to aggregation of nanoparticles, and accumulation in the liver and spleen resulting
in toxicity (145). Polymer coatings decrease protein binding and phagocytosis compared
to their non-coated counterparts, and show resistance to accumulation in the spleen and
liver (146,147).
Finally, the material chosen for nanoparticle construction has a large effect on
interaction with the immune system and accumulation in vivo. Analysis of the
accumulation of many different types of nanoparticles in tumors showed that inorganic
materials have the highest percent accumulation (132). Even inside the realm of inorganic
nanoparticles, gold nanoparticles seem to be better than QDs or iron oxide nanoparticles.
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However, as inorganic materials degrade slowly over time, there are potential hazards with
repeated administration and buildup of inorganic material. However, universal throughout
all these studies is that cancer type and tumor model are the two most important factors
when determining nanoparticle accumulation in tumors (132). This suggests that for each
type of cancer, the ideal nanoparticle is not identical.
The tunable nature of RNA nanoparticles advances drug delivery
The fact that tumors arising from different cancer types are so diverse is a big
challenge in cancer nanotechnology drug delivery. It is difficult to decide which
nanoparticle system to use for each situation, due to the heterogeneity of different tumor
types as well as heterogeneity within a single tumor. One major finding of this thesis is that
the properties of RNA nanoparticles can be controlled during design and construction. As
discussed above, the properties of nanoparticles have a huge effect on in vivo behavior.
RNA nanoparticles are defined in size, shape, and properties, and are highly consistent in
their assembly. Their properties are near identical from particle to particle, as the base
pairing mechanism allows controlled self-assembly, not a random and aggregative
assembly like in some other nanoparticles. It is possible that the in vivo behavior of RNA
nanoparticles can be optimized based on the controllable size, shape, and properties that
the nanoparticle engineer has on the system.
The nanoparticle designer can easily scan through varieties of RNA secondary and
tertiary structural motifs from which to design and construct an RNA nanoparticle (ex.
bulges, stems, hairpin, loops, and junctions). Such motifs are used as building blocks to
design nanoparticles with diverse size and shape by engineering parameters such as motif
angle and sequence length (103,126,148-150). Other parameters such as nucleotide type
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can alter nanoparticle properties, including enhancing chemical stability using base or
backbone modifications, or incorporating fluorescent dyes for nanoparticle tracking. The
physiochemical properties of RNA nanoparticles can easily be fine-tuned to tailor-make
the nanoparticle for desired applications in vitro and in vivo.

Copyright © Daniel L. Jasinski 2017
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Chapter 2: Design, Construction, and Characterization of RNA
Nanoparticles with Tunable Size, Shape, and Physicochemical Properties
Based on phi29 pRNA-3WJ Core Motif

Chapter 2 was reproduced (with some modification) with permission from:
Khisamutdinov, EF*; Li, H*; Jasinski, DL*; Chen, J; Fu, J; and Guo, P. “Enhancing
immunomodulation on innate immunity by shape transition among RNA triangle, square,
and pentagon nanovehicles.” Nucleic Acids Research, 2014. 42(15), 9996-10004. DOI:
10.1093/nar/gku516. Copyright 2014 Oxford Publishing; Jasinski, DL; Khisamutdinov,
EF; Lyubchenko, YL; and Guo P. “Physicochemically tunable polyfunctionalized RNA
square architecture with fluorogenic and ribozymatic properties.” ACS Nano. 2014. 8(8),
7620-7629. DOI: 10.1021/nn502160s. Copyright 2014 American Chemical Society.
Special thanks to Dr. Emil F. Khisamutdinov for help in preparation of data for
figures 2.1, 2.5, 2.6, and 2.12, and to Dr. Luda S. Shlyakhtenko and Dr. Yuri Lyubchencko
for AFM images in figures 2.5, 2.8, and 2.10.

Chapter 2.1: Design and Construction of RNA Nanoparticles with Tunable Shape
INTRODUCTION:
One area of biomimetic nanotechnology involves the construction of nano-scale,
supramolecular architectures utilizing modular units of functional nucleic acids. The aim
is to design nanostructures that undergo self-assembly in controllable and recyclable
fashion. RNA was discovered as an attractive material to build nanoparticles via
nanotechnology (12), offering a variety of structural modules and motifs that can be
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manipulated into 1D, 2D, and 3D architectures (for review see reference (90)). In the past
decade, a variety of geometric RNA nanoparticles and nano-scaffolds have been obtained
via the approaches of hand-in-hand (12,105,151), foot-to-foot (50,104), branch extension
(55,116,152,153), loop-receptor contact (113,154), loop-loop (108,114), “sticky” or
“dangling" ends (104,124), and synthetic RNA-protein complex interactions (155). These
motifs are available in data bases and can be used to build artificial nanostructures by
manipulating their interchangeable units (156,157). Recently, RNA rolling circle
transcription has been utilized to generate RNA sponges (38,158). In RNA tectonics,
structural motifs like double helices, loops, and junctions can be isolated from large and
complex RNA molecules appearing in structural data bases and used to build artificial
nanostructures by manipulating their interchangeable units (99,159). As such, previously
reported designs of RNA nanoparticles, e.g. tecto-square (109), square-shaped nanoscaffolds (110,111), RNA nano-rings (108), pRNA dimmers, tetramers, and hexamers
(12,160-162), as well as RNA nano-cubes (124), RNA polyhedron (116), RNA bundles
(163), RNA filaments (113,154), utilize fundamental principles of RNA structure and
folding (75,164-167). Overall stability of conventional constructs though, mainly relies on
the stability of canonical and non-canonical base pair (bp) forming by loop-loop, receptorloop, or “sticky-ends” with only a few pairing nucleotides usually not exceeding six. A
new approach is needed to increase overall stability of RNA nanoparticles, one that uses
naturally-selected stable RNA building blocks for structure building, one example being
the 3WJ motif from pRNA of bacteriophage phi29 DNA packaging motor. In addition to
discovering that the pRNA-3WJ shows exceptional stability under physiological
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conditions and in the presence of strong denaturing agents (55,152), recent studies also
suggest that the thermodynamic stability of the 3WJ is entropy driven (63).
Previous studies constructed RNA triangles form the pRNA-3WJ module (Fig 2.1).
In this report, we introduce a conceptual approach to the rational design of stable RNA
architectures by stretching the 60°AOB angle () (Fig 2.2) of the thermodynamically
stable pRNA 3WJ motif utilizing a modular design technique (Fig 2.3). We demonstrate
that it can be stretched to wide conformations resulting in different 2D polygons: triangle
(AOB =60°), square (AOB = 90°), and pentagon (AOB = 108°). Intermolecular
interactions such as kissing loops, receptor loop, or “sticky-ends” were avoided by
introducing linkages through base pairing between corners of the polygons using RNA
double helices. Therefore, this system is advantageous with an increased thermo-stability
in the overall construct.
MATERIALS AND METHODS:
RNA nanoparticles design, synthesis, and self-assembly
The 3WJ crystal structure of the pRNA molecule (PDB ID: 4KZ2) was primarily
used for designing polygon models using Swiss PDB viewer, as previously described
(168). RNA strands for corresponding triangle, square, and pentagon, were synthesized by
in vitro T7 transcription using polymerase chain reaction (PCR) generated DNA templates.
RNAs were purified by denaturing polyacrylamide gel electrophoresis (PAGE) and were
either Cy5 whole chain RNA labeled (Mirus Bio LLC) or 5′-end [-32P] ATP (PerkinElmer)
labeled, as previously described (151).
RNA polygons were assembled in one pot by mixing equimolar concentrations
(final concentration of 1 µM) of four RNA strands for the triangle, five RNA strands for
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the square, and six RNA strands for the pentagon in 1 X TMS buffer (50 mM Tris pH =
8.0, 100 mM NaCl, and 10 mM MgCl2). Samples were annealed for 1 h in a thermocycler
with controlled, slow cooling (1 °C/ min) from 80 - 4 °C.
Native PAGE, TGGE, and boiling resistance assays
RNA assemblies were evaluated on 7% (29:1) native polyacrylamide gels in the
presence of 1 X TBM (89 mM Tris, 200 mM boric acid, 5 mM MgCl2) buffer. Gels were
run at constant 90 V, +4°C. Gels were imaged with Typhoon FLA 7000 (GE Healthcare)
to visualize RNA strands. Temperature gradient gel electrophoresis (TGGE) analysis was
performed on 7% native PAGE in a buffer containing 50 mM TRIS pH = 8.0, 100 mM
NaCl, and 0.2 mM MgCl2, as previously described (109,110,116). A gradient temperature
of 30-70°C was applied perpendicular to electrical current, and the experiment was run for
1 h at 20 W. A total RNA concentration of 100 nM was used in TGGE analysis. Apparent
TM values corresponded to the temperature at which half of the polygons fractions were
dissociated, and apparent KD values for multiple RNA strands were calculated, as described
previously (50).
Boiling resistance assay was performed in 10 µL containing 1 µM preassembled
polygons in TMS buffer or in the presence of 8 M urea. Samples were incubated at 100°C
for five minutes, then snap cooled on dry ice to prevent refolding following evaluation on
7% native PAGE at 4 °C. Boiling experiments were repeated 3 times and standard deviation
measurements are indicated by error bars.
Quantification analysis was performed using ImageJ (169). Equal-sized boxes were
drawn around the lanes corresponding to the triangle, square, or pentagon complexes and
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corresponding quantified values for each type of polygon were divided by the sum of the
values presented in the corresponding lane.
RESULTS:
RNA polygons: triangle, square, and pentagon fabrication and self-assembly
The structural features of the recently discovered ultrastable pRNA 3WJ module
from the bacteriophage Phi29 DNA packaging motor were utilized for in silico design of
the RNA triangle, square, and pentagon 2D polygons. During computer modeling we used
the angle of the 3WJ formed by H1 and H2 as an inner angle of the polygons as we
hypothesized that the angle could be stretched to a more open conformation. Throughout
this report the intra-helical angle between H1 and H2 is denoted as AOB, as shown in
figure 2.2A. Each RNA model contained a pRNA 3WJ motif at each vertex, and the inner
angles correspond to AOB. The resulting 3D models exhibited flat conformations, as
expect from the plane geometry of the 3WJ motif (168) (Fig 2.4A).
Each polygon was composed of a different number of RNA strands classified as
short strands (external) and long strands (internal) (Fig 2.4B). By increasing the number of
external strands and the propagation of the central strand, the tension on the inter-helical
AOB increased to 60°, 90°, and 108°, allowing for 2D formation of corresponding
triangle, square, and pentagon shapes. The measured widths, from one corner to another,
were 10.2 nm, while the heights differed as follows: triangle = 9.1 nm, square = 10.2 nm,
and pentagon = 12.7 nm. Following the transcription of individual RNA strands, selfassembly properties of the triangle, square, and pentagon designs were evaluated on 7%
native polyacrylamide gel electrophoresis (PAGE) (Fig 2.4C). All polygon formations
were obtained by one-step self-assembly (50,55,124,152). Each component strand of each
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nanoparticle was whole chain labeled with Cy5 to evaluate participation of all RNA strands
in their corresponding assemblies. Yield of correctly assembled polygons was estimated to
be >90% based on native PAGE gel evaluations (Fig A.1.1). Equilibrium constants of
dissociation were obtained from apparent KD gels, and KD values were determined to be
18.8 nM, 20.3 nM, and, 22.5 nM for triangles, squares, and pentagons, respectively (Fig
A.1.2).
These results demonstrate that each RNA nanoparticle assembles into the desired
nanostructure, and indicates stretching of the 60°AOB to wider conformations. The
assembly of RNA strands into specific-shaped nanoparticles based on the 60°AOB of the
pRNA 3WJ motif was controlled by modulating the number of short external stands and
the length of the long internal strand.
Structural characterization of polygons by AFM and DLS
To further evaluate the size and shape of the resulting RNA assemblies, structural
characterization of each polygon was conducted using atomic force microscopy (AFM).
AFM images of the pRNA 3WJ based polygons revealed that the shapes of resulting
polygons were similar to their predicted, theoretical 3D models (Fig 2.5A). The estimated
average dimensions were found to be 13 ± 1.1 nm, 14 ± 1.8 nm, and 17 ± 1.6 nm for
triangles, squares, and pentagons, respectively. These values do not reflect the true sizes of
the RNA polygons due to the AFM tip convolution, but rather demonstrate that the average
size of the nanoparticles increases from triangle to pentagon. In addition, the central cavity
of each RNA shape is visible, and the size of the cavity gradually increased with the number
of polygon vertices. The measured heights for all nanoparticles was found to be ~2 nm, in
agreement with previously reported heights of nucleic acid double helices (109,170).
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Quantification analysis was performed to compare apparent yields between
polygons observed on AFM mica surface. Equal concentrations (1 nM) of the polygons
were deposited on a mica surface and correctly folded polygons were manually counted in
a 0.5 µm2 area, resulting in 48 triangular particles, 33 square particles, and 17 pentagon
nanoparticles (Fig A.1.3). The estimated number of triangular nanoparticles adsorbed on
the mica was ~1.5 times more than that of the square, and three times more than that of the
pentagon. However, native PAGE revealed that the yields among the three polygons were
almost equal. The difference in adsorption amounts between polygons on the mica surface
was presumably due to variation in their sizes and 3D conformations, resulting in different
dynamic and physical properties.
DLS was performed to determine the apparent hydrodynamic diameters for each of
the polygons. The diameters were found to be 9.1, 11.2, and, 13.5 nm for triangles, squares,
and pentagons, respectively (Fig 2.5B). The increase in number of 3WJ cores corresponds
with the larger observed diameter. The measured diameters agreed with their
corresponding 3D models. However, there was a discrepancy between polygon sizes
determined by AFM and DLS. This could be attributed to the fundamentally different
techniques, as DLS determines the average size distribution profile of nanoparticles in
solution assuming that the polygons have globular shapes [refer to manual at
http://www.malvern.com], while AFM imaging can produce images larger than the real
diameter due to tip size used (171) and the resolution of imaging equipment. Nevertheless,
the two techniques demonstrated that the relative size of the nanoparticles increased from
triangle to square to pentagon.
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Accordingly, native PAGE, AFM, and DLS showed the formation of compact
molecular 2D assemblies of triangle, square, and pentagon based on the pRNA 3WJ
AOB. Consequently, the naturally preserved 60° AOB could be stretched to reach the
formation of square and pentagon. The stretching, or tension, that the angle underwent
could have had a significant impact on the overall stability of the nanoparticles. Therefore,
it was of great interest to evaluate and compare the polygon's stabilities.
Stability comparison between triangle, square, and pentagon
The stabilities of polygons were studied using a perpendicular temperature gradient
gel electrophoresis (TGGE) (Biometra GmbH). This convenient technique has garnered
widespread use for measuring melting temperatures of RNA nanoparticles with multiple
strands (50,108-110,116,172). The preassembled polygons were subjected to 7% native
TGGE with a gradient temperature of 30-70 °C perpendicular to electrical current. The
following apparent TM values were obtained for the polygons at 100 nM total concentration
(Ct) in presence of 0.2 mM MgCl2: triangle TM = 56 °C, square TM = 53 °C, and pentagon
TM = 50 °C (Fig 2.6A). The triangular nanoscaffolds were more stable than squares and
pentagons, although the number of RNA bp was much higher in the pentagon construct, as
compared to the square and triangle. Usually, the stability of nucleic acids with the same
base-pair content is directly dependent on metal ion and total nucleic acid concentrations.
Since these two criteria were the same, it was assumed that the higher the number of bp in
each RNA structure the higher the stability. Therefore, the most stable shape produced
should be the pentagon. However, based on TGGE data the opposite was found. This was
likely due to the tension caused by the stretching of the native pRNA 3WJ 60° AOB. The
triangular construct angle was preserved (60°), the square and pentagon angles were
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stretched to the wider conformations of 90° and 108°, respectively. Previously it has been
shown that any nucleotide mutations or deletions within the native core structure of the
pRNA 3WJ motif would also result in the loss of its thermodynamic stability (55).
Interestingly, the measured triangle and square TM values differed by +3 °C, as did the
square and pentagon. Boiling resistance assay in the presence and absence of 8 M urea
further confirmed that the triangle was the most stable nanoparticle (Fig 2.6B). The
quantification of nanoparticle bands after heating to 100 °C resulted in 75 ± 4% recovery
of the triangular assembly, suggesting a TM >100 °C. By definition, TM is the measured
temperature when half the RNA concentration has melted, i.e. 50% recovery. The
percentage of recovery for square was 28 ± 2% and for pentagon was 16 ± 5%, much lower
than the value estimated for triangle recovery. The experiment with the presence of 8 M
urea in boiling solution showed that the overall trend of stability remained the same, but
the percentage of recovery was 55 ± 4% for triangle, 8 ± 3% for square, and no pentagon
fraction was detected. Overall, the nanoparticle with fewer 3WJ motifs (triangle) resulted
in a higher thermostability and resistance in chemical degradation, and the change in
stability was in large part due to the stretching of the AOB.
DISCUSSION AND CONCLUSIONS:
Artificial construction of RNA nanoparticles requires knowledge of the structural
properties of RNA motifs, such as interhelical or intrahelical distances, X-Y and X-Y-Z
angles, number and orientations of RNA branches in multi-way junctions, canonical and
non-canonical interactions, binding sites for proteins, metal ions, and small molecules
(75,90,154,159,160,173). Progression in RNA structural biology allowed for the analysis
of RNA 3D motifs from existing RNA structures at atomic resolution and various data
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bases, including www.pdb.com, RNA multi-way junction (68), and find RNA motif
(174,175). This study, based on the previously reported versatile pRNA 3WJ 3D motifs
(PDB accession ID: 4KZ2), shows that the 3WJ structure can be folded into desired
conformations based on the dynamics of the 60°AOC, demonstrating the ability to tune
the physical and structural properties of RNA polygons for a variety of technological,
biological, and medicinal needs. This approach, based on the propagation of the central
RNA strand used to direct the folding of corresponding short or external strands into planar
triangle, square, and pentagon conformations, resulted in the 60º, 90º and 108º bending of
interhelical AOB of the pRNA 3WJ. This is especially important for medical applications
where one needs to construct different RNA nano-scaffolds based on a non-toxic and
thermodynamically stable building block. The following advantages result from this
technique: i) the number and combination of therapeutic molecules can be tuned to an
RNA-based nano-carrier; ii) the nano-scaffold has a controllable size and shape; and iii)
variable thermodynamic and RNase resistance properties can be applied depending on the
application of the nano-scaffold.
ACKNOWLEGEMENTS:
We thank Luda Shlyakhtenko for AFM imaging at the Nanoimaging Core Facility
supported by the NIH SIG program and the UNMC Program of ENRI to Yuri Lyubchenko.
This work was supported by the National Institutes of Health EB003730 and CA151648 to
P.G. The content is solely the responsibility of the authors and does not necessarily
represent the official views of NIH. Funding to Peixuan Guo’s Endowed Chair in
Nanobiotechnology position was by the William Fairish Endowment Fund.

28

Chapter 2.2: Design and Construction of Physicochemically Tunable RNA
Nanoparticles with Controllable Size
INTRODUCTION:
DNA, RNA, and proteins from living systems produce a variety of highly ordered
nano-scale structures to perform diverse functions (55,90,176-178). The intricacies of these
natural biomaterials have inspired their applications as building blocks to fabricate
sophisticated nanodevices (99,115,156,179-187). In nanotechnology, RNA can be
manipulated to assemble nanostructures with simple approaches as in DNA
nanotechnology, while displaying versatility in structure and function similar to proteins.
Thus, RNA has the advantage of two worlds, which garners tremendous interest in the
directed design of a variety of RNA nanoarchitectures. Natural RNA molecules form a
wide variety of complex structures by hierarchical folding that generates different motifs
or modular units (75,106). These modular units can be “manually” extracted and used to
fabricate artificial self-assembling RNA complexes of diverse 1D, 2D, and 3D
nanoarchitectures with novel and unique functional features (50,55,99,152). Many RNA
motifs exhibit phenomenal flexibility (68,168,188) and the angles needed to form many
nanoassemblies are encoded in the primary sequence of the structural motifs. The structure
of a complex RNA architecture can be engineered by programming the information of a
3D structural motif into the nanoparticle's primary sequences. However, the flexibility of
RNA motifs has seldom been used to construct diverse shaped nanoparticles utilizing the
same core structure.
Previous work in this lab has detailed the construction of RNA nanoparticles
utilizing the pRNA from bacteriophage phi29 DNA packaging motor. Dimers, trimers,
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tetramers, and hexamers have been constructed utilizing hand-in-hand and foot-to-foot
interactions as well as arm extension technologies which implement kissing-loop, stickyend,

and

complementary

interactions(12,50,55,90,91,104,105,152,168,189,190).

Additionally, the 3WJ and X-way motifs from the phi29 motor pRNA, themselves, have
proven successful as therapeutic delivery systems (50,55,63,105,152). Other RNA
nanoparticle-based delivery systems have shown potential as therapeutic carriers
(108,110,113,116,124,187,191-193).
Size and shape play an important role in the delivery efficacy, biodistribution and
circulation time of nanoparticles (194). Control over these properties can be of paramount
importance for in vivo applications. However, in many cases fine tuning of size, shape, and
physicochemical properties of nanoparticles is difficult to achieve. Having a library of
diverse size nanoparticles with tunable properties is advantageous as pharmacokinetic
mechanisms of drug delivery, distribution, and clearance are hard to predict (194-197).
These facts are the motivation behind the development of a simple method to tune the size
and thermodynamic and chemical properties of RNA nanoparticles.
The complexity of RNA's tertiary structure complicates de novo design of such
nanostructures; however, by utilizing a pre-defined 3D motif as the design template many
complications can be avoided. This approach utilizes a modular design technique,
sometimes referred to as RNA biomimetics. It involves the use of pre-defined structural
motifs taken from biology as building blocks to construct RNA nanostructures of defined
shape and size for a variety of applications including nanomedicine (156,198). The use of
pre-defined RNA motifs has shown to be a successful method towards the rational design
of RNA nanoarchitectures (50,90,99,108). Naturally, the first step in applying the pRNA

30

3WJ in modular design was to construct triangles based on the native 60° angle of the
pRNA 3WJ motif (Fig 2.7A) (168), ideal for the construction of an equilateral triangle.
Utilizing this native angle triangular nanoparticles were constructed using the modular
design technique (126). To create more diversity in size and shape, square shaped geometry
was the next goal. By stretching the 3WJ, triangle, square, and pentagon can be formed
(103). The next question to be addressed is whether we can tune the size of one polygon
by using the same 3WJ while altering the length of each side.
In this report, we show the construction of multiple variants of square-shaped RNA
architectures based on a modular design technique using the same core structure, the pRNA
3WJ. By simply increasing or decreasing the length of the RNA duplex between each
corner of the square, nanoparticles of 5, 10, and 20 nanometers (nm) were constructed with
diverse thermal stabilities. The thermodynamic stability of certain RNA tertiary motifs and
the strong Watson-Crick base pairing in RNA folding ensure predictability in structure that
make it possible to increase or decrease size by simply adding or removing nucleotides,
directly affecting size. Further control over nanoparticle stability was demonstrated by
modulating the oligonucleotide used as the “core” strand during construction of the square
nanoparticle. Exploiting the different stabilities of RNA, DNA, and 2’-fluorine modified
(2’F) RNA it is possible to add another dimension of regulation over the physicochemical
properties of RNA nanoparticles. Moreover, due to the unique construction technique used,
we show that it is possible to completely avoid intermolecular interactions such as kissing
loop and sticky-end interactions during construction of the nanoparticles. The potential of
using the resulting RNA square assembly for biomedical and imaging applications is
evidenced by the incorporation of therapeutic RNA, ribozyme, and fluorogenic aptamers.
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As shown here, the assembly properties and tunability of RNA nanoparticles can be easily
exploited to determine a suitable combination of size and stability for a wide array of
applications.
MATERIALS AND METHODS:
RNA synthesis, purification and labeling.
RNA oligomers were prepared by in vitro T7 transcription from dsDNA containing
the T7 promoter prepared by polymerase chain reaction (PCR). Single-stranded (ss) DNA
oligomers were purchased from Integrated DNA Technologies (IDT). Cy5 whole chain
labeling was carried out on the RNA oligomers following the Mirus Cy5 Label IT Nucleic
Acid whole chain labeling procedure. For TGGE analysis of core strand hybrid squares,
Perkin Elmer [γ-32P]-ATP was used to label one of the short external strands at the 5’ end.
Assembly of RNA Nanoparticles
Equimolar amounts of RNA oligomers were mixed to a final concentration of 1 µM
in 1 X TMS buffer. The mixture was heated to 80°C for 5 minutes and then slowly cooled
to 4°C over one hour using an Eppendorf Mastercycle Thermocycler. Confirmation of the
assembly products were then run on native PAGE.
Native PAGE and TGGE analysis
All assembly experiments were performed on 7% (29:1) native PAGE and run at
100 V in a 4°C cold room for 120 minutes. Cy5 labeled RNAs were then scanned on the
Typhoon FLA 7000 and total RNAs were stained with ethidium bromide (EB).
TGGE analysis was performed on 7% native PAGE in a buffer containing 50 mM
TRIS pH = 8.0, 100 mM NaCl, and 0.2 mM MgCl2. A gradient temperature of 40-75°C
was applied perpendicular to electrical current, and experiment was run for 1 h at 20 W. A
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total RNA concentration of 80 nM was used in TGGE analysis of the core strand hybrid
constructs and 100 nM RNA concentration was used for TGGE comparison of the different
sized squares. Apparent TM values corresponded to the temperature at which half of the
square fractions were dissociated, and apparent TM values for multiple RNA strands were
calculated, as described previously (50).
Quantification analysis was performed using ImageJ software (169). Equal-sized
boxes were drawn around the lanes corresponding to the square complexes and
corresponding quantified values for each hybrid square were divided by the sum of the
values presented in the corresponding lane. All plots were generated using OriginPro 8
software.
AFM Imaging
AFM images were taken using a MultiMode AFM NanoScope IV system (Veeco),
as per previously reported methods (199). Briefly, the RNA samples were diluted with 1 X
TMS buffer to a final concentration of 3-5 nM. Then, the droplet of samples (5-10 μL) was
immediately deposited on the specifically modified APS mica surface (170,171), excess
samples were washed with DEPC treated water and dried under a flow of Argon gas. AFM
images in air were acquired using MultiMode AFM NanoScope IV system (Veeco/Digital
Instruments, Santa Barbara, CA) operating in tapping mode.
FBS resistance assay
The square nanoparticles with RNA, 2’F RNA, and DNA core strands were
incubated in 2% FBS solution at 37°C for 14 hours. After removal from 37°C incubation
at their respective time points, samples were frozen on dry ice to prevent any further
degradation. The samples were then analyzed on 7% Native PAGE. ImageJ software was
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used to integrate the intensities of the assembled square nanoparticles in the gel. Integration
areas for each time point were compared to the integration area for the 0 minute time point
to construct an RNAse degradation comparison between the RNA, DNA, and 2’F-RNA
hybrids. All plots were generated using OriginPro 8 Software.
Spinach and Malachite Green Aptamer Fluorescence Measurements
Native 7% PAGE was used to detect the fluorescence emission of fluorogenic
nanoparticles. The gel was stained simultaneously in a mixture of 5 μM MG and 5 μM
DFHBI and scanned for the MG-apt fluorescence λexc centered at 635 nm, and for
SPINACH-APT fluorescence λexc centered at 473 nm. After recording images at different
excitation wavelengths, total RNA staining in EB solution was performed to detect all
RNAs in the gel.
Fluorescence emission in solution was measured, as previously reported (153). Briefly,
assembled square nanoparticles (0.1 μM) harboring MG and SPINACH aptamers in TMS
buffer were mixed with MG (2 M) and DFHBI (2 M) (Lucerna, Inc,
http://www.lucernatechnologies.com) and incubated at room temperature for 30 min.
Fluorescence was measured using a fluorospectrometer (Horiba Jobin Yvon), excited at
450 nm (565–750 nm scanning for emission) for SPINACH and 615 nm (625–750 nm
scanning for emission) for MG dyes.
Dual Luciferase Assay
Experiments were carried out as previously described (200). For square
experiments carried out here, controls of cell only, plasmid only, and Lipofectamine
2000(Lipo) only were used. Cell only contains luminescence data of cells only, with no
transfection reagent or plasmid DNA. Lipo only samples contained just Lipofectamine
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2000 transfection reagent. The plasmid only samples contained DNA plasmid only, which
were transfected into the cell utilizing the transfection reagent Lipofectamine 2000. For
RNA controls, the 3WJ with luciferase siRNA was used, which has previously been shown
to cause knockdown (201). Square scaffold and a square utilizing scrambled siRNA
sequence were utilized as negative controls.
HBV Ribozyme Activity Assay
HBV ribozyme activity assay was carried out as previously detailed (66). Briefly,
HBV RNA substrate was 5’-Cy5 labeled using the Mirus Cy5 labeling kit. The labeled
substrate was incubated with square nanoparticle conjugated with HBV ribozyme for 60
minutes at 37°C in buffer containing 20 mM MgCl2, 20 mM NaCl, and 50 mM Tris-HCl
(pH 7.5). pRNA conjugated to HBV ribozyme served as a positive control and pRNA with
a disabled HBV ribozyme was used as a negative control. The cleaved fragments were
analyzed on the Typhoon Fluorescent Imaging system.
RESULTS AND DISCUSSION:
RNA Square Design
Square-shaped RNA nanoarchitectures were designed in silico utilizing planar
geometry of the 3WJ structural motif. Swiss PDB Viewer (www.spdbv.vital-it.ch) was
used to align four 3WJ building blocks (PDB ID: 4KZ2) (168) in a planar configuration
utilizing the internal ~60° angle, created by helix one (H1) and helix two (H2), at each
corner of the square (Fig 2.7A). A-type duplex RNA was then inserted to connect helix
one H1 and H2 (Fig 2.7A). The resulting design featured a square with four "arms"
extruding outwards from each of vertex of the square, facilitating the incorporation of
additional RNA sequences, motifs, or functionalities. The final square contains five RNA
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strands, whereby four short strands (A, B, C, D) are complimentary to one long “core”
strand E (Fig 2.7B, Fig A.1.4). This results in a nanoparticle containing a 3WJ at each
vertex and A-type duplex RNA along each edge. Extension of both the core and external
strands by increasing the number of complementary nucleotides was exploited to obtain
RNA squares with variable but predictable sizes (Fig 2.8A). By such means, small,
medium, and large square architecture were designed using Swiss PDB Viewer and the
sequences for all five strands were optimized to avoid non-specific interactions using the
Mfold program (202).
Structural Characterization
Based on models, the sizes of the resulting square structures should be 5.1 nm, 10.2
nm and 20.1 nm along each edge. The size increase results from extension of the duplex
RNA connecting the 3WJs at each corner. Based on nearest-neighbor thermodynamic
parameters, larger size squares are expected to exhibit increased thermodynamic stability.
As none of the 3WJ angles have a right angle according to its crystal structure (Fig 2.7A)
the 3WJ motif must be stretched from ~60° to ~90° to accommodate square geometry. As
a result, efficiency of self-assembly might be decreased. Consequently, our first
experiments were aimed at characterizing the physical properties of the square constructs.
Native PAGE was first used to test the assembly and analyze assembly efficiency.
Nanoparticle assembly was performed via “one-pot” self-assembly procedure by thermal
denaturation of all RNA strands in TMS buffer and gradual cooling over one hour. ImageJ
software was used to analyze the intensity of gel bands and the yield of correctly folded 10
and 20 nm squares was estimated to be more than 90% with a slight decrease in folding
efficiency observed for the 5 nm square (Fig 2.7C). Additionally, the hypothesis that each
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strand was involved in the assembly, and that strand substitution was not occurring, was
tested. For this assay, each strand A through E was fluorescently labeled. Five different
squares, each with one of five strands labeled, were then assembled and analyzed by native
PAGE. The results demonstrate that each strand contributes to the assembly and therefore
the overall stability of the square (Fig A.1.5).
While native PAGE experiments suggest the formation of compact, homogeneous,
and distinct RNA nanoparticles, atomic force microscopy (AFM) was performed to
demonstrate the formation of the square shaped RNA nanoarchitecture (Fig. 2.8B).
Resulting AFM images strongly support the formation of the medium and large square
shaped RNA architecture. Image resolution of RNA nanostructures is in many cases limited
by tip size. Due to the resolution limits of the AFM images shown in this report, the small
square only appears as dots with no square geometry obviously visible. The results are
expected as the size of the small square model is 5.2 nm, a size too small to be clearly
resolved. A small percentage of squares appear as diamond shape straying from square
geometry. This can be attributed to the fact that AFM images were taken in air and not in
solution, distorting shape when the nanoparticles are dried onto the mica surface.
Alternatively, diamond shapes could be due to the flexibility of the 3WJ (168). Using the
large square AFM images, particles were manually counted to determine efficiency of
assembly by AFM. It was revealed that the large square formed with 70% efficiency.
When considering a nanoparticle for use as an in vivo therapeutic the size of the
particle greatly affects the delivery efficacy. Too small a size and the particle will simply
be excreted; too large a size and entry into the cell will be greatly hindered. Previous studies
showed that the optimal size for the cellular uptake of nanoparticles is 10-50 nm (90,203-
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206). Using dynamic light scattering (DLS), the average hydrodynamic diameters (Dh) of
RNA square nanoparticles were determined to be 4.0 ± 0.9 nm, 11.2 ± 1.3 nm, and 24.9 ±
0.5 nm for the small, medium, and large size squares, respectively (Fig 2.8C). These values
are in close agreement with the predicted size of the model structures. At sizes of 4.0 nm,
11.2 nm, and 24.9 nm we have constructed variable size nanoparticles with potentially
diverse physicochemical properties.
We have presented a simple method to adjust the size of RNA nanoparticles,
however we aim to show that adjustment of size leads to diverse thermodynamic properties
among square variants. To compare the thermodynamic stability of the squares,
temperature gradient gel electrophoresis (TGGE) was used to determine the melting
temperatures (TM) of each square (TM = 50% square formation). A temperature gradient
perpendicular to electrical current was applied and increasing TM corresponding to an
increase in size was observed (Fig A.1.6). Since each of the square constructs contains four
3WJ motifs, the increase in melting temperature can be attributed directly to an increase in
the amount of base-pairing in the structures. This trend follows the nearest-neighbor
predictions for increasing of thermodynamic stability.
Taken together, structural analysis by computer modeling, DLS, and AFM suggest
the formation of compact, flat, square RNA nanoparticles. The native geometry,
determined by crystallization, has H1 and H2 of the 3WJ in planar configuration (168).
The computer model also results in planar geometry based on duplex alignment of
connecting helices H1 and H2, strongly supporting the formation of planar square
nanoparticles. Furthermore, the presence of square structures on AFM, and not triangular
shapes, which would result from a 3D tetrahedron like structure (207), also supports flat,
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square geometry. As expected, AFM imaging demonstrates the size differences among the
small, medium, and large squares.
Previously, RNA triangles have been constructed using the same pRNA-3WJ (126).
After analysis of the square nanoparticle, it was determined that the square and triangle
display diverse properties in thermodynamic stability, size, shape, and stoichiometry:
functions possible per nanoparticle. Although not explored in depth in this study, it is
possible that utilizing these particles in different applications, where size and shape play
an important role, could be beneficial.
Physicochemical Properties are Tunable
Native RNA structures are inherently sensitive to degradation by cellular nucleases,
potentially limiting the application of RNA nanoparticles in clinical applications.
Modifications to RNAs, such as 2’F on the ribose sugar of the RNA backbone, have been
shown to reduce their sensitivity to cellular nucleases (55,64). These same 2’F
modifications have also been shown to increase the thermodynamic stability of RNA
nanoparticles (63). DNA has also proven to be more resistant to the degradation caused by
cellular nucleases (55,90). To be useful as an in vivo therapeutic, modifications must be
made to the native square nanoparticles to gain resistance to RNase while retaining the
same structure. Previous studies demonstrating different chemical and thermodynamic
stabilities of the pRNA 3WJ constructed of RNA, DNA, and 2’F-RNA were the driving
force behind the replacement of the core strand of the square nanoparticle (63,64). Due to
these diverse stabilities, it was predicted that replacement of the core strand with different
oligonucleotides would result in a nanoparticle with diverse physicochemical properties.
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To impart tunable chemical and thermodynamic stabilities onto the 10 nm square
nanoparticle the internal core strand E was replaced with both 2’F-C/U modified RNA and
with single stranded DNA. Analysis by native PAGE demonstrated that all the nanosquares
co-migrated indicating formation of the same geometry (Fig 2.9A). Moreover, all
nanoparticles assembled with comparable yields of ~90% as determined by integration of
the intensity of gel bands (Fig 2.9A).
A degradation assay in fetal bovine serum (FBS) was performed on each 10 nm
hybrid square assembly. It was observed that substitution of 2’F modified core strand for
unmodified RNA greatly enhances the stability of the nanoparticles in FBS (Fig 2.9B).
After 14 hours, ~92% of square nanoparticles with 2’F modified core strand remained, as
compared to ~20% for square nanoparticles with RNA and DNA core strands (Fig 2.9B,
Fig A.1.7). While different hybrid duplexes exhibit different stabilities or susceptibilities
to different RNases (208,209), serum comparison mimics more closely an in vivo
environment and allows the direct comparison of each hybrid square. Overall, resistance
to nuclease degradation was enhanced by replacing the core strand with 2’F modified RNA.
To further examine the effect the core strand has on nanoparticle stability, TGGE
analysis was performed to determine the TM of each hybrid. A temperature gradient,
perpendicular to electrical current, was applied from 40°C-80°C. The TM’s for the 2’FRNA, RNA, and DNA hybrid square nanoparticles were calculated to be 68.4 ± 0.1 °C,
57.7 ± 0.2 °C, and 51.8 ± 0.1 °C, respectively (Fig 2.9C, Fig A.1.8). Melting temperatures
were determined at 0.2 mM MgCl2, simulating physiological conditions in which the
cytoplasmic magnesium ion concentration is generally lower than 1 mM. At 10 mM
magnesium concentrations, no melting below 80 °C was observed (Fig A.1.8D-F). Tertiary
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structure greatly affects the melting temperature, and therefore thermodynamic stability, of
an RNA structure. The duplex cannot be solely responsible for the trend in melting
temperature from 2’F-RNA hybrid to DNA-RNA hybrid as a large portion of each structure
is 3WJ. It has been shown that complicated tertiary structures are more stable in RNA than
DNA resulting in a less stable a DNA-RNA hybrid 3WJ (63). Interestingly, the melting
temperatures correlate with the FBS resistance assay indicating that the 2’F-RNA hybrid
square was the most stable, followed by the native RNA square, and the DNA hybrid
architecture was the least stable.
In clinical applications, considering pharmacokinetics, biodistribution, and
toxicity, the most stable nanoparticles will not always be the most effective treatment (195197). Our results show that it is possible to tune the stability characteristics of the RNA
square nanoparticles by substituting the core strand and varying the ratio of 2’F
nucleotides. This simple modification produces physicochemically diverse structures that
can be easily tuned based on application.
Functionalizing the Square Scaffold
For the square architecture to be useful as a potential therapeutic in nanomedical
applications, functional molecules (RNAi, aptamers, ribozymes) must be successfully
fused into the core structure while it retains native folding and properties. Thus, the
question of whether the RNA scaffold can harbor different RNA functional moieties such
as siRNA, ribozymes, and RNA fluorogenic aptamers was addressed. More importantly, if
the functional molecules retain their activity when incorporated into the square scaffold.
As such, four functional RNA groups, RNA spinach (SPIN) aptamer (210), RNA
malachite green (MG) aptamer (211,212), hepatitis B virus (HBV) ribozyme (213), and
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siRNA targeting luciferase gene (160) were incorporated at each corner of the 10 nm square
nanoparticle (Fig 2.10A, Fig A.1.9). The multi-functional square assembly showed more
than 90% efficiency as analyzed by integration of gel bands (Fig 2.10B). Additional AFM
imaging was performed to demonstrate the retention of square geometry with the fused
functionalities (Fig 2.10C).
The MG and SPIN aptamers are synthetic RNA aptamer sequences, previously
obtained through SELEX (Systematic Evolution of Ligands by Exponential Enrichment)
(92) that bind the malachite green and DFHBI dyes respectively (210,212). Free
fluorophores in solution do not exhibit fluorescence and emit light only upon binding to
their correctly folded RNA aptamer structures (210,214). To assay if folding was retained
when incorporated into the multi-functional square, fluorometer measurements were taken
for the malachite green and DFHBI chemicals alone and in the presence of the functional
RNA square (Fig 2.11). The multi-functional square was simultaneously incubated with
both fluorophores and fluorescence measurements were then taken. Both aptamers retained
their folding and bound their respective fluorophore as evidenced by an increase in
malachite green and DFHBI emission upon binding. As a positive control, a 3WJ with the
MG aptamer and the SPINACH aptamer were used, both of which have been previously
shown to exhibit increased fluorescence signal when incubated with their respective
fluorophores (55,153). Furthermore, we aimed to show the simultaneous dual-mode
fluorescent properties of the functional square architecture. The PAGE gel was stained for
both MG and spinach aptamer dyes. Individual fluorescence of each aptamer was detected
when incorporated into the same nanoparticle (Fig A.1.10).
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The HBV ribozyme is a hammerhead ribozyme that cleaves hepatitis B genomic
RNA. Ribozymes show potential as therapeutic agents; however, they traditionally have
shown low efficiency when tested in vivo. This can be attributed to the misfolding of
ribozymes in an intracellular environment and their susceptibility to exonucleases (215).
One method to protect ribozymes and prevent their misfolding is to harbor them in larger,
more complex structures. However, ribozymes must maintain their native folding, to retain
functionality, when fused to RNA or incorporated into nanoparticles (101). Upon
incubation of the multi-functional square with HBV genomic RNA, cleavage of the RNA
genome occurs. Figure 2.12A demonstrates that the HBV ribozyme retains its catalytic
activity when fused with the RNA square, as the cleaved products are clearly seen on the
gel and the bands are comparable with a positive pRNA-HBV control construct (66).
To test the ability of the RNA square to carry siRNA for gene silencing effects, an
in vitro assay was performed with a dual-luciferase reporter system (201). An siRNA antisense strand, which targets the firefly luciferase gene, was hybridized with its
complimentary sense strand used as a sticky end fused onto the multi-functional square
(Fig 2.10A). A decrease in target gene, firefly, luminescence compared to reference gene,
renilla, indicates a decrease in target gene protein production, designating a positive result.
In comparison to the positive control, a 3WJ nanoparticle with fused luciferase siRNA
(201), the multi-functional square harboring luciferase siRNA caused a similar decrease in
luminescence indicating similar gene knockdown activity (Fig 2.12B). Overall, the results
indicated that the RNA square nanoparticles carrying luciferase siRNA displayed ~40%
gene knockdown activity.
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For DICER to recognize and process double stranded (ds) RNA, the 3’-overhang
must be accessible and not trapped inside the inner cavity of the square nanoparticle. This
possible obstruction proves to be no problem. This newly constructed square makes it
simple to incorporate other diverse functional moieties into one of the four "arms" of the
square. This can be done by simply fusing siRNA into one of the four external scaffold
strands.
The results demonstrate that diverse functionalities retain their activity when
incorporated into the square scaffold, making the RNA square an addressable and
programmable poly-functional nanoscaffold for potential delivery of RNA therapeutics for
application in medicine. Due to the unique five-strand construction of the square
architecture functionalities such as RNA aptamers and siRNA for gene therapy can be
added by simply encoding for functionalities in the primary sequence of one strand in the
square.
CONCLUSIONS:
Here we report the design and construction of poly-functional RNA square
architectures utilizing the 3WJ motif of bacteriophage phi29. The conserved 60° angle from
the 3WJ was expanded to 90°, and formation of square geometry was achieved. The length
of the connecting helix was increased or decreased to generate three distinct sizes of
nanoparticles. These three sizes of nanoparticles demonstrate diverse thermodynamic
stabilities. By modulating the oligonucleotide used as the core strand we tuned the
physicochemical properties of the square scaffold. The four arms extending from the four
corners of the square were used to incorporate RNA functionalities, each of which was
demonstrated to fold independently and correctly while retaining their authentic
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functionalities. The square nanoscaffold shows great promise for biomedical and imaging
applications due to its tunable thermodynamic and biochemical stabilities. The technique
shown here for simple design to finely tune physicochemical properties adds a new angle
to exploit RNA nanoparticles in a clinical setting.
ACKNOWLEDGEMENTS:
We thank Drs. Luda Shlyakhtenko and Yuri Lyubchenko for preparing the AFM
images. The work was supported by NIH grants CA151648 and EB003730, and funding to
Peixuan Guo’s Endowed Chair in Nanobiotechnology position from the William Fairish
Endowment Fund. The content is solely the responsibility of the authors and does not
necessarily represent the official views of NIH. We would like to acknowledge the core
facilities of the Markey Cancer Center at the University of Kentucky.

45

Secondary structure of
pRNA

pRNA 3WJ region in 2D and 3D representation
“Right-hand” loop

H-1

U

H2
GUAUG -3'
CAUAC -5'H-2
U
U
~60°
U
U G
A U
A U
C G
H1
| |
5' 3'

5'- UUGUCAUG

H-1 3'- AACGGUAC
H-2

“Left-hand” loop

Triangle model

B 5’

Optimized secondary structure
20
|

D

30
|

40
|

60
|

50
|

3'5'
U
U
U
GCGGACAC UUGUCAUG GUAUG CGUGUAUA UUGUCAUG GUAUG CUCUAUCG UUGUCAUG GUAUG
CGCCUGUG AACGGUAC CAUAC GCACAUAU AACGGUAC CAUAC GAGAUAGC AACGGUAC CAUAC
|
U
U 30|
U
20
U
U
U
U
U
U
U G
U G
U G
U
A
A U
A U
A U
A U
A U -40
C G
10- C G
C G
G C
C G
U A
U A
G C
G C
G C
A U
C G
C G
C G
C G
5'- G G G A G C
5'- G G G AG C
5'- G G G AC G
A
G
A
3' C
3' G -48
3' G

A

H3

H-3

H-3

10
|

pRNA 3WJ

C

D

B

C 5’

pRN
A
3WJ
5’

A

~12 nm

Figure 2.1. RNA triangle design scheme. Design scheme of triangular nanoparticle. Step
#1: the atomic resolution structure of pRNA 3WJ motif highlighted by the rectangle was
obtained and analyzed. The flexible angle ~60° formed by H1 and H2 was used for triangle
design on Swiss-PDB viewer as shown in following step. Step #2: The 3D model of triangle
shape was designed by carefully joining extended helices (H1 and H2) using Swiss PDB
viewer software. Step #3: the sequences and secondary structure of the triangle is obtained
based on free energy sequence optimization algorithm using mfold. The resulting
secondary structure contains four RNA strands: three identical in length (48 nt) A (red), B
(blue), and C (brown) as well as longer strand D (green 66 nt). Figure reproduced from
(126) copyright American Chemical Society 2014.

46

A

B

Figure 2.2. Structural features of the pRNA 3WJ motif. (A) Secondary structure of 3WJ
motif with base pairs annotated with Leontis-Westhof nomenclature56. (B) Tertiary
structure of 3WJ motif with indication of AOB ~ 60 ° angle formed between H1 and H2.
Angle corresponds to inner angles of polygons.
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design of RNA triangles from the 3WJ.

48

A

B

External strands

Internal strands

polygons

D = 66 nt
A
48 nt
A
B
C
D
E

ABCD

D B
C
B

E = 88 nt
A

E

C

D
A

F = 110 nt
E

B
F

C

D

C
D D D D*
C C C C* C
B B B B* B B
A* A* A* A* A A A

T
D
M

D
C C
B B B
A* A* A* A*

E
D
C
B
A*

E E
D D
C C*
B* B
A A

E
D*
C
B
A

E*
D
C
B
A

D
C C
B B B
A* A* A* A*

tetr
T
D

pent
tetr
T
D

M

M

E
D
C
B
A*

F
E
D
C
B
A*

F
E
D
C
B*
A

F
E
D
C*
B
A

F F
E E*
D* D
C C
B B
A A

F*
E
D
C
B
A
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Figure 2.7. Design and assembly of the RNA squares. (A) Crystal structure of pRNA3WJ showing the three component strands of the pRNA-3WJ, 3WJ-a (blue), 3WJ-b
(purple), and 3WJ-c (green). (B) Three-dimensional structure of square shaped
nanoparticle modeled on Swiss PDB Viewer, based on pRNA-3WJ. (C) Native PAGE
assembly gel with ethidium bromide total RNA staining showing assembly of each square
structure: Lane 1 is 5 nm square, Lane 2 is 10 nm square, and Lane 3 is 20 nm square.
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Figure 2.8. Physical Properties of the squares. (A) Schematic of small, medium, and
large squares drawn to scale for size comparison. Four external strands (blue, purple, red,
orange) are complimentary to the core internal strand (green). (B) AFM imaging of small,
medium, and large RNA squares. Zoomed pictures of individual squares located on the
right. On the far right is a mixture of squares, each square is indicated by arrows. (C)
Dynamic light scattering (DLS) to determine the size of square nanoparticles. Far right
panel shows comparison of all three square constructs.
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Figure 2.9. Comparison of RNA, 2’F-RNA, and DNA core strand hybrids. (A)
Structure and native PAGE assembly of square nanoparticle hybrids.

Blue strands

represent RNA, red strands represent 2’F-RNA, black strands represent DNA. Lane 1
through 4 show the stepwise assembly from monomer to tetramer. (B) Nanoparticle
stability in serum was compared among the square hybrid constructs (C) TGGE melting
temperature profiles of square RNA nanoparticle along with 2’F and DNA core strand
hybrids.
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square nanoparticle and multi-functional square assessed by 7% native PAGE. (C) AFM
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corners of the nanoparticles.
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ribozyme. Cleaved products are boxed. pRNA-HBV-Rbz was used as a control (B)
Luciferase siRNA activity assay. Gene knockdown was measured by a decrease in
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Chapter 3.1: The Effect of RNA Nanoparticle Size and Shape on Biodistribution
INTRODUCTION:
The past decades have seen the emergence of nanotechnology as the next potential
solution for advancing the field of medicine (13,14). Diverse types of nanoparticle
platforms have been developed (3,4,7-12) that display distinct advantages over traditional
treatments due to their increased circulation time, high therapeutic payload, and ability to
harbor multiple functional groups (15,16). When combined with targeting ligands,
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peptides, or aptamers, nanoparticles possess the potential for cell-specific drug delivery
(29,32). The enhanced permeability and retention (EPR) effect allows even non-targeted
nanoparticles to accumulate in tumor tissue due to the large amount of vascularization at
the tumor site (216). However, many nanoparticles, while effectively targeting tumor and
cancerous cells, accumulate non-specifically in healthy tissues, causing toxicity and off
target effects (132). Non-biocompatible materials cause toxicity as they are never fully
excreted from the body. Particles that do not cause toxicity, such as DNA and lipid based
particles, then suffer from low stability in vivo.
Size and shape have been shown to greatly affect pharmacokinetics and
biodistribution profiles of nanoparticles (127,128,134). Small particles (< 5 nm) are filtered
by the kidneys and excreted in the urine (129). Large particles are engulfed by macrophages
or sequestered in healthy tissue, never successfully navigating to the desired target (130).
Many nanoparticles currently under investigation are rigid in nature, allowing no
deformation from their size and shape. Rigid nanoparticles cannot penetrate pores smaller
than themselves in size, resulting in low amounts of nanoparticles at the tumor site, which
is normally heterogeneous in its structure. Alternatively, large, rigid particles that get stuck
in healthy organs cannot escape, remaining trapped.
RNA nanotechnology, where the scaffold and ligands are composed solely of RNA,
is an emerging technology that has shown promise to overcome several current challenges
in nanotechnology (55,90). RNA nanoparticles can be engineered to diverse size and shape
while retaining high thermostability necessary for in vivo applications (50,103,126,150).
Simple sequence engineering can be used to employ the same RNA motif for construction
of multiple RNA nanoparticles, reducing the number of single stranded RNA oligomers
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needed for the construction of myriad of RNA nanoparticles. Furthermore, modifications
to the ribose sugar (such as 2’ fluorine, 2’F) of RNA bases confers stability in serum for
more than 24 hours (h) (64,217). The unique base pairing mechanism that occurs during
the assembly of RNA nanoparticles leads to consistent assembly properties, resulting in
defined size nanoparticles with a narrow size distribution. Thus, a particular RNA
nanoparticle will display homogeneity from batch to batch of assembly. In order to
optimize drug delivery, it is important to have nanoparticles that are consistent in assembly
that will display a narrow size distribution, as this will lead to consistent pharmacokinetic
and biodistribution in vivo (218). Furthermore, RNA is a flexible biomaterial by nature,
therefore allowing some structure deformity, unlike many rigid nanoparticles under
development (219,220).
The pRNA three-way junction (3WJ) derived from the packaging RNA (pRNA) of
bacteriophage phi29 has recently been shown to display high thermostability (55,63), fast
kinetic assembly (62), and has been successfully used in vivo for miRNA and siRNA
delivery and tumor growth suppression (56-58). The addition of aptamers and targeting
ligands allow the 3WJ to successfully enter tumor cells specifically. Interestingly, 3WJ
particles have repeatedly displayed little to no accumulation in healthy tissue, including the
liver, kidneys, lung, and spleen (55,57,58). Despite the small size of the nanoparticles (<5
nm), total clearance by the kidneys does not occur while accumulation in tumor tissue is
still observed (56-58).
The effects of RNA nanoparticle size and shape on biodistribution were
investigated using previously constructed and characterized RNA triangles, squares, and
pentagons (103,150). Analysis by fluorescence imaging of whole mice and their organs
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demonstrated a strong correlation between increased size and increased circulation time
using RNA nanosquares. However, shape showed to have less of an effect on
biodistribution, despite the appearance of different elimination routes. Unlike many
nanoparticle systems where it is hard to study size and shape independently, RNA
nanoparticle size and shape is precisely controlled from nanoparticle conception.
Therefore, in this study, different size nanoparticles that have identical shape could be
studied.
MATERIALS AND METHODS:
RNA Nanoparticle Synthesis and Assembly
RNA strands were prepared as previously detailed (105) by either T7 in vitro
transcription (strands longer than 70 nucleotides) or typical phosphoramidite
oligonucleotide chemical synthesis (strands shorter than 70 nucleotides) using an
automated oligo-synthesizer. DNA strands used as primers for dsDNA transcription
templates were ordered from Integrated DNA Technologies (IDT). Assembly was carried
out by mixing equimolar amounts of RNA strands followed by thermal denaturation at
85C for 5 minutes and then slow cooling to 4 C over one hour. For each nanoparticle,
one strand was fluorescent labeled with AlexaFluor647 for fluorescent tracking in vivo.
In Vivo Biodistribution Experiments
KB cells were cultured in vitro and subcutaneously injected under the skin of 4week old male nude mice (NU/NU, Taconic). A total of 2 X 106 cells were injected into
each mouse. Tumors were grown for 2 weeks before mice were injected IV through the tail
vein. Mice were administered with PBS as a blank control. Mice were imaged for whole
body fluorescence at time points of 0.5, 1, 2, 4, 8, 12, and 24 h with an In Vivo Imaging
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System (IVIS) imager (Caliper Life Sciences, Waltham, MA). For this study, two mice
were used for the 0.5 through 12 h time points. At the 12 h time point, one mouse was
sacrificed and its organs removed. At 24 h the second mouse was sacrificed and its organs
removed and imaged. Tumors, hearts, kidneys, livers, spleen, and lungs were collected and
imaged on the IVIS system.
Serum Stability Assays
2’F nanosquares were assembled and purified using polyacrylamide gel
electrophoresis prior to serum degradation testing. After purification, 0.5 M fluorescently
labeled squares were incubated at 37C in 10% fetal bovine serum (FBS). Enzymatic
degradation was stopped by freezing on dry ice at 0, 1, 2, 4, 8, 16, and 32 h. Samples were
then analyzed using 2% agarose gel electrophoresis. Gels were then scanned for
AlexaFluor647 fluorescent signal. Gel band intensity was integrated using ImageJ software
(169). Values were normalized to initial band intensity and then plotted using OriginPro.
RESULTS:
Design and assembly of RNA polygons with variable size and shape
In vivo biodistribution studies of RNA nanoparticles was carried out using
previously designed, constructed, and characterized RNA polygons (150). The
nanosquares tested were designed to be 5, 10, and 20 nm along each edge (Fig 3.1A), and
were previously measured by dynamic light scattering (DLS) to be 4.0 ± 0.9, 11.2 ± 1.3,
and 24.9 ± 1.5 nm (150) while RNA triangle, square, and pentagons were each designed to
be 10 nm along each edge (Fig 3.1B) (103). Throughout this paper, the nanosquares will
be referred to by their designed edge length (5, 10, 20 nm). As previously described, RNA
polygon size is determined by selecting the number of base pairs between each 3WJ at each
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vertex, and the shape is determined by selecting the number of total 3WJs in the particle
(103,126,150). Each polygon is constructed from multiple single stranded (ss) RNA
oligonucleotides: short external strands (one along each edge), and one long core strand
connecting each external strand. RNA strands were chemically synthesized with fluorine
modifications at the 2’ sugar position of cytosine and uracil, which confers enzymatic and
thermodynamic stability (64). Polygons were assembled by mixing equimolar amounts of
each strand in buffer followed by thermal denaturation at 85 ºC and slow cooling to 4 ºC
over one hour.
A bi-partite fluorophore labeling approach, where only one of five strands was
fluorescently labeled with AlexaFluor 647, was used to confirm that the particles were not
dissociating in vivo. It has been shown previously that single stranded 2’F RNA is
eliminated within five minutes after intravenous (IV) injection (184). Therefore, if the
nanosquares were indeed dissociating, signal would have been lost within five minutes of
polygon injection.
In vivo biodistribution of RNA polygons with variable sizes
Subcutaneous xenograft tumors were developed in male nude mice with KB cells.
After tumors were fully developed (~2 weeks), 100 µL of 15 µM nanosquares harboring
chemically conjugated AlexaFluor647 were injected IV via the tail vein. Whole body
fluorescent images were taken at 0.5, 1, 2, 4, 8, 12, and 24 h (Fig 3.2). A diverse set of
biodistribution profiles is seen when comparing different size 2’F nanosquares. 20 nm
nanosquare fluorescence is observed throughout the mice at four hours, while both the 5
and 10 nm nanosquares are mainly sequestered in the tumor. As seen previously, the 3WJ
nanoparticle shows no accumulation in vital organs in mice (55-58).

63

The same trend is seen from the organ images as from whole body scans of the
mice. At 12 and 24 h, mice were sacrificed and their liver (Li), spleen (S), kidneys (K),
heart (H), lung (Lu), and tumors (T) were collected (Fig 3.3). The 5 nm nanosquare is
eliminated quickly from vital organs, localizing in only the tumor after 12 h. For the 10
and 20 nm nanosquares, fluorescence is much more intense in organs, especially after 12
h. However, 10 nm nanosquares localize only to the tumor after 24 h. Some fluorescence
is still seen in the liver and kidneys of mice injected with 20 nm nanosquares after 24 h,
however, we expect at longer time points the nanosquares would circulate out of all healthy
organs.
Serum degradation testing was performed on the 2’F nanosquares (Fig 3.4).
Nanosquares labeled with AlexaFluor647 were incubated at 37 ºC in 10% fetal bovine
serum (FBS) solution and time points were taken by immediately freezing the samples on
dry ice to stop enzymatic degradation. After incubation, nanosquares were analyzed using
2% agarose gels scanned for AlexaFluor647 fluorescent signal (Fig 3.4A). ImageJ was
used to quantify gel band intensity and values were plotted (Fig 3.4B). Gel band intensity
was normalized to the well displaying highest fluorescence intensity. The results indicate
half-lives in excess of 12 h for all nanosquare constructs. It is important to note that the
half-lives of each nanoparticle are far greater than their apparent fluorescent half-lives seen
during in vivo biodistribution experiments.
In Vivo Biodistribution of RNA polygons with variable shapes
Next, we investigate the role that shape plays in biodistribution profiles of RNA
nanoparticles using previously constructed RNA polygons: triangle, square, and pentagon.
The shape of RNA nanoparticles is easily controlled by modulating the inner angle of the
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3WJ motif, which was used as the module for polygon construction. The inner angle is
increased by extending the core strand by 22 nt, corresponding to two helix turns of A-type
RNA duplex, and adding one external strand (103). RNA polygons were assembled using
the same method as the nanosquares, mentioned above. 2’F modified polygons were used
for in vivo biodistribution analysis.
Subcutaneous xenograft tumors were developed in male nude mice with KB cells.
After tumors were fully developed (~2 weeks), 100 µL of 15 µM 2’F polygons harboring
chemically conjugated AlexaFluor647 were injected IV via the tail vein. After 12 and 24
h, mice were sacrificed, their organs collected, and imaged for AlexaFluor647 signal (Fig
3.5).
It is evident that shape plays some part in the excretion routes and times of 2’F
nanoparticles. Triangular nanoparticles appear to clear the fastest, showing only low
fluorescent signal in the kidneys after 12 h, and only fluorescence in the tumor after 24 h.
Square shaped nanoparticles show high fluorescent signal in the kidneys and low
fluorescent signal in the spleen after 12 h. However, after 24 h fluorescent signal only
remains in the tumor. Pentagon shaped nanoparticles show low signal in the kidneys after
12 h, with higher fluorescence seen in the spleen. Importantly, pentagonal, along with
triangular and square- shaped nanoparticles only show fluorescence in the tumors after 24
h of circulation.
DISCUSSION:
Effect of Size on RNA Nanoparticle Biodistribution
In cancer treatment, nanoparticles accumulate at solid tumors by taking advantage
of the EPR effect. However, EPR is principally affected by the circulation time of

65

nanoparticles (216). Larger nanoparticles generally show much higher circulation times,
allowing them to capitalize on the EPR effect. Therefore, size is an important factor for
nanoparticles that rely on the EPR effect to localize at tumors.
RNA nanoparticle size is easily controlled, and the assembly process is highly
reproducible and homogenous, resulting in narrow size distributions and batch-to-batch
reproducibility. This is an advantage of RNA nanoparticles over other systems, whose
assembly processes are less controlled. Demonstrated by in vivo biodistribution results, the
size of RNA nanoparticles greatly affects circulation time and accumulation in healthy
organs and tumors. A strong correlation between increased nanosquare size and increased
circulation time is seen, indicated by higher fluorescent signal in whole body and organ
images of mice (Fig 3.2, 3.3). There are numerous reasons for these observations. Particles
less than 15 nm, such as the 5 nm nanosquare, are excreted primarily through the kidneys,
a quicker route of elimination compared to liver excretion (129). Larger particles up to 100
nm, such as the 10 and 20 nm nanosquares, have more interaction with macrophages, and
are excreted more slowly through the liver (130). Another reason for different observed
rates of RNA nanoparticle clearance is protein binding to the nanosquares, referred to as
the protein corona (138). Differences in nanoparticle size have shown to dictate the amount
and identity of proteins bound to nanoparticles, affecting their circulation time and
excretion pathways (218). It is possible that differences in protein binding to the
nanosquares greatly effects their elimination routes and therefore how long they stay in
circulation.
Due to the high-fidelity assembly of RNA nanoparticles, they have a high
likelihood to display consistent and controllable in vivo properties. Therefore, the same
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nanoparticle system can be employed, easing nanoparticle preparation strategies, while
displaying diverse but controllable in vivo properties. Based on the trend found in this
study, it is possible that the construction of larger RNA nanoparticles would extend their
circulation times even further.
Effect of Shape on RNA Nanoparticle Biodistribution
While size is a determining factor of in vivo circulation properties of nanoparticles,
shape is also very important. Like size, the shape of RNA nanoparticles can be easily tuned.
In this study, RNA polygons of different shape but same size along each edge, were
analyzed in mouse models. The organ biodistribution was similar among the particles after
24 h, however, after 12 h there appears to be differences in biodistribution, per the intensity
of fluorescent signal in different organs (Fig 3.5). For example, nanosquares show high
fluorescence in kidneys after 12 h, while the triangle shows none, and the pentagon very
little. And in the spleen, the highest fluorescence is seen in mice injected with pentagon
nanoparticles.
Different shaped nanoparticles interact very differently with the in vivo
environment (134). The protein corona is drastically changed by the shape of nanoparticles,
which will affect the elimination pathways of nanoparticles. Additionally, previous studies
have shown that symmetric nanoparticles can increase interaction with the immune system
and trigger toxicity due to similarity in size and shape to pathogenic microorganisms (221).
While RNA nanoparticles have been proven to trigger very low immune responses (103),
shape is still something to consider and each nanoparticle should be tested to determine
immune responses.
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Additionally, when considering entry into cells, both size and shape will be very
important. Cell receptors vary in size and shape, and it will be beneficial to design
nanoparticles that can fit precisely into the receptor binding pockets, enhancing recognition
and uptake (222). This is an area where RNA nanoparticles could potentially excel, as size,
shape, and properties of RNA nanoparticles can be controlled and finely tuned to fit
specific receptors.
CONCLUSIONS:
Herein, we have shown that size of RNA nanoparticles have a large effect on
circulation time and biodistribution in vivo. A strong correlation between increased size
and increased circulation time was observed, evidenced by the increased duration of
fluorescent signal in whole body images of tumor bearing nude mice over 24 h. Despite
increased size, there was still minimal fluorescent signal in healthy organs such as the liver
and kidneys after 24 h compared to tumors. Here, shape was seen to have less effect on the
biodistribution of RNA nanoparticles. However, fluorescent signal after 12 h suggests that
elimination pathways could be different based on the shape of RNA nanoparticles. This
study demonstrates a unique property of RNA nanoparticles that allows them to evade
accumulation in healthy organs while still accumulating in tumor tissue by the EPR effect.
Importantly, we have shown that the circulation time of RNA nanoparticles can be tuned
simply by modulating their size. Circulation time is an important factor in drug delivery,
as sometimes a short-lived particle is preferred to reduce toxicity, and other times a long
circulating particle could be beneficial for slow acting therapies. RNA is an advantageous
biomaterial for nanoparticle construction, as the base pairing self-assembly mechanism
results in defined size and shape nanoparticles. Thus, in vivo drug delivery attributes, such
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as circulation time, can be controlled from the conception of the design of a nanoparticle.
It will be possible to utilize this unique property of RNA nanoparticles to enhance the
current state of nucleic acid nanotechnology and drug delivery.
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Chapter 3.2: The Effect of RNA Nanoparticle Hydrophobicity on Biodistribution
INTRODUCTION:
Interactions of nanoparticles with their in vivo environment is an important factor
and affects nanoparticle characteristics such as protein binding, toxicity, pharmacokinetics,
and biodistribution (127,128,131-133,137,141,142). Accumulation of nanoparticles in
healthy organs, such as the liver, kidneys, spleen, and lungs can lead to toxicity and lower
efficacy of the administered dose of nanoparticles. While researchers are attempting to
overcome this challenge with myriad of different nanoparticle systems, generally, less than
2% of the administered dose reaches the treatment site with the remaining dose sequestered
by filtration organs, which leads to toxicity and off-target drug effects (132).
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Recently, RNA nanoparticles derived from the packaging RNA (pRNA) of
bacteriophage phi29 have seen increased use as an in vivo delivery system (50,5558,103,126,148,150). RNA was once thought to have little potential for in vivo use due to
biological and thermodynamic stability issues. However, these issues have been solved
systematically by: (1) Finding of a thermodynamically stable three-way junction (3WJ)
motif (55); (2) Findings that chemical modifications to RNA nanoparticles confer
enzymatic stability in vivo (64); and (3) Finding that RNA nanoparticles exhibit little to no
immunogenicity in vivo (103). RNA nanoparticles are also water soluble and anionic due
to the charged phosphate backbone. RNA nanoparticles show no accumulation in healthy
organs, navigating to tumors after four hours of circulation (55,57,58).
It is well known that a nanoparticle’s size, shape, and physical properties affect
interactions in vivo, and will therefore play a large role in determining their
pharmacokinetics and biodistribution(128,134,140). Thus, tremendous efforts are made by
nanoparticle engineers to overcome inherent downfalls in nanoparticle construction. For
example, polyethylene glycol (PEG) is frequently used to increase water solubility of
otherwise insoluble nanoparticles (143,144).
Conjugation of chemicals, such as fluorophores, drugs, and targeting ligands, is a
popular method to decorate nanoparticles with functional moieties. However, many studies
using hydrophobic fluorophores (fluors) show nanoparticle accumulation in vital organs
such as the liver, kidneys, lung, and spleen (223-227). It is possible that the hydrophobic
conjugates, in this case fluors, are promoting interaction with cell membranes and plasma
proteins, causing accumulation of the nanoparticles in organs. In order for a nanoparticle
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to display low toxicity and low accumulation in vital organs, it is important to understand
how conjugation of chemicals to nanoparticles affects their in vivo properties.
Previous in vivo studies using pRNA nanoparticles were carried out using charged
and water soluble fluors to make sure the properties of the nanoparticles were not changed
drastically (55,57,58,228). However, as RNA nanotechnology progresses it will be
important to know to what extent an RNA nanoparticle can be decreased in water solubility
before accumulating in vital organs. Many potential applications such as chemical drug
delivery and ligand based targeting involve conjugation of chemical groups to RNA
nanoparticles. When chemicals are conjugated externally and not encapsulated, the impact
of the conjugate is likely to be more significant.
To investigate this, three fluors of different hydrophobicities were conjugated to
the 3WJ RNA nanoparticle to serve as model chemicals: Cyanine5.5 (C5.5); SulfonatedCyanine 5.5 (SC5.5); and AlexaFluor700 (A700). All three fluors display similar excitation
and emission spectra, despite minimal differences in their structures and solubility
(229,230). HPLC analysis demonstrated that conjugation of the fluors increased RNA
nanoparticle hydrophobicity to differing extents. Hydrophobicity induced by chemical
conjugates resulted in higher accumulation of RNA nanoparticles in vital organs of mice.
Additionally, we observed weaker organ accumulation for hydrophobic chemicals after
they were conjugated to RNA nanoparticles, suggesting that RNA can increase the
solubility of hydrophobic chemicals. To offer a physical explanation for in vivo results,
predictive compound logP (ClogP) values of the fluors and 3WJs were compared to
experimentally determined hydrophobicity scales of amino acids, which are used to predict
trans-membrane protein residues (231-234). This study offers insight into drug
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development concerning the reduction of organ accumulation and drug toxicity or side
effects of nanoparticles that are modified with chemical conjugates such as targeting
ligands, fluors for tracking, and chemical drugs.
MATERIALS AND METHODS:
RNA Synthesis and Fluor Conjugation
RNA oligomers were chemically synthesized using typical phosphoramidite
chemical synthesis on an automated oligo synthesizer. Following synthesis, oligomers
were deprotected and desalted using conventional methods (235). Each 3WJ strand was
synthesized using 2’-fluorinated cytidine and uracil. 3WJ-c strand was 5’ modified with a
primary amine (Cat. No: 10-1947-90, Glen Research). Cyanine5.5-NHS ester and SulfoCyanine5.5-NHS ester were purchases from Lumiprobe. AlexaFluor700-NHS Ester was
purchased from Molecular Probes. Conjugation reactions were carried out by mixing a 1:10
molar ratio of primary amine labeled 3WJ-c: NHS Ester-Fluorophore in 0.1 M sodium
bicarbonate buffer, pH = 8.5. The conjugation reactions were incubated at room
temperature for 16 hours while protected from light. Following incubation, the reactions
were ethanol precipitated and washed twice with cold 75% ethanol to remove the majority
of unreacted fluorophore, facilitating purification.
HPLC Purification and Analysis of RNA-Fluor Conjugates
Samples were purified using IPRP-HPLC. Due to different hydrophobicities of
each RNA-fluor conjugate, different HPLC gradient methods were used for each conjugate.
Buffer A was 0.1 M triethylamine acetate (TEAA) (Glen Research) in water and buffer B
was 0.1 M TEAA in 75% acetonitrile and 25% water. All purifications were performed
using an Agilent 1260 HPLC and Agilent PLRP-S HPLC column (Agilent Cat. No:
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PL1512-5500). A flow rate of 1.5 mL/min was used throughout all HPLC methods and
absorbance was monitored at 260 nm (RNA), 675 nm (C5.5, SC5.5), and 700 nm (A700).
3WJ-c-C5.5 was purified by a 5-100% gradient of buffer B over 15 minutes. 3WJ-c-SC5.5
was purified by 5-18% gradient of buffer B over five minutes followed by an 18-39%
gradient over 15 minutes. 3WJ-c-A700 was purified by 5-18% gradient of buffer B over
five minutes followed by an 18-38% gradient over 15 minutes. Fractions were collected
when RNA absorbance and fluor absorbance eluted simultaneously. After fraction
collection, RNA-fluor conjugates were dried to completion under vacuum.
For %ACN elution comparison, an identical gradient of 5-100% buffer B over 20
minutes was used to analyze 3WJ-fluor nanoparticles, 3WJ-c-fluor conjugates, and fluors.
%ACN elution was calculated based on elution times of RNA oligoes or 3WJ complexes.
Delay time was calculated by injection of an RNA sample in a high hydrophobic
environment (100% acetonitrile) to prevent interaction with the column. The
experimentally determined delay time was then subtracted from sample elution time, which
was then used to calculate %ACN elution.
Chromatograms were plotted using OriginPro. Plots comparing 3WJ %ACN
elution show 3WJ absorbance at 260 nm, 3WJ-Cy5.5 and 3WJ-SCy5.5 absorbance at 675
nm, and 3WJ-A700 absorbance at 700 nm. Comparison of %ACN elution of dye species
were values taken from analysis chromatograms of dye species (Fig A.2.1B, C, D). Values
were plotted and then slope determined using a linear fit.
Determination of Predictive ClogP Values
ChemDraw Professional 16 was used to predict ClogP values of amino acids,
fluors, and nucleotide-fluor conjugates. Amino acids, fluors, and nucleotide-fluor
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conjugates were drawn with charges analogous to their charged state at physiological pH
= 7.4. Only the side chains of the amino acids were used for predictive ClogP calculations.
Predicted ClogP values of amino acid side chains were then plotted versus previously
published hydrophobicity scales of amino acids (233,234,236,237). Four different
hydrophobicity scales were chosen for comparison (Fig A.2.2) and it was found that the
Cornette hydrophobicity scale was the best match to predictive ClogP values. The Cornette
scale is based on 28 published scales and demonstrates one of the best overall scales of
amino acid hydrophobicity. High values indicate higher degree of hydrophobicity.
In vivo Biodistribution
Male BALB/c mice, 5 weeks old, (Taconic) were injected intravenously (IV)
through the eye using retrorbital injection (238). At 1, 4, and 8 hours mice were sacrificed
and their hearts, kidneys, livers, spleen, and lungs collected and imaged for Cy5.5, SCy5.5,
and A700 fluorescent signal using an In Vivo Imaging System (IVIS) imager (Caliper Life
Sciences). Mice were administered PBS as a blank control. 100 L of 20 M nanoparticle
sample or dye sample were injected. It is important to note that the concentrations of dyes
was kept consistent in all in vivo experiments.
RESULTS AND DISCUSSION:
3WJ-fluor HPLC analysis
The 3WJ is composed of three component RNA oligomers: 3WJ-a, 3WJ-b, and
3WJ-c (Fig 3.6A). Mixing equimolar amounts of each component strand at room
temperature in physiological buffer yields homogeneous RNA nanoparticles (Fig 3.6B)
(55). To fluorescently label the 3WJ nanoparticles, NHS-Ester derivatives of C5.5, SC5.5,
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and A700 were conjugated to primary amine labeled 3WJ-c strand (Fig 3.6C). Fluor
conjugated oligomers were purified from un-labeled RNA by IPRP-HPLC.
Following assembly of fluor labeled 3WJ nanoparticles (3WJ-C5.5, 3WJ-SC5.5,
3WJ-A700), polyacrylamide (PAGE) gel analysis was used to determine assembly
efficiency. A decrease in migration rate of fully assembled 3WJ nanoparticles compared to
monomer and dimer species indicates successful formation at high yield (Fig 3.7A). Gels
were stained with ethidium bromide (EB) for total RNA visualization followed by scanning
for EB and fluor signal. Co-migration of EB and fluor signal indicates successful
incorporation of fluor-labeled oligomers into 3WJ nanoparticles.
3WJ particles were then analyzed by IPRP-HPLC to compare elution times and
%ACN elution (Fig 3.7B). Table 3.1 shows a summary of nanoparticle elution times and
%ACN elution. There is a strong correlation between the number of charged sulfate groups
per fluor and the %ACN elution. 3WJ-C5.5 has the highest %ACN elution of 46.39
followed by 3WJ-SC5.5 at 22.72% and finally 3WJ-A700 at 21.49%. 3WJ with no fluor
eluted at 14.13 %ACN. HPLC analysis indicates that different chemicals conjugated to
RNA nanoparticles will increase the nanoparticle’s hydrophobicity to differing degrees.
Fluorophore hydrophobicity vs biodistribution
Following HPLC analysis, the fluors were injected retroorbitally into mice and
fluorescent signal was whole body imaged 1, 4, and 8 h post-injection. Mice were then
sacrificed and their organs collected and imaged for fluorescent signal. Fluorescent signal
from whole body images show low fluorescent signal for A700 and SC5.5 and higher
fluorescent signal for C5.5 (Fig 3.8A). Organ images of the mice injected with the fluors
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all show fluorescent signal after 8 h (Fig 3.8B). These observations correlate well with the
increased hydrophobicity of C5.5 over both SC5.5 and A700.
3WJ-fluor hydrophobicity vs biodistribution
The in vivo properties of the 3WJ-fluor nanoparticles were analyzed by testing their
biodistribution profiles in mice. Mice were injected retroorbitally and sacrificed at 1, 4,
and 8 h post-injection. Organs were collected and scanned for fluorescent signal. Whole
body images indicate faster clearance of 3WJ-SC5.5 and 3WJ-A700 compared to and 3WJC5.5 (Fig 3.8). 3WJ-C5.5 showed high fluorescent signal in the organs compared to mice
injected with PBS as a blank, primarily accumulating in the liver and kidneys after 8 h (Fig
3.8B). 3WJ-SC5.5 does show fluorescence in organs after 8 h, albeit much less intense than
observed for 3WJ-C5.5. 3WJ-A700 shows no fluorescence in organs after 8 h. These in
vivo results demonstrate a strong correlation between the increased hydrophobicity of the
fluorophore and increased accumulation of nanoparticles in organs. Furthermore, these
results show the ability of the 3WJ nanoparticle to increase the solubility of the fluors as
less accumulation in vital organs of 3WJ-fluor nanoparticles is seen when compared to
fluors.
Physical basis for hydrophobicity effect on biodistribution
After in vivo results, we sought a physical explanation for our observations. One
likely explanation for accumulation of the nanoparticles is interaction with proteins and
cell membranes in vivo. It is our hypothesis that the increased hydrophobicity of the fluors
conjugated to the 3WJ nanoparticles initiates interaction with the hydrophobic regions of
proteins and cell membranes, causing the nanoparticles to accumulate in organs. Many
studies have been done on the hydrophobicity of proteins and how the amino acid
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arrangement creates pockets of hydrophobicity and hydrophilicity (231-234,236,237).
These studies have generated amino acid hydrophobicity scales, which are used to predict
hydrophobic regions in proteins and determine trans-membrane protein regions.
We hypothesized that the increased hydrophobicity of 3WJ-C5.5 was increasing
the strength of the interactions between the hydrophobic regions of proteins and cell
membranes and the nanoparticles. Because the RNA nanoparticles are extremely
hydrophilic with a hydrophobic fluor attached, we expect them to exhibit an amphipathic
property. This is akin to trans-membrane proteins, which are amphipathic to cross cell
membranes.
A logP (partition coefficient) value is the ratio of a compounds solubility in two
immiscible solvents, normally octanol: water, and is a good indication of hydrophobicity.
Additionally, logP values are useful in estimating the biodistribution of drugs. More
hydrophobic logP values generally indicate accumulation of drugs in hydrophobic areas
such as the lipid bilayers of cells, while more hydrophilic logP values indicates
accumulation of drugs in hydrophilic regions such as blood serum (239). A ClogP value
uses experimentally determined logP values of small fragments, and then adds these values
together with correction factors to obtain a ClogP value (240). When dealing with complex
molecules, such as those containing aromaticity, ClogP values tend to be quite accurate.
ChemDraw version 16.0 was used to predict the ClogP values of the amino acids
(Tbl 3.2). These values were then plotted alongside hydrophobicity values from different
hydrophobicity scales (Fig A.2.2). We chose the Cornette(233) hydrophobicity scale as we
observed the best correlation between predicted ClogP values and Cornette values (Fig
3.9A). A dotted line represents a neutral value of 0.
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Next, ClogP values of C5.5, SC5.5, and mono, di, and trinucleotide derivatives of
the fluors were predicted (Tbl 3.2). The structure of A700 is proprietary, and no structural
information was available, however, SC5.5 and A700 demonstrate similar hydrophobicity
based on IPRP-HPLC. The ClogP values were then plotted alongside ClogP values of
amino acids (Fig 3.9B). Interestingly, C5.5 displays a high ClogP value while SC5.5
displays an extremely low ClogP value. Only when C5.5 is in trinucleotide form does the
ClogP value reduce to near zero. ClogP values beyond trinucleotide form could not be
predicted due to the increased number of atoms and software limitations. However, we
expect as more nucleotides are added (54 in one 3WJ nanoparticle), the ClogP value would
drastically decrease.
Importantly, comparison of the predicted ClogP values of the amino acids with the
fluors and their nucleotide derivatives provides some insights into the effect of
hydrophobicity on cell membrane interaction. We see a highly-correlated trend between
high ClogP value and organ accumulation in vivo. We also see a highly-correlated trend
between high ClogP value and high value in the Cornette hydrophobicity scale. This shows
that conjugates with high predicted ClogP values conjugated to a nanoparticle may cause
interaction with the cell membrane, much like trans-membrane proteins.
Interestingly, while 3WJ-SC5.5 and 3WJ-A700 display similar %ACN elution by
HPLC analysis, they demonstrate different behaviors in vivo. This suggests that the
interaction of the nanoparticle conjugate with cell membranes is determining organ
accumulation, not the overall hydrophobicity of the nanoparticle conjugate. Also, factors
other than hydrophobicity, such as structure of the conjugate, could contribute to
entrapment in vital organs.
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RNA nanoparticles solubilize hydrophobic chemicals
The hydrophilic property of RNA nanoparticles enables them to solubilize many
hydrophobic chemicals. IPRP-HPLC demonstrates an increase in solubility (decrease in
%ACN elution) from fluor alone to 3WJ-c-fluor to 3WJ-fluor (Fig A.2.1B-D).
Interestingly, we see a much larger decrease in %ACN elution for the hydrophobic Cy5.5
fluor than for both hydrophilic fluors, indicated by more negative slope for Cy5.5 (Fig
3.10). The effect of RNA nanoparticles increasing solubility is evidenced by decreased
fluorescent signal in vital organs when comparing 3WJ-fluor to fluor alone (Fig 3.8B).
However, despite the high overall hydrophilicity, we still see both increased %ACN
elution and accumulation with hydrophobic cell membranes when using a hydrophobic
conjugate. This once again leads us to believe that the conjugate itself is interacting with
cell membranes, and if the interaction of the conjugate with the cell membrane is strong
enough it can overcome the hydrophilic nature of the RNA nanoparticle and the anionic
property of RNA. Thus, not only is the overall hydrophilicity of the nanoparticle important,
but so are the specific surface properties of the nanoparticle.
While this study uses fluors to demonstrate how hydrophobicity affects
nanoparticles in vivo, we expect it to extend to other conjugates such as chemical drugs or
targeting ligands. For future use, it will be beneficial to determine beforehand if a conjugate
will or will not cause nanoparticles to accumulate non-specifically in vivo. It is possible
that using a screening method, such as the one presented in this study, will greatly benefit
nanoparticle engineers looking to optimize their nanoparticle’s physical properties.
Specifically, for RNA nanoparticles, it could be beneficial to use encapsulation methods to
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protect the hydrophobic molecules from strong interactions with cell membranes or other
proteins (148).
CONCLUSIONS:
Our study demonstrates a strong correlation between increased hydrophobicity of
an external conjugate and increased accumulation of nanoparticles in vital organs.
Comparison of ClogP values of C5.5, SC5.5, and A700 to amino acids showed a strong
correlation between hydrophobic dyes, which accumulate in vivo, to amino acids that are
commonly seen in hydrophobic regions of trans-membrane proteins. Our results
demonstrate a method to pre-screen nucleic acid based nanoparticle conjugates for their
hydrophobic properties using a common method of HPLC analysis. As shown here, careful
consideration must be taken when choosing to externally conjugate chemical drugs, fluors,
or targeting ligands to water soluble nanoparticles, as their effect on water-solubility, and
in turn in vivo biodistribution, could be detrimental to the safety of patients in future clinical
settings. This study offers some insight into drug development concerning the reduction of
organ accumulation of nanoparticles and reduction of drug toxicity and side effects.
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Table 3.1. Elution Times and %ACN Elution of Fluorophore Species.
RNA-Dye
Elution Time
Conjugate
(min)
Cy5.5
22.29/26.14
SCy5.5
13.10/16.20
A700
13.19/15.07
2'F-3WJ-C
11.48
2'F-3WJ-C-Cy5.5
20.58
2'F-3WJ-C-SCy5.5
13.67
2'F-3WJ-C-A700
13.27
2'F-3WJ
10.70
2'F-3WJ-Cy5.5
19.76
2'F-3WJ-SCy5.5
13.11
2’F-3WJ-A700
12.77

%Acetonitrile
Elution
55.41/69.13
22.69/33.69
22.97/29.68
16.90
49.31
24.72
23.26
14.13
46.39
22.72
21.49
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In vivo Result
High in organs
Low in organs
Low in organs
High in organs
Low in organs
No Organs

# of Sulfate
Groups
0
4
?
2
4
?
0
2
?

Table 3.2. Amino Acid Hydrophobicity Comparisons to Fluorophore Species.

D
K
Q
P
T
E
N
S
G
A
H
W
R
Y
C
M
F
V
I
L

Amino Acid

Cornette

ClogP

%ACN Elution

Aspartic Acid
Lysine
Glutamine
Proline
Threonine
Glutamic Acid
Asparagine
Serine
Glycine
Alanine
Histidine
Tryptophan
Arginine
Tyrosine
Cysteine
Methionine
Phenylalanine
Valine
Isoleucine
Leucine
SCy5.5-NHS-Ester
SCy5.5-MonoNT
SCy5.5-DiNT
SCy5.5-TriNT
Cy5.5-NHS-Ester
Cy5.5-MonoNT
Cy5.5-DiNT
Cy5.5-TriNT
A700-NHS
MonoNT
DiNT
TriNT
3WJ-SCY5.5
3WJ-Cy5.5
3WJ-A700

-3.10
-3.10
-2.80
-2.20
-1.90
-1.80
-0.50
-0.50
0.00
0.20
0.50
1.00
1.40
3.20
4.10
4.20
4.40
4.70
4.80
5.70
-

-4.19
0.96
-0.59
0.83
-0.24
-3.67
-1.11
-0.76
-1.32
1.10
0.36
2.63
-0.45
1.97
0.65
1.37
2.64
2.28
2.81
2.68
-11.59
-14.22
-16.06
Highly Neg.
7.66
5.43
3.59
0.90
??
-4.67
-7.16
-9.85
Highly Neg.
Neut to Neg.
Highly Neg.

22.69/33.69
69.13
22.97/29.68
22.72
46.39
21.49
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Figure 3.1. (A) Structures of the 5, 10, and 20 nm 2’F nanosquares. (B) Structures of 10 nm RNA
triangle, square, and pentagon
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Figure 3.2. In vivo biodistribution time course fluorescence images of 5, 10, and 20 nm
2’F nanosquares. Mice were imaged for fluorescent signal using an in vivo imaging system
(IVIS) scanning for AlexaFluor647 signal.
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Figure 3.3. Organ images of 5, 10, and 20 nm 2’F nanosquares after 12 and 24 h. Organs
were fluorescently imaged using an in vivo imaging system (IVIS) scanning for
AlexaFluor647 signal.
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Figure 3.4. (A) Gel images of serum degradation of 5, 10, and 20 nm 2’F nanosquares. (B)
Plots of gel band intensity from serum degradation gels of 5 (green), 10 (red), and 20 (blue)
nm 2’F nanosquares.
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Figure 3.5. Organ images of 2’F RNA polygons after 12 and 24 h. Organs were
fluorescently imaged using an in vivo imaging system (IVIS) scanning for AlexaFluor647
signal.
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Figure 3.6. 3WJ Introduction and Dye Conjugation. (A) pRNA-3WJ secondary
structure and sequences. (B) Atomic force microscopy images of pRNA-3WJ with 60 base
pair extensions from each helix to show overall shape. (C) Reaction and assembly scheme
of fluorescently labeled 3WJ nanoparticles.
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Figure 3.7. 3WJ Assembly and HPLC Analysis. (A) Native PAGE assembly gels of
fluorescently labeled 3WJ nanoparticles. (B) IPRP-HPLC chromatograms of fluorescently
labeled nanoparticles. Demonstrates the effect of the fluorophore conjugation on
hydrophobicity of the nanoparticles.
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Figure 3.8. Biodistribution in Mice. (A) Whole body fluorescent images of mice IV
injected with C5.5, SC5.5, A700, 3WJ-C5.5, 3WJ-SC5.5, and 3WJ-A700. Mice were
scanned after 1, 4, and 8 h of circulation. (B) Fluorescent scans of organs.
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Figure 3.9. Hydrophobicity Comparison. (A) Plots of Cornette hydrophobicity scale
values along with predicted ClogP values of the amino acids. A strong correlation is seen
between the previously determined Cornette hydrophobicity scale and predicted ClogP
values of the amino acids. The dotted line is a value of zero. (B) ClogP values were
predicted for SulfoCy5.5 and their mono- and di-nucleotide derivatives (green), Cy5.5 and
their mono- and di-nucleotide derivatives (blue), and mono-, di-, and tri-nucleotides
(black).
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Figure 3.10. RNA nanoparticles solubilize hydrophobic ligands. Each colored line
represents a different fluorophore: SulfoCy5.5 (blue), AlexaFluor700 (pink), and Cy5.5
(red). Three species of each fluorophore were plotted: fluorophore alone, 3WJ-cfluorophore, and 3WJ-fluorophore. A decreasing %ACN elution is seen as more
nucleotides are added. Linear fitting was performed for each fluorophore. A more negative
slope is seen for Cy5.5, indicating the RNA nanoparticle can help to solubilize the
hydrophobic ligand.
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Chapter 4: Development of Three-Dimensional RNA Nanocages with
Novel Small Molecule Encapsulation and Release Mechanism

Chapter 4 was reproduced (with some modification) with permission from
Khisamutdinov, EF*; Jasinski, DL*; Li, H; Zhang, K; Chiu, W; and Guo, P. “Fabrication
of RNA 3D Nanoprisms for Loading and Protection of Small RNAs and Model Drugs.”
Advanced Materials, 2016. 28(45), 9996-20004. DOI: 10.1002/adma.201603180.
Copyright 2016 Wiley Publishing.
Special thanks to: Dr. Emil F. Khisamutdinov for help in preparation of data for
these figures; and to Dr. Luda S. Shlyakhtenko and Dr. Yuri Lyubchencko for AFM images
in figures 4.2; and to Dr. Kaiming Zhang and Dr. Wah Chiu for cryo-em images and
reconstructions in figure 4.2; and to Dr. Hui Li for cell data and confocal images in figure
4.8.

INTRODUCTION:
In RNA Nanotechnology, canonical Watson-Crick pairs combined with noncanonical base pair interactions create a large variety of RNA structural building blocks or
motifs

such

as

multi-way

junctions

(55,68,73,90,109),

kissing

loops

(12,100,101,162,241,241,241,242), and sticky ends (104,104,126) that have been utilized
to create two-dimensional (2D) RNA structures (243). Combining diverse RNA
connectivity into one nanostructure imparts complexity and allows for the addition of a
third dimension in nanoparticle design. As a result, three-dimensional (3D) RNA
nanoarchitectures have been explored (116,117,124,244). 3D nanostructures are of
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particular interest as they hold tremendous potential for the encapsulation of small
molecule drugs and therapeutic RNAs. Importantly, encapsulation may hold the distinct
ability for controlled release of therapeutic modalities. Previously reported 3D DNA cages
such as tetrahedrons, cubes, icosahedrons, and triangular prisms have been used as nanocontainers to hold proteins (245,246), gold nanoparticles (247,248), as well as organic
molecules (249). Although construction of 3D RNA nanocages has been previously
reported, their potential to encapsulate small reporter molecules, drugs, and proteins is yet
to be realized.
RNA aptamers are important candidates for therapeutic and diagnostic applications
as they display high affinity and specificity for their target molecules. Binding of malachite
green (MG), a triphenylmethane dye, to its respective RNA aptamer, the malachite green
aptamer (MGA), causes a drastic increase in MG fluorescence (212,250). This
fluorophore/RNA complex has been widely utilized as a marker in the construction of
functional RNA nanoparticles (108,124,126,152,201,251). However, the application of
MGA in vivo is limited due to RNA specific exo- and endonucleases inside cells. To
prevent this, ribose ring modification at 2’-C/U in RNA is a common strategy to enhance
RNA’s nuclease resistance (160). However, due to either structural hindrance or
redistribution of the nearest neighbor landscape, 2’ ribose sugar or other chemical
modifications can hamper the activities of aptamers selected with native RNA libraries.
For example, 2'-fluorine (2’F) modification to the MGA eliminates binding of the
fluorophore (201). Protection of RNA aptamers would be beneficial as their lifetimes could
be significantly increased, thereby increasing their utility in vivo. One possibility to extend
their lifetimes is encapsulation inside nuclease resistant nanocages.
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One advancement utilized for constructing RNA architectures was the finding of
an unusually thermostable three-way junction (3WJ) derived from the pRNA of
bacteriophage phi29 DNA packaging motor (55). The 3WJ can be used as a vehicle to
integrate multiple functional RNA modules into one nanoparticle while retaining folding
and function in vivo (12,55). Utilizing the crystal structure of the 3WJ (168), various RNA
nanoparticles including triangles, squares, and pentagons were constructed (252). Upon
systemic injection in mice, the RNA nanoparticles bind to xenograft and metastatic cells
specifically and strongly with little or no accumulation in the liver or other healthy organs
(253).
Herein, we describe a strategy to fabricate 3D RNA nanocages resembling
triangular prisms based on pRNA 3WJ. Importantly, this 3D nanoparticle was used to
demonstrate encapsulation of a small fluorescent dye, MG, while increasing its
fluorescence half-life in an RNA unfriendly environment. The modularity of the triangular
nanoprism design also allowed single strand oligonucleotide-drug conjugates to be
positioned precisely inside the inner cavity of the RNA complex. The functional properties
of the RNA nanocage to simultaneously carry 5 folate ligands for cell targeting were
further evaluated in vitro. This work paves the way towards the application of RNA based
nanocaging as a delivery system for small reporter or therapeutic molecules.
MATERIALS AND METHODS:
RNA sequence design and 3D modeling
RNA sequences were optimized using RNA 2D folding software Mfold
(www.mfold.bioinfo.rpi.edu) prior to synthesis. Computer models of the RNA prism were
assembled from two copies previously constructed RNA triangles (126). The vertices of
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the triangles were assembled by overlapping helical domains of the triangular "arms" to
position them at the correct angle and distance using the 'autofit' tool in Swiss-PDB Viewer
(www.spdbv.vital-it.ch) and manual adjustment. The detailed procedure for the triangle
design can be found in our previous reports (126). Each triangle vertex contains a 21 nt
ssRNA tethered to the 3’-end using a poly-uracil (poly-U) linker. The poly-U is inserted to
provide a hinge allowing for the flexibility of the ssRNA when hybridized with its
complementary sequence of another triangle. The resulting 21 bp RNA duplexes were
chosen to have similar lowest free-energy secondary structures (calculated ∆G =-39.0 ±
2.0 kcal/mol). The sequence of the RNA MGA module was extracted from the PDB
databank (www.pdb.org), PDB ID: 1F1T (212). Detailed 2D structures and sequence of
the nanoprisms as well as synthetic oligonucleotides containing conjugates are provided in
Tables A.3.1, A.3.2, and A.3.3.
RNA synthesis, purification and assembly
Templates for RNA transcription were prepared by standard protocols described in
detail elsewhere (105). Briefly, PCR was used to prepare transcription templates using PCR
reaction kit (Promega Corporation, GoTaq® FlexiDNA Polymerase) for the amplification
of DNA primers (IDT). Following purification of DNA templates on spin columns
(QIAGEN), the RNA strands or 2’F-U/C modified RNA strands were transcribed using
home-made T7 RNA polymerase. The RNA was precipitated with cold ethanol, then the
pellets dried and resuspended in ddH2O. Homogeneity of individual RNA strands is
checked by denaturing 10% PAGE. For assembly assays, equimolar RNA strands (0.5 µM
each) were mixed in 1 X TMS buffer. The RNA mixture was heated to 80 °C for 5 min and
slowly cooled to 4 °C over one hour in a thermocycler. RNA assembly products were
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checked on native 6% or 7% PAGE (29:1 acrylamide: bis-acrylamide ratio) in 1 X TBM
running buffer. All native PAGE experiments were run at 4ºC at constant 90 V for 2 hours.
Gels were stained in Ethidium Bromide buffer for total RNA strand visualization or in MG
binding buffer (20 µM MG dye, 10 mM HEPES pH = 7.4, 100 mM KCl, 5mM MgCl2) for
detection of MG aptamer signal as previously reported (103).
Cryo-electron microscopy
2 μl of RNA triangular prism nanoparticle solution (1 mg/ml) was applied onto a
glow-discharged 200-mesh R1.2/1.3 Quantifoil grid. The grids were blotted for 3 s and
rapidly frozen in liquid ethane using a Vitrobot Mark IV (FEI). Then the girds were
transferred to JEM2200FS cryo-electron microscope (JEOL) operated at 200 kV with incolumn filter for screening. Micrographs of 10 nm RNA prism were recorded with a direct
detection device (DDD) (DE-20 4k×5k camera, Direct Electron, LP) operating in movie
mode at a recording rate of 25 raw frames per second at 25,000×microscope magnification
(corresponding to a calibrated sampling of 2.51 Å per pixel) and a dose rate of ~20
electrons per second per Å2 with a total exposure time of 3 s. Micrographs of 5 nm RNA
prism were recorded with a 4k × 4k CCD (Gatan) at 80,000× microscope magnification
(corresponding to a calibrated sampling of 1.36 Å per pixel) and a dose rate of ~20
electrons per second per Å2 with a total exposure time of 3 s. A total 52 images of 10 nm
RNA prism and 30 images of 5 nm RNA prism were collected with a defocus range of 2~4
μm.
Single particle image processing and 3D reconstruction
The image processing software package EMAN2 was used for the micrograph
evaluation, particle picking, CTF correction, 2-D reference-free class averaging, initial
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model building and 3-D refinement of the cryo-electron microscopy data. We boxed total
2340 particles for 10 nm RNA prism and 2206 particles for 5 nm RNA prism to generate
the 2D class averages for building the initial models. Finally, 1514 particles for the 10 nm
RNA prism and 1648 particles for the 5 nm RNA prism were used for final refinement,
applying the D3 symmetry. The resolution for the final maps was estimated by the 0.143
criterion of FSC curve without any mask. 25 Å and 22 Å Gauss low-pass filter were applied
to the final 3D maps displayed in the Chimera software package.
AFM images
For all samples, specially modified mica surfaces (APS mica) were used. The APS
mica was obtained by incubation of freshly cleaved mica in 167nM 1-(3-aminopropyl)
silatrane following previously reported protocol (171). The RNA samples were diluted
with 1 × TMS buffer to a final concentration of 3 - 5 nM. Then, 5-10 µL was immediately
deposited on APS mica. After 2min incubation on the surface, excess samples were washed
with DEPC treated water and dried under a flow of Argon gas. AFM images in air were
acquired using MultiMode AFM NanoScope IV system (Veeco/Digital Instruments, Santa
Barbara, CA) operating in tapping mode.
Dynamic light scattering
The hydrodynamic diameter of the RNA nanoprisms was determined at a
concentration of 10 µM in 50 µL TMS buffer using a Zetasizer nano-ZS (Malvern
Instrument, LTD) at 25°C.
Prism MG degradation assay
The function of the MGA within the triangular prism nanoparticles was assayed by
mixing the RNA complex at a concentration of 0.1 μM with 1 μM MG dye in 1X TMS
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buffer. The solutions were allowed to equilibrate at room temperature for 10 minutes. The
fluorescence emission spectrum (recorded from 630 – 750 nm) of the complexes was
measured using a fluorospectrophotometer (Horiba Jobin Yvon) with an excitation
wavelength positioned at 615 nm. 1 µL of 500 U/µL RNase T1 (Thermo Scientific) was
added to 99 µL of the above RNA-MG complex directly in a fluorometer cuvette.
Fluorescence at λmax = 650 nm was immediately recorded and monitored every 1 sec for a
total time of 3600 sec. Fluorescence life time measurements were performed by the
software integrated within the fluorometer. The obtained data were fit using exponential
decay function I(t) = I0 e (-t/τ), where I0 is the initial intensity (at time zero) and τ is the mean
life time defined as the time for the intensity to drop by 1/e or to 37%. All fluorescence
decay experiments were conducted in triplicate with indication of ± for mean standard error
(SEM).
RESULTS AND DISCUSSION:
Computer-aided rational design and fabrication of 3D RNA nanoprism from planar
pRNA 3WJ geometry
The triangular nanoprism was designed employing the structural information of
pRNA 3WJ following a bottom-up approach (90). As such, two helices of three adjacently
arranged 3WJs were connected with duplex RNA to form flat triangular nanoparticles, a
nanoparticle construction method devised previously (126). To extend 2D triangle particles
into a 3D RNA complex, two triangular nanoparticles (T1 and T2) containing 21 nucleotide
(nt) single stranded (ss) complementary linker (L) regions on each vertex were tethered
(Fig 4.1A, Fig A.3.1). Each ssL region was designed to interact specifically with its
compliment strands L1-L1’, L2-L2’, L3-L3’ forming RNA-RNA duplex of 21 bp. To
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provide structural flexibility and allow the linkers to bend to a 90° angle necessary for
triangular prism complex, poly uracils (poly-Us) were embedded between the ssL and
triangle vertices. This resulted in the formation of a "face-to-face" dimer with a total of 8
RNA strands. The overall geometry was manually computed using SwissPDB Viewer
software (254), the structure resembling triangular prism geometry with the pRNA 3WJ
motif at the corners. The 3D RNA model displays a size of ~11 nm, measured from one
vertex to an adjacent vertex, and a size of ~10 nm measured from one vertex to its nearest
edge, as measured by the modeling software (Fig 4.1B). The largest diameter of the inner
cavity of the prism was measured to be ~7 nm while the height was ~ 6 nm. Based on these
dimensions, we assume that the central cavity of the prism could accommodate a spherical
object of approximately 6 nm in diameter.
Assembly efficiency of the RNA strands into the desired conformation was first
assayed by 6% native polyacrylamide gel electrophoresis (PAGE). Upon addition of each
of eight component strands, a step-wise decrease in electrophoretic migration can be clearly
seen, indicating association of each complimentary ssRNA oligomer into the complex
RNA structure (Fig 4.2A). The distinct band in lane 7 indicates the formation of a stable
RNA complex containing all 8 RNA strands. Integration of the intensity of gel bands results
in an estimated assembly yield of 43.0 ± 3.1%. A large fraction of RNA aggregates are
localized in the top of lane 7. Presumably, this is due to non-specific interactions between
the 21nt RNA single stranded sticky ends. Interestingly, the RNA complex with no D and
d’ stands has much a higher assembly efficiency with estimated yield of 90% (Fig 4.2A,
Lane 6).
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DLS was utilized to measure the apparent dimensions of the purified RNA prism.
As measured by DLS, the hydrodynamic diameter of the RNA complex is 11.5 ± 1.6 nm,
consistent with the 3D model structure of the nanoprism (Fig 4.2B). AFM imaging of the
pure RNA complex revealed that the particles do in fact display prismoidal-like
architecture (Fig 4.2C). AFM is 2D observation of the 3D RNA prism and cannot be used
to conclusively indicate the formation of the triangular prism geometry, nevertheless, the
particles do resemble the designed triangular prism in two dimensional projections.
Cryo-EM imaging studies revealed triangular prism geometry
To address the concern whether the folding of 8 RNA stands resulted in 3D
geometry, the purified RNA complex was visualized by single-particle cryo-electron
microscopy (cryo-EM) (Fig 4.2D, E). Cryo-electron microscopy is a useful method to
show the true 3D nature of the RNA nanoprisms, as AFM analysis causes distortion of 3D
nanoparticles imaged in 2D (255). The 3D reconstruction of the RNA nanoparticles was
achieved implementing single-particle reconstruction using the EMAN2 approach as
described in the methods section. Reconstruction of the 3D structure of the RNA complex
were determined at a resolution of 2.5 nm (10 nm RNA prism) and 2.2 nm (5nm RNA
prism), and demonstrated that the RNA particles have average sizes of 10 nm and 5nm,
respectively, in agreement with DLS and AFM results. More importantly, the overall
geometry is similar to computer modeled 3D RNA prisms. It is important to note that the
reconstruction of the RNA prism by Cryo-EM clearly demonstrates the presence of an inner
cavity. Collectively, the data from native PAGE, DLS, AFM, and Cryo-EM clearly indicate
the formation of closed and compact RNA nanoprisms.
Design and construction of RNA aptamer encapsulated nanoparticle
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The MGA is a commonly used tool in biochemistry for structure-function
verification (50,103,153). This is attributed to its unique properties as free MG dye in
solution displays little to no fluorescent signal, yet when bound to MGA the photoemission
increases more than 2000-fold (211,256). However, fluorescence can only occur if the
RNA MGA folds into its authentic 3D conformation. Previous attempts to achieve
fluorescence using 2’F modified RNA bases resulted in little to no fluorescence (201).
Therefore, for RNA MGA to remain a useful tool within a cellular environment, it must be
placed into a container that will protect the RNA. This is a common problem among many
small RNAs and small molecule drugs with therapeutic utility. Using 2’F modified RNA
to construct the prism’s frame (2’-fluoro uridine (2’F-U) and 2’-fluoro cytosine (2’F-C)),
which are known to display resistance to a degrading environment (150), we hypothesize
that the RNA MGA will be protected when positioned inside the 2’F modified nanocage.
As a proof-of-principle, we employed the MGA RNA sequence by embedding it
within the "D" and "d’" strands at their 3' ends. Throughout this chapter, we refer to the
stable RNA complex formed by six 2’F modified RNA strands without D or d' strands as
a "frame". It was interesting to find that this complex is highly stable with apparent melting
temperature (TM) of 74 °C, with the assembly efficiency being Mg2+ dependent (Fig A.3.2).
Using SwissPDB Viewer, we first modeled the complex structure of the RNA
nanocage with encapsulated MGA by positioning the 3D structure of the MGA inside the
inner cavity formed by the Nanoprism. This allowed us to estimate the distance constraint
in base pairs required to mount the RNA MGA (extracted from PDB ID: 1F1T (212)) into
the inner cavity of the prism. The complexation of the RNA MGA within the nanocage
was evaluated on native PAGE (Fig 4.3). The apparent gel shift of the band localized in
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lane 4 (2’F-RNA frame with MGA) compared to lane 1 (2’F-RNA frame only) shows
complexation of the MGA sequences with the frame structure detected by total RNA stain
with Ethidium Bromide (EB). Staining of the same gel in the presence of MG dye resulted
in strong fluorescence emission from the distinct band on lane 4, indicating correct folding
of the RNA MGA (Fig 4.3). We performed additional control experiments based on
migration properties of the closed (compact) and open (relaxed) 3D RNA complexes as it
is generally accepted that more compact RNA structures migrate faster in comparison to
relaxed RNA conformations. To fabricate the open 3D prism conformation, the interaction
of one of the complementary sticky ends linking two RNA triangles together were
intentionally disrupted though sequence design. Comparing migration of the open RNA
prism to the closed version revealed slight differences in migration distance (Fig 4.3:
Lanes 4 and 5, Fig A.3.3). This indicates that the prism is closed and that the MGA was
located, presumably, within the inner cavity of the nanocage. Data obtained from the
mobility shift assay alone do not provide a concrete conclusion whether the RNA MGA
formed inside of the closed cage; additional data supporting our assumption comes from
RNase T1 cleavage experiments as described below.
RNase T1 protection assay confirmed the encapsulation of the MG RNA aptamer by the
nanocage
Encapsulation of an RNA module inside the negatively charged RNA nanoprism is
challenging due to the repulsion forces caused by the negatively charged phosphodiester
backbone of both the inner cavity of the RNA cage and the RNA MGA. Development of a
method to overcome this challenge would be exceptionally beneficial as the activity of
functional RNA modules could be retained by protecting them from enzymatic degradation
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in vivo. To further confirm that the RNA MGA was localized inside the cavity of the
nanocage, we treated the RNA complex with endonuclease RNase T1, which specifically
cleaves unpaired guanosine (Gs) nucleotides (257). While the single stranded Gs are absent
from the 2’F-RNA prismoidal construct, there are several ss Gs present in the RNA MGA
itself that are essential for MG binding. Thus, we hypothesize that RNase T1 will cleave
the exposed Gs of the MGA sequence resulting in the loss of fluorescence. However, if the
cage were to restrict RNase T1 access to the MG aptamer within the nanoprism,
fluorescence emission would be retained or decay at a slower rate.
According to the modeled 3D structure of the prism, the estimated average
dimensions of the inner cavity of the prism could accommodate a spherical object of about
6 nm. The average size of the RNase T1 structure was measured (PDB ID: 1YGW) to be
3.7 nm in diameter (258) (Fig 4.4) allowing RNase T1 to easily access the inner cavity and
quench the fluorescence of the MGA. To address this obstacle, a nanoprism having a
smaller cavity size of 3 nm was designed by decreasing the length of the RNA prism helical
regions by one half. The schematic design of the experiment is summarized in Figure 4.5B.
The smaller prism is expected to insulate the MGA from RNase T1 cleavage, thus
extending fluorescence activity.
The assembly of the small prism is highly efficient, and RNA MGA is functional
according to native PAGE analysis (Fig 4.5C: Lanes 1 and 2). Next, we carried out timedependent MG fluorescence decay in the presence of RNase T1 to test the activity of the
MGA embedded inside the large and small nanoprisms. Figure 4.5D shows the
fluorescence decay profiles of the large (black squares) and small (red circles) nanoprisms.
The calculated lifetimes () were found to be 445.5 sec and 781.4 seconds (s) for the large
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and small nanoprisms respectively. The small prism displayed a half-life almost double
that of the large prism, suggesting that RNase T1 has limited access to MGA encapsulated
inside of the small nanoprism. Complete protection against RNase T1 has not been
observed presumably due to the dynamic nature of the interacting linker arms of two
triangles. This is also supported by AFM images where fractions of prisms are in an open
state, which allows RNase T1 to digest the MGA. Notably, fluorescence emission of the
small prism was still observed after 1 hour of incubation with RNase T1 while fluorescence
in the large prism was negligible (Fig 4.5E). Additional control experiments were
performed using a variety of other RNA control complexes containing RNA MGA. The
calculated values of  are summarized in Table 4.1. Mean lifetime comparison of the small
RNA prism to the controls demonstrates that no control construct has greater  than the
small prism. Thus, the RNase T1 cleavage assay indicates the successful encapsulation of
MGA encapsulated in both the small and large nanocages. More importantly, we have
shown that by tuning the size of the inner cavity, fluorescence half-life can be significantly
increased. This is synonymous with increasing the release time of a drug that can be
potentially used an in vivo system.
Encapsulation of oligonucleotide-drug conjugates inside the nanocage
Taking advantage of the programmability of the D and d’ prism strands, we next
demonstrated the encapsulation of single stranded oligodeoxynucleotides (ssODN)
containing functional moieties such as fluorescence reporters and drugs. To this end, one
long ssRNA was designed to connect D and d’ strands through a 22 nt linker. The resulting
RNA sequence will be referred as a “core” RNA strand. While the 5’- and 3’-ends of the
core RNA strand interact with the triangular edges of the prism, its single stranded middle
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region is designed to localize inside the nanocage. The portion of the core strand inside the
prism was utilized for encapsulation of either ssDNA or ssRNA carrying different
functional groups via base pair hybridizations (Fig 4.6A). Hence, we anticipate that the
encapsulation of the functional moieties will prevent them from enzymatic degradation and
increase their cellular life-time. Alternatively, this principle can be applied as a safety
mechanism. For instance, carrying highly toxic compounds that should be released only
upon reaching its target.
Due to the programmable nature of the RNA prism, the size of the nano-container
can be adjusted by simply increasing or decreasing the sides of the prism by complete
helical turns as shown previously (150,228). This is advantageous as the capacity of the
RNA nano-container can be controlled enabling encapsulation of diverse size biomolecules
or inorganic nanoparticles, as well as increase the payload of a single nano-container for
increased detection sensitivity and increased efficacy in the treatment of disease. Moreover,
from a medical point of view, size alternation of the nano-prism imparts differences in
toxicity, cellular binding and internalization, renal clearance, physicochemical features, as
well as pharmacokinetic and biodistribution profiles. As such, the prismoidal nanocontainer provides a unique system to further exploit these factors.
The principle behind chemical drug encapsulation relies on the conjugation of a
drug at the 3'/5'-end or at both ends of DNA /RNA oligonucleotides, followed by
hybridization of this conjugate inside the cavity of the RNA nanoprism. To demonstrate
this in practice, short DNA sequences (22nt) labeled at the 5’-end with different chemicals
including folic acid (FA), cyclodextrin, taxol, Cy5 fluorophore, and biotin. To verify the
formation of the RNA nanoparticle with the conjugated DNA sequence, prism strands and
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corresponding DNA oligonucleotides were assembled in one-pot by mixing at equimolar
concentrations, followed by native PAGE analysis (Fig 4.6B). Formation of distinct bands
corresponding to the frame structure and frame containing the core RNA sequence are
shown in Figure 4.6, lanes 1 and 2, respectively. The additional lanes correspond to loaded
nanocage with the 22nt DNA containing a variety of small molecules. Based on the slower
rate and almost identical distance of all five loaded cargoes as compared to the bands in
lanes 1 and 2, we can conclude that the conjugated ssDNA were successfully hybridized
inside the nanocage structure. Additionally, co-migration of Cy5 and EB signal of Cy5
loaded nanocage indicates correct assembly.
To demonstrate incorporation and function of the DNA-biotin conjugate within the
RNA 3D cage, biotin-streptavidin binding was utilized (259) (Fig 4.6C). To separately
visualize the biotin-nanoprism and the streptavidin, the DNA-biotin conjugate was tagged
with Cy5 and the streptavidin with Cy3. The ensuing gel shift assay demonstrated
complexation between the encapsulated biotin and streptavidin as the complex migrates
much slower than the biotin-nanoprism or streptavidin alone (Fig 4.6C: Lane 1 vs Lane 2
and 5). Co-localization of EB (RNA), Cy3 (streptavidin), and Cy5 (DNA-biotin) signals
in the distinct band in lane 1 reveals the functional properties of the encapsulated molecule
(Fig 4.6C). Although PAGE results cannot directly confirm whether the functionalities
were located inside the nanocage, results based on computer modeling and fluorescence
functional assays are a strong indication of the encapsulation mechanism. Utilizing the
programmability of RNA D and d’ strands as well as modularity of the ssDNA-drug
conjugates we were able to demonstrate feasibility of the encapsulation approach, in
addition to RNA MGA aptamer encapsulation, for caging of small molecules and proteins.
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Varying RNA Chemical Modifications Allows Control over Nanoprism Serum Stability
and Drug Release
One potential advantage of RNA 3D nanocontainers is the ability to safely deliver
and release encapsulated drugs in a fine-tunable fashion. Development of controlled release
is extremely challenging yet highly desirable in RNA nanotechnology (90). To release the
encapsulated drug(s), one approach is to use the help of naturally occurring nucleases
to break down RNA 3D nanoscaffold. It was our hypothesis that changing the percentage
of 2’F nucleotides in the nanoprism scaffold would result in diverse degradation profiles.
To change the amount of 2’F nucleotides in the nanoprisms, the ratio of 2’F cytidine
triphosphate (CTP) and uridine triphosphate (UTP) nucleotides to unmodified CTP and
UTP were adjusted during in vitro transcription reactions to 4:0, 3:1, 2:2, 1:3, and 0:4,
respectively. After transcription and purification, five different nanoprisms were
assembled with 2’F-C/U modifications of approximately 100%, 75%, 50%, 25%, and 0%.
The degradation profiles of each nanoprism were observed over the course of one hour in
2% fetal bovine serum (FBS) solution at a final concentration of 200 nM and analyzed on
3% agarose gel (Fig 4.7A). Gel band intensity was integrated using ImageJ software and
intensity at each time point was compared to initial gel band intensity for each individual
nanoprism (Fig 4.7B). As shown by the time course plot, decreasing the percentage of 2’F
nucleotides increases the digestion rate of the nanoprism scaffold. This approach shows
feasibility of controlled drug release by degradation of the partially 2’F modified nanocontainer, which can be fine-tuned to the scale of minutes.
In vitro cell binding studies revealed high binding affinity to cancer cells by RNA
nanocage carrying ssDNA-Cy5.
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The ability of the RNA nano-container to successfully bind and deliver drugs or
reporter molecules into cancer cells would tremendously benefit the advancement of
nanomedicine. To investigate whether the RNA nanocage can serve as a container to
deliver small molecules, the 2’F RNA frame structure was decorated with 5 copies of DNA
oligonucleotide-folate conjugates and 1 copy of DNA-Cy5, as shown in Figure 4.8
(Assembly in Fig A.3.4). Folate-containing nanoconstructs are known to have a strong
affinity to cancer cells of epithelial origin as these types of cancer cells overexpress folatebinding protein receptors (260). After incubation of the folate functionalized RNA
nanoprism with KB cells, strong binding of the RNA complex with the cells was observed
(Fig 4.8A) in comparison to control complex having the same RNA 3D nanostructure but
lacking folate molecules. This result demonstrates applicability of the 3D RNA system for
detection and delivery of the reporter molecules.
CONCLUSIONS:
The proof-of-concept for a technique to construct 3D RNA nanocontainers to
encapsulate small RNA molecules and a method for loading the nanocontainers with model
drugs was demonstrated. The assembly of RNA triangular nanoprism utilizes pRNA 3WJ
motifs positioned at the prism vertices, imparting stability into the system and allowing for
future in vivo delivery. Loading the container with model drugs (MG) was accomplished
via diffusion of the model drug into the container with subsequent immobilization by RNA
receptors (MGA) pre-encapsulated within the nanoprism. The concept of RNA aptamer
encapsulation is a promising platform for exploring new applications in pharmaceutical
and materials science. The RNA-directed triangular prism brings together the functionality,
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biocompatibility, and self-assembly potential with fine control of geometry, positioning,
and the responsive characteristic of RNA nanoparticles.
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Table 4.1. Fluorescence half-lives of prism constructs and control constructs. a The
analysis of the electrophoretic migration of controls 2 and 3 are shown in Figure A.3.4.
b.

The standard error of the mean was obtained from three independent experiments.
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Figure 4.1. Triangular Nanoprism design and 3D model structure. (A) Fabrication of
the triangle nanoprism from two planar equilateral RNA triangles. The triangle prism
nanostructure forms by hybridization of the flexible 21 nt ssRNA “linkers” of each triangle.
The overall prismoidal construct contains the preserved geometry of the pRNA 3WJ
structural building block. (B) Computer model structure of the triangular nanoprism
demonstrating its average dimension in 3D space.
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Figure 4.2. RNA Triangular nanoprism self-assembly and characterization. (A)
Assembly efficiency of the RNA triangle nanoprism complex evaluated by 6% native
polyacrylamide gel electrophoresis (PAGE). Step-wise association of the 8 RNA strands
(0.5 µM each) into the final complex was conducted in 1 X TMS buffer using one-pot
assembly. (B) Typical dynamic light scattering (DLS) data demonstrating average
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hydrodynamic diameter of the prism. (C) Atomic force microscopy (AFM) images of the
triangle nanoprism (5 nM) taken in air. (D) CryoEM image of the large (10 nm) triangular
RNA prism. Each white box indicates an individual RNA complex. Class averages of RNA
nanoprisms as observed by cryo-EM. Reconstructed three-dimensional nanoprism at 2.5
nm resolution. (E) CryoEM image of the small (5 nm) triangular RNA prism. Each white
box indicates an individual RNA complex. Class averages of RNA nanoprisms as observed
by cryo-EM. Reconstructed three-dimensional nanoprism at 2.2 nm resolution.
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Figure 4.3. Assembly of triangular prism and MG fluorescence assay. Fluorescence
emission in lane 4, and faster migration than in lane 5, indicates the formation of compact
triangular nanoprisms with encapsulated MG aptamer.
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Figure 4.4. Swiss PDB viewer was used to fit RNase T1 inside the designed 3D nanoprism.
The inner cavity of the large prism will fit RNase T1 inside, allowing digestion of the MG
aptamer. RNase T1 cannot fit inside the small prism, enhancing the fluorescence half-life
of MG.
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Figure 4.5. Encapsulation of the RNA MGA and fluorescence assay. (A) Schematic
design approach for the RNA MGA encapsulation. The RNA MGA sequence is embedded
within the 3’-end of D and d’ strands. Upon hybridization MGA folds into native
conformation. (B) Schematic representation of the RNase T1 protection experiment
demonstrating the relative dimensions of RNase T1 and nanoprisms. (C) Assembly
efficiency and relative migration of the triangle prisms on native 6% PAGE. The smaller
RNA prism migrates much faster compared to the regular prism and emits fluorescence
signal indicating proper folding of the functional RNA complex. Lane “L” is 100 bp DNA
ladder (Thermo Scientific). (D) Time-dependent fluorescence emission profile of the 0.1
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µM RNA MGA aptamer in the presence of 500U of RNase T1 and its absence (control).
(E) The remaining fluorescence signal of the triangle prisms after one hour of RNase T1
treatment.
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Figure 4.6. (A) Schematic of ssDNA and ssRNA oligonucleotides with functional modules
encapsulation inside of the triangular nanoprism. (B) Assembly of encapsulated functional
modules conjugated to ssRNA and ssDNA oligonucleotides. (C) Encapsulation and
functional assays of streptavidin encapsulation inside the triangular nanoprism.
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Figure 4.7. Tuning degradation profile of nanoprism in fetal bovine serum. (A) Gel
images of nanoprisms with different percentages of 2’F modified pyrimidines used during
assembly. Nanoprisms of 200 nM concentration were incubated in 2% FBS solution and
analyzed by 3% agarose gel. (B) Prism relative gel band intensity plotted versus time. The
intensity of each band was normalized to the zero time point for each nanoprism.
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Figure 4.8. Evaluation of the RNA triangle prism to carry functional moieties.
Confocal microscopy images of KB cells incubated with RNA nanoprism decorated with
5 folates as targeting modules.
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Chapter 5: Large-scale In Vitro Synthesis and Purification of RNA
Nanoparticles using Rolling Circle Transcription (RCT)

Chapter 5 was reproduced (with some modification) with permission from Jasinski,
DL; and Guo, P. “Co-Transcriptional Assembly of RNA Nanoparticles via Rolling Circle
Transcription of Fully Double Stranded Circular DNA.” Currently under submission and
Jasinski, DL; Schwartz, CT; Haque, F; and Guo, P. “Large scale purification of RNA
nanoparticles by preparative ultracentrifugation.” Methods in Molecular Biology. 2015.
1297, 67-82. DOI: 10.1007/978-1-4939-2562-9_5.

Chapter 5.1: Co-Transcriptional Assembly of RNA Nanoparticles via Rolling Circle
Transcription of Fully Double Stranded Circular DNA
INTRODUCTION:
RNA nanotechnology is an emerging field that has grown in complexity and
diversity, as RNA is an attractive material to construct nanostructures with defined physical
properties (38,90,126,261-263). Many apparent issues of RNA instability were overcome
to achieve a nanoparticle platform with potential for treatment of disease, especially cancer
(62-64,90). Targeting aptamers and functional RNAs such as siRNA, miRNA, ribozymes,
and riboswitches are available to construct diverse multi-functional nanoparticles.
Development of RNA nanotechnology has been accelerated by the finding of an unusually
stable three-way junction (3WJ) RNA motif from the packaging RNA (pRNA) of the phi29
DNA packaging motor (55). The 3WJ has been used for targeted delivery of therapeutic
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modalities to multiple cancer types and has been used as a scaffold for the construction of
RNA nanoparticles with controllable size and shape (56,60,103,148,150,264-266).
In a lab setting, RNA is most commonly synthesized by two methods: in vitro runoff transcription and chemical synthesis. While useful and widespread, both methods have
their limitations. Chemical synthesis is hindered by limits on length and low RNA coupling
efficiency while in vitro run-off transcription is limited by yield and time efficiency due to
delayed RNA polymerase binding and initiation (219,267-269).
Isothermal amplification of nucleic acids, rolling circle amplification (RCA) for
DNA and rolling circle transcription (RCT) for RNA, are gaining popularity due to the
simplified processes for amplification and the unique capabilities of RCA and RCT
(125,270,271). Isothermal reactions can be carried out in conjunction with other biological
processes or in the presence of sensitive enzymes that would otherwise be destroyed by
heating during thermocycling. Sensitive detection systems using padlock probes and
fluorescent nucleic acid sequences have also been used for the detection of antigens or
nucleic acids such as mRNA or miRNA (272,273).
RCT is especially useful as there are many functional RNA motifs, such as
aptamers, miRNA, siRNA, and ribozymes that can be continually synthesized in a normal
RCT reaction. Short single stranded (ss) circular DNAs encoding for ribozymes that selfprocess into unit length functional ribozymes have been synthesized. These ribozymes
show biological functionality in trans, cleaving HIV-1 RNA targets (274,275). RCT has
been used to synthesize siRNA loaded microsponges that show successful gene knockdown
in vivo (38,270,276). Showing the versatility of RCT, nanowires (277), millimeter sized
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RNA membranes (278), mRNA nanoparticles (279), and tandem repeats of fluorogenic
RNA aptamers have all been synthesized (280).
While functional RNA motifs are useful in therapeutic settings, RNA biology could
be implemented to produce defined RNA oligomers during RCT by, for example, using
self-cleaving ribozymes (281-283). Previous methods to create defined RNA oligomers
include the use of ssDNA oligomers and RNAseH during RCT, allowing site-specific
cleavage (284). Encoding for a self-cleaving ribozyme in the DNA template for RCT will
allow simpler experimental processes and more widespread application. Additionally, in
vivo expression of specific RNA oligomers and RNA nanoparticles could be possible.
Increased use of nucleic acids in nanoparticle applications necessitates the
development of high yield synthesis methods other than those available today. RCT’s
increased transcription efficiency over traditional run-off transcription could help to
increase the production yield of RNA oligomers and RNA nanoparticles (125). In vitro
transcription is not limited by length and one-strand or multi-strand nanoparticle assembly
can occur co-transcriptionally, which has been shown to increase assembly efficiency
(191,285).
However, traditional methods of circular DNA preparation for RCT are not
amenable for DNA templates displaying stable secondary structure. Bacterial RNA
polymerases are sensitive to secondary structure, falling off template DNA when
encountering stable DNA hairpins and loops (125,274,286). Ribozymes have a stable
secondary structure and when combined in the same ssDNA template as an RNA
nanoparticle sequence, the ∆G of the DNA template is quite low. For successful
transcription of a circular DNA encoding for self-cleaving ribozymes and nanoparticle
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sequences, it was necessary to develop a new method for the construction of short circular
dsDNA for transcription to process in an RCT reaction. While other short dsDNA
molecules have been constructed through click chemistry, we questioned if disturbing the
phosphate backbone could cause polymerase stalling and dissociation (287).
Herein, we describe a method for the construction of short circular dsDNA
templates that code for self-cleaving ribozymes and RNA oligomers or RNA nanoparticles.
Upon in vitro transcription, the ribozymes self-cleave with high efficiency, producing large
amounts of target RNA. The phi29 pRNA 3WJ was assembled from its three component
strands both co-transcriptionally and by self-assembly after RNA oligomer purification.
Also, single strand RNA nanoparticles were synthesized via RCT by addition of loops to
link adjacent 3WJ strands. The malachite green fluorogenic RNA aptamer (MGA) was
fused to one helix of the 3WJ and malachite green dye (MG) fluorescence was observed in
real time during in vitro transcription. SYBR GreenII fluorescence, a dsRNA specific
fluorophore that fluoresces only upon binding to RNA, was also used to monitor
transcription in real time. Fluorescent signals from transcription reactions using circular
dsDNA were 8-10 times higher compared to identical sequences in linear dsDNA,
indicative of the increased efficiency of the RCT reaction.
MATERIALS AND METHODS:
Sequence Design
Sequences for target oligomers were derived from the pRNA-3WJ nanoparticle as
reported previously (55). Additional nucleotides were added to the 5’ and 3’ ends of the
native 3WJ sequences, 5’-GAC-3’ and 5’-GUC-3’ respectively, aiding in ribozyme
stability and cleavage efficiency. For the synthesis of single stranded RNA nanoparticles,
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loops (5’-GAGA-3’) were used to join adjacent 5’ and 3’ ends of the multi-strand RNA
nanoparticles. Ribozyme sequences were adapted from previously solved structures of the
hammerhead ribozyme (283). For ribozyme efficiency assays, ribozyme sequences were
mutated to abolish activity as previously described (283). The malachite green aptamer
sequence was adapted from previously published sequences (212). All sequences are
summarized in Table A.4.1.
DNA and RNA Preparation
RNA oligomers were prepared in vitro using T7 RNA polymerase from linear and
circular dsDNA containing the T7 promoter. Linear dsDNA was prepared by PCR using
ssDNA primers purchased from Integrated DNA Technologies (IDT). Circular dsDNA was
prepared from ultramer oligomers purchased from IDT. The assembly method of circular
dsDNA is detailed in Figure 5.1. ssDNA anti-sense to the RNA strand (including T7
promoter, ribozymes, and target RNA) was self-cyclized intramolecularly using Epicentre
CircLigase following the manufacturer’s protocol. Remaining linear ssDNA was removed
by addition of DNA Exonuclease I. ssDNA complementary to the cyclized ssDNA was
annealed by thermal denaturation at 85°C for five minutes followed by slow cooling to 4°C
at over one hour at 4 µM concentration. Following annealing, T4 DNA ligase closed the
nick in the circular dsDNA. Ligations were performed at a DNA concentration of 2.5 µM
in 1 X DNA ligase buffer, 5% (w/v) PEG4000, and a ligase concentration of 0.25 U/µL.
The ligation mixture was incubated at 25°C for 4 hours followed by heating at 65°C to heat
denature the enzyme. Control constructs without T4 ligation were also assembled.
Gel Analysis and Quantification
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Assembly of linear and circular dsDNA constructs and RNA products was
confirmed using 10% (29:1) PAGE in a buffer containing 50 mM TRIS, 100 mM NaCl,
and 5 mM EDTA, and DNA or RNA was stained using ethidium bromide (EB) solution or
MG dye solution (final concentration of 5 M MG Dye, HEPES pH=7.4, 100 mM KCl, 5
mM MgCl2).
Ribozyme Cleavage Efficiency
Time course experiments were run to analyze ribozyme cleavage efficiency. A
typical transcription reaction was quenched at specific time points by addition of DNase.
Equal aliquots of each time point were then analyzed on PAGE and gel band intensity was
integrated using ImageJ software (169). Cleavage efficiency was calculated by dividing
band intensity of the cleaved fractions by total band intensity per lane. Cleavage percentage
versus time was then plotted using OriginPro.
Gel Analysis of Transcription Kinetics
dsDNA constructs, both linear and circular, were transcribed following typical T7
in vitro transcription protocols with a 250 nM final DNA concentration. At 0.5, 1, 2, and 4
hours, transcription reactions were stopped using DNase. Equal aliquots of transcription
from each time point were analyzed on PAGE and target RNA bands were integrated using
ImageJ software. Gels were stained separately for total RNA (EB) and MG fluorescence.
Gel band intensity versus time was then plotted using OriginPro. Gel assays were carried
out in triplicate with standard deviations indicated by error bars.
Fluorescence Monitoring of RNA Transcription
To monitor transcription in real time, MG dye or SYBR GreenII were added at a
final concentration of 5 µM to transcription reactions. Solutions were incubated at 37°C in
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96 well plates and fluorescent signal was monitored every 15 minutes using a BioTek
Synergy 4 Microplate Reader. MG signal was read from excitation and emission
wavelengths of 590 nm and 630 nm, respectively. SYBR GreenII fluorescence was read
from excitation and emission wavelengths of 496 nm and 520 nm, respectively. OriginPro
was used to plot fluorescent signal versus time. Transcription analysis was performed at
DNA concentrations of 10, 100, and 250 nM.
Large-Scale Purification Using Gel Electrophoresis Column
Transcription reactions were purified on a BioRad model 491 Prep Cell using
continuous-elution gel electrophoresis following the manufacturer’s standard protocol. 20
mL of 8% polyacrylamide gel were prepared in a buffer containing 50 mM TRIS, 100 mM
NaCl, and 5 mM EDTA. The gel was polymerized and to a column height of 5.5
centimeters and pre-run at 300 V for 1 hour. Large-scale, 1 mL transcriptions with final
DNA concentration of 250 nM, transcriptions were diluted to 2 mL with 2X gel loading
dye and loaded onto the column. After two hours of electrophoresis at 300 V, fractions
were collected at a rate of .25 mL/min for 4 minutes for a total fraction volume of 1 mL. A
total of 60 fractions were collected for four hours. Fractions were analyzed by adding 20
µL of 10 X MG binding buffer (final concentration of 5 M MG Dye, HEPES pH=7.4,
100 mM KCl, 5 mM MgCl2) to 180 µL of each fraction. Fluorescence was analyzed as
described previously. RNA concentrations were measured by reading absorbance at 260
nm.
RESULTS:
Sequence Design and Ribozyme Optimization Using Linear dsDNA
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Due to the processive nature of RCT, long RNA concatamers are the result, unless
a strategy is devised to reduce the products into defined oligomers. In our case, the goal
was to produce short RNA oligomers that would then then fold into higher order RNA
nanoparticles. Thus, self-cleaving ribozymes were incorporated into the sequences to
cleave the RNA during transcription, resulting in short RNA oligomers. However, as it was
necessary to optimize ribozyme sequence to obtain high cleavage efficiency, sequences
were first optimized using traditional run-off transcription of linear dsDNA templates.
These sequences were then used in the circular constructs, as described in a later section.
Linear dsDNA containing the T7 RNA polymerase promoter sequence, selfcleaving ribozymes 5’ and 3’ of the target RNA sequence, and the target RNA sequence
were designed and constructed using PCR (sequence layout in Fig 5.1). The initial goal
was the assembly of the pRNA-3WJ, as it is well characterized in our lab. Therefore, the
target RNA sequences for ribozyme optimization were 3WJ-a, 3WJ-b, and 3WJ-c (55).
Hammerhead ribozyme sequences were chosen as they are well characterized and display
high cleavage efficiency (281,283,288,289). Ribozyme sequence optimization was carried
out experimentally by gel analysis using linear dsDNA. While active site bases of the
ribozyme sequence must be conserved to maintain cleavage, non-active site duplex
sequences can be modified, aiding in self-cleavage optimization (281,283).
Size controls were transcribed to represent the possibilities of RNA transcript
length with and without cleavage. Failed 5’ and 3’ ribozyme cleavage, failed 5’ ribozyme
cleavage only, failed 3’ ribozyme cleavage only, and ribozyme only were used as RNA
size controls (Fig A.4.1A). Ribozyme activity was abolished in RNA size controls by
sequence mutation (283) to maintain identical sequences in RNA size controls. Target
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RNA strands were chemically synthesized as size and assembly controls. Cleavage
efficiency was calculated by comparing target RNA band intensity to total band intensity
per lane over two-hour time course experiments (Fig A.4.1B). ImageJ software was used
to integrate the gel band intensity. Cleavage kinetics assays were done using truncated
versions of the dsDNA. For example, 5’ ribozyme efficiency was assayed using dsDNA
template with no 3’ ribozyme. The cleavage efficiency of each ribozyme, 5’ and 3’ of the
target RNA, was calculated independently. Kinetics of full length constructs with
ribozymes 5’ and 3’ of the target RNA were also assayed (Fig A.4.1B).
The first iteration of ribozyme sequences contained a two base-pair (bp) “closing”
duplex resulting in cleavage efficiencies ranging from 36% - 65% cleavage. Upon
lengthening the “closing duplex” to five bp (Fig A.4.1C), to increase the stability of the
ribozyme sequence, cleavage efficiencies increased to 65% - 78%. When full length
constructs with both active ribozymes were tested, cleavage efficiencies were more than
80% (Tbl A.4.2).
Circular dsDNA Construction and RCT Reaction
Circular and fully double stranded DNA templates were prepared for the RCT
reaction (Fig 5.1). Ribozyme sequences used in circular dsDNA were identical to those
optimized previously using linear dsDNA. First, phosphorylated ssDNA complimentary to
the T7 polymerase promoter, 5’ and 3’ ribozymes, and target RNA sequences was selfligated intramoleculary using Epicentre ssDNA Circ Ligase to form circular ssDNA. To
confirm cyclization, non-denaturing polyacrylamide gel electrophoresis (PAGE) was used
to visualize DNA bands before and after ssCirc ligation (Fig 5.2A). Upon self-cyclization,
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an increase in migration rate is seen presumably due to the compact structure of the now
self-folded ssDNA.
To form circular dsDNA, the cyclized ssDNA and phosphorylated ssDNA
compliment were mixed in equimolar concentrations. ssDNA strands were thermally
denatured at 85°C for five minutes to remove any secondary structure, and then cooled to
4°C over one hour. Assembly of the compliment strands was confirmed using PAGE
analysis. Assembly of the compliment strands resulted in a dramatic decrease in migration
rate, indicating successful hybridization (Fig 5.2A). Importantly, compared to linear
dsDNA controls, circular dsDNA migrates much slower, indicating circular conformation.
After assembly, T4 DNA ligase was used to ligate the nicked circular dsDNA (Fig 5.2A).
No apparent shift is observed by gel analysis after T4 ligation. Successful T4 ligation can
be confirmed using in vitro transcription.
To prove RCT was occurring, ribozyme activity was abolished by sequence
mutation on one circular dsDNA construct (Fig 5.2B) (283). No ribozyme activity will
result in template length RNA using linear dsDNA template and long concatemeric RNA
using circular dsDNA template. The target RNA sequence in this assay was 3WJ-a for both
active and inactive ribozyme constructs. After in vitro transcription and termination by
DNase, denaturing PAGE analysis was used to analyze RNA transcripts (Fig 5.2B).
Significant accumulation of long RNA transcripts is seen from the RCT reaction (Fig 5.2B,
Lane 5) compared to transcription of both the linear dsDNA template (Fig 5.2B, Lane 3)
and the nicked circular dsDNA template (Fig 5.2B, Lane 4), indicating successful
construction of circular dsDNA and successful RCT reaction. When ribozyme activity was
restored, successful cleavage and release of target RNA strand was observed (Fig 5.2B,
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Lanes 6-8), evidenced by the appearance of short RNA transcripts not seen in inactivated
ribozyme constructs. Assembly confirmation of all circular dsDNA constructs is shown in
Figure A.4.2.
Co-Transcriptional Assembly of 3WJ Nanoparticles
RNA nanoparticles have the unique ability to self-assemble co-transcriptionally, as
they are being transcribed, under isothermal conditions (191,285). To assemble the pRNA
3WJ co-transcriptionally, 3WJ-b and 3WJ-c were incorporated into separate circular
dsDNA constructs. The transcription of both 3WJ-b and 3WJ-c constructs were confirmed
using PAGE analysis. Both constructs demonstrated correct cleavage and release of their
target RNA in both linear and circular form (Fig 5.2C, red box). Compared to linear
dsDNA controls, the band patterns of circular dsDNA are identical. Size controls of failed
transcripts and resulting ribozyme sequences migrate much slower than the target RNA,
further showing evidence of target RNA release (Fig 5.2C). Additionally, target RNA
strands are equal in size to that of their chemically synthesized size controls, indicating
cleavage and release of correct size ssRNA target sequences (Fig A.4.3A). To confirm the
sequence of released ssRNA was correct, each fragment was isolated by gel purification.
Assembly of the pRNA-3WJ from the ssRNA fragments isolated from the RCT reactions
indicates cleavage specificity and target RNA release (Fig A.4.3B).
pRNA 3WJ nanoparticles were assembled co-transcriptionally by mixing 3WJ-a,
c, and c dsDNA constructs in an equimolar ratio followed by in vitro transcription. PAGE
analysis of both linear and circular co-transcription products indicates successful assembly
of 3WJ nanoparticles when compared to the assembled 3WJ from gel purified RCT product
(Fig 5.2D).
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Alternatively, 3WJ nanoparticles were co-transcriptionally assembled from one
ssRNA oligomer. Circular dsDNA encoding for the full sequence of the pRNA-3WJ, with
the helix ends closed with loops or aptamer sequences, was constructed (Fig 5.3A). To
facilitate monitoring of transcription and RNA folding, the MGA was incorporated on one
of the helix loops (Fig 5.3B). Following transcription, the RCT reaction mixture was
analyzed by non-denaturing PAGE (Fig 5.3C). Total RNA staining with ethidium bromide
indicates correct size RNA oligomers compared to the DNA ladder. RCT-3WJ assembled
from purified 3WJ monomers and one piece 3WJ with loops were used as size controls.
The one-stranded nanoparticles migrate slower due to increased size from the incorporation
of loop sequences used to connect helix ends. Additionally, gel staining with MG shows
binding of the MG-3WJ nanoparticle to its fluorophore, indicating correct sequence and
folding of the MG-3WJ as the MGA must fold correctly to produce MG fluorescence. No
MG signal from the 3WJ, which lacks the MGA, indicates specific binding of MG to MGA
in the MG-3WJ. Higher order concatamers (dimers, trimers, etc.) are present in the RCT
reactions, indicating that ribozyme cleavage is not 100%.
Real-Time Monitoring of Transcription by Fluorescence
Fusion of the MGA onto the 3WJ allows for monitoring and comparison of
transcription kinetics between traditional run-off transcription and RCT (Fig 5.4A). Gel
assays were used to compare the transcription rate of linear and circular dsDNA (Fig 5.4B).
After in vitro transcription was commenced, DNaseI was added at 0.5, 1, 2, and 4 hours to
terminate the transcription reaction. After termination, an equal aliquot of transcription
reaction was analyzed by PAGE. Gels were separately stained for total RNA, ethidium
bromide (EB), and for MG signal. ImageJ software was used to integrate gel and intensity.
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The integration results clearly show that RCT generates RNA nanoparticles much faster
with a higher yield than that of run-off transcription (Fig 5.4C).
To monitor transcription rates in real-time, transcription was analyzed using a
BioTek plate reader monitoring transcription kinetics in a 96-well plate. MGA fluorescence
was monitored by adding MG dye to a final concentration of 5 M in the transcription
mixture while total RNA production was monitored by adding SYBR GreenII, an RNA
specific probe which fluoresces only upon binding to RNA, to a final concentration of 1 X
to the transcription mixture. Fluorescence measurements were taken every 15 minutes and
fluorescence intensity was plotted versus time using OrignPro (Fig 5.4D, E). Among three
different DNA template concentrations of 10(), 100 (), and 250 () nM, the RCT
reactions (red lines) consistently outperformed run-off transcription (black lines) in both
nanoparticle production rate and overall transcription yield. Across the three DNA template
concentrations, RCT produced on average 10 times more RNA at the termination of the
transcription reaction, consistent with previous findings on the rate of RCT (125,280).
Interestingly, circular dsDNA template with a nick present, without T4 ligation, is similar
in transcription rate to linear dsDNA at the same concentration, suggesting that T7
polymerase does not proceed to RCT with nicked circular dsDNA (Fig 5.4D, E).
Next, substrate (DNA template) concentration dependent kinetics of total RNA
transcription was analyzed by comparing SYBR GreenII fluorescence values at different
time points among different DNA template concentrations (values from Fig 5.4E). Time
points from 60 – 165 minutes were chosen as these were during and after the highest
increase of observed fluorescence. Fluorescence values from 10, 100, and 250 nM
concentrations at each time point were plotted and fit linearly (y = mx + b) (Fig A.4.4A,
134

B). A strong linear correlation is seen between different DNA template concentrations
relative to their RNA output, represented by SYBR GreenII fluorescence (Fig A.4.4C).
Interestingly, the slope (x) values for circular DNA template, x average equal to 5.27, are
much higher than those observed for linear DNA template, x average equal to 1.27. These
values can be correlated to fluorescence output per nM (RFU/nM) of DNA template. Thus,
these results support that RCT reaction results in an apparent increase in transcription
efficiency. At these DNA template concentrations, the relationship appears to be linear.
However, as biological systems are quite complicated, it is possible that higher DNA
concentrations could saturate the transcription reaction.
Large-Scale Purification Post RCT
Purification of the MG-3WJ nanoparticles was carried out using a prep-scale
version of typical gel electrophoresis. The BioRad Model 491 Gel Electrophoresis Prep
Cell was used to purify large-scale transcription products of RNA nanoparticles transcribed
from circular dsDNA encoding for the MG-3WJ. Fractions were analyzed for both MG
fluorescent signal and absorbance at 260 nm (Fig 5.5A). Three distinct peaks were seen by
MG fluorescence: fractions 5-7 (peak 1), 7-23 (peak 2), and 25-32 (peak 3). PAGE analysis
was used to determine the identity of each peak compared to crude transcription mixture.
Each lane was loaded with ~200 ng of RNA sample, based on absorbance at 260 nm. Peak
1 was smaller in size than the target RNA, peak 2 contained the target RNA, and peak 3
contained both the target RNA and larger RNA bands. Gel bands were integrated to
determine purity with peaks 2 and 3 giving averages of 93.6% and 84.2%, respectively. Of
note is the large absorbance value of the first fractions, which has been attributed to
remaining nucleotides from the transcription mixture, as no band was seen by gel analysis.
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DISCUSSION:
RCT offers many advantages over traditional in vitro transcription methods
including higher transcription rate (125,280), template DNA economy, and the potential
for in vivo expression of artificial RNA sequences and RNA nanoparticles (153). The most
popular method for circular DNA preparation contains a long ssDNA phosphorylated at
the 5’ end, which is assembled to a splint ssDNA followed by DNA ligation, resulting in
circular DNA with double stranded promoter region and single stranded regions
complimentary to the target RNA sequence. Alternatively, ssDNA templates with no
promoter region can also be transcribed. While this method is amenable for ssDNA
templates with little secondary structure (∆G of self-folding close to zero or a positive
value, Tbl A.4.3) (125,275,290,291) or stable dumbbell sequences (38,270,280,292), it
was not amenable for ssDNA templates encoding for 3WJ based nanoparticles. The ∆G of
self-folding for the ssDNA templates constructed here range from -11.6 kcal/mol to -27
kcal/mol (Tbl A.4.3), resulting in stable secondary structures. Transcriptions using current
methods for preparing circular DNA template were attempted, however the stable
secondary structure of the sequences hindered transcription, despite successful ligation,
even in the presence of single stranded binding proteins and elevated transcription
temperatures at 42°C (data not shown).
Therefore, a new method for circular DNA template preparation was conceived
using dsDNA throughout the entire template DNA. While it well known that RCT
transcribes much faster than run-off, the real novelty lies in the preparation of dsDNA that
codes for nanoparticles with stable secondary structure, something that would not have and
did not work with the traditional DNA preparation method. Removing the issue of stable
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secondary structure in the DNA template was only possible by making the entire circular
template double stranded. Making circular dsDNA is a widespread procedure in molecular
biology with the construction of artificial DNA plasmids, in most cases multiple kilobases
long, using cloning and other techniques. While the RNA nanoparticle sequence could have
been cloned directly into a plasmid, complications arise from the inclusion of extra DNA
such as the origin sequence, antibiotic resistant sequences, among others. Because the goal
of this method was for in vitro synthesis, these sequences were not necessary and in fact
would hamper reaction efficiency due to transcription of useless RNA. The most
straightforward method to make circular dsDNA starting with two long, but identical
length, phosphorylated ssDNAs, as depicted in Figure 5.1.
RCT results in the synthesis of long concatamers of ssRNA due to the progressive
nature of the polymerase around the circular dsDNA. In this study, RNA oligomers and
RNA nanoparticles with defined sequences were desired, so a cleavage method was
devised to release the target RNA sequence from the rest of the transcript. Ribozymes are
RNA motifs that cleave RNA, and can be engineered to cleave a specific sequence and
even self-cleave. Their catalytic property was implemented to self-cleave cotranscriptionally and release specific RNA sequences, in this case those target sequences
being 3WJ-a, b, and c (Fig 5.2C). This allows a hands-off method for the transcriptional
production of short and defined RNA oligomers in high yield without the use of additional
enzymes and will aid in the future scale up of this method for large-scale synthesis of RNA
nanoparticles in vitro and in vivo.
The real power of RCT coupled with release of defined RNA oligomers it the ability
of RNA nanoparticles to fold co-transcriptionally. As soon as each RNA monomer is
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released by ribozyme cleavage, it can find its partner sequences in the transcription mixture
and assemble isothermally into the nanoparticle. This is evidenced by comparison of
purified monomers assembled into the 3WJ to the co-transcriptional reactions (Fig 5.2D).
To increase nanoparticle assembly yield, a second approach was taken to cotranscriptionally assemble RNA nanoparticles. Alternate to assembling the nanoparticle
from three individual RNA monomers, loop sequences were used to join the 5’ and 3’ ends
of adjacent monomers resulting in a nanoparticle from one RNA strand (Fig 5.3A). To
demonstrate this concept, 3WJ with loops was synthesized as well as 3WJ with one loop
and the other helix being closed by the malachite green fluorogenic aptamer. Including an
aptamer in the sequence serves two purposes: (1) monitoring transcription kinetics by
fluorescence; (2) shows accurate cleavage and correct folding of the RNA nanoparticle, as
MG will not bind to MGA unless the sequences is correct. A decrease in gel migration
grate compared to 3WJ assembled form cleaved 3WJ ssRNA “RCT-3WJ” and the 3WJ
assembled from one RNA piece, “3WJ-Loop,” of the MG-3WJ indicates increased size
from the addition of the MGA (Fig 5.3C). Both linear and circular constructs show
identical size. It is important to note that the MG-3WJ from RCT shows upper bands,
indicating cleavage is not 100%.
The advantage to preparing circular dsDNA for transcription is the hypothesis that
RCT will result in higher amounts of RNA nanoparticles from the same starting DNA
concentrations, therefore being more efficient and faster in nanoparticle production. To test
this hypothesis, we performed two methods of transcriptional kinetics monitoring using
one piece MG-3WJ in linear and circular dsDNA. The first was by gel analysis and band
intensity comparison. Gel band intensity indicates a much higher rate of transcription and
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overall RNA production yield, both by total RNA staining and MG staining (Fig 5.4B, C).
This supports the hypothesis that RCT will result in higher production of RNA
nanoparticles. The results are also the same for real-time fluorescence monitoring (Fig
5.4D, E). While the ribozyme cleavage for circular dsDNA is not 100%, gel staining
represents an accurate comparison of production of RNA nanoparticles as the gel band that
was quantified was the target RNA nanoparticle. Fluorescence monitoring of the actual
transcription mixture monitors the entire transcription reaction, including non-cleaved
RNAs, reflecting slightly less accurate quantification of RNA nanoparticle production
yield.
In both cases, a leveling of RNA transcription is observed. We hypothesized that
buildup of magnesium salts from transcription byproducts or loss of enzyme activity could
be the cause. To test this, separate transcriptions were performed with the addition of
inorganic pyrophosphatase enzyme and additional T7 polymerase after two hours of
transcription. In both cases, the same quenching of transcription occurred (data not shown).
It is possible that the buildup of significant amounts of RNA in the transcription mixture
could abolish enzyme activity, due to increased viscosity of the solution.
Failed ribozyme cleavage during circular transcription leads to long RNA stands,
which are multimers of the desired RNA product. These impurities are observed by gel
analysis (Fig 5.4C). It is important to remove unwanted products as nanomedical
applications require a high degree of product purity. In this application, the most efficient
method was purification by gel electrophoresis due to somewhat close size of products
(impurities are as close as only two times larger than desired product). However, typical
gel set ups are not amenable to large-scale purification due to large sample volumes
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required for transcription and loss of sample during elution from gels. A continuous elution
gel electrophoresis apparatus was, therefore, ideal for purification. After purifying of
transcription samples, a purity of 93.6% was achieved, compared to 44.8% in the crude
product.
While this procedure produces native RNA, most applications with RNA
nanotechnology implement modified nucleotides, such as 2’-fluorine modification to the
ribose sugar of purines (cytosine and uracil). Modifications increase thermodynamic and
in vivo stability allowing their use in medical applications. Transcriptions with modified
nucleotides, using mutant polymerase, were attempted, and while transcription processed
normally ribozyme cleavage failed resulting in no release of target RNA oligomers.
Presumably, this is due to the hydrolytic mechanism of ribozyme cleavage, requiring a 2’
hydroxyl at the cleavage site (281). The sequence design used contains a cytosine at the
cleavage site, which contains a fluorine at the 2’ site in modified transcription. This
sequence was mutated to adenine at the cleavage site and, despite the presence of a 2’
hydroxyl, ribozyme cleavage failed (Fig A.4.5). It is apparent that duplex structure is
extremely important for this ribozyme to maintain activity. Modification of the nucleotides
to 2’F RNA changes the duplex structure, abolishing ribozyme activity. While this is a
current challenge in the large-scale production of modified RNA nanoparticles, work is
underway to find alternate cleavage methods to implement RCT for large-scale synthesis
using modified nucleotides. Nonetheless, RNA nanoparticles show increased enzymatic
stability over ssRNA and other endogenous dsRNA due to increased size and their complex
structure protecting 5’ and 3’ ends from exonucleases.
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CONCLUSIONS:
DNA template used for RCT reactions is generally made up of long ssDNA regions
with dsDNA in the promoter region for RNA template binding. However, if long stretches
of ssDNA in the template code for RNA displaying stable structure, such as RNA
nanoparticles, the ssDNA template will also have stable secondary structure due to the
complementary mechanism of transcription. Therefore, a new method was devised to
construct fully double stranded and circular DNA encoding for RNA nanoparticles with
extremely stable secondary structure. The method for circular dsDNA preparation is
broadly applicable to the field of RNA nanotechnology as functional nanoparticles, in most
cases, are stable by nature due to base pairing of complimentary nucleotides within the
nanoparticle. To release RNA nanoparticles transcribed during RCT, self-cleaving
ribozymes were coded for in the template allowing release of the target sequence and
assembly co-transcriptionally. Furthermore, RCT produced eight times as much RNA than
traditional transcription from dsDNA templates of identical sequence. RNA
nanotechnology has been emerging as a new drug delivery platform and shows great
promise to help advance the current state of nanomedicine. The methods introduced here
allow large-scale production of RNA nanoparticles and will be needed for future clinical
applications of RNA nanotechnology. As well as large-scale batch synthesis, in vivo
expression and production of RNA nanoparticles could be possible using the methods
introduced here, helping to solve the current challenges of scale and cost in RNA
nanoparticle production.
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Chapter 5.2: Large-scale Purification of RNA Nanoparticles using Preparative
Ultracentrifugation
INTRODUCTION:
Since the first example of RNA nanotechnology in 1998 (12), RNA has shown to
be a promising therapeutic delivery system to target cancers, viral infections, and genetic
diseases (91,293). Recent advances in RNA nanotechnology have led to the construction
of

diverse

nanoparticles

with

varying

sizes

and

structural

features

(50,64,103,105,126,150,152,190). Many of these nanoparticles have the potential for
imaging, disease diagnosis, and drug and therapeutic RNA delivery (91,293-297). RNA is
a polymer made up of four different nucleotides: adenine (A), cytosine (C), guanine (G),
and uracil (U). Much like DNA, RNA can be easily manipulated to form precise structures,
while at the same time retaining flexibility in structure and diversity in function much like
proteins (90).
RNA nanoparticles assemble with high efficiencies; however, fully assembled and
contamination-free nanocomplexes are required for most in vitro and in vivo applications.
Besides HPLC, in many cases, purification is performed by polyacrylamide gel
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electrophoresis (PAGE) or agarose gel electrophoresis (AGE), through which the correctly
folded structures migrate in a sharp and distinct band and are separated from the faster
migrating single stranded (ss) RNA and the slower migrating misfolded and aggregate
structures (105,298). While these methods have proven to be effective, there are downsides
to using PAGE and AGE. After electrophoresis, the RNA must be extracted from the gel,
which is labor intensive and often requires an additional purification step to remove
contaminating gel residue. Also, some nanoparticles do not enter PAGE and AGE gels
efficiently due to the large branched structures of these complexes. Finally, PAGE and
AGE lack the scalability needed to purify large quantities of nanostructures. HPLC is often
used for the purification of chemically synthesized and chemically modified
oligonucleotides, however HPLC is not conducive to large RNA nanoparticles (299).
Ultracentrifugation is a useful method for the scalable and efficient purification of RNA
supramolecular complexes on the large scale (300-302). Here, we describe a scalable, costeffective, and contamination-free method to purify RNA synthesized by in vitro
transcription and supramolecular RNA nanoparticles by preparative ultracentrifugation
(303-305).
While analytical ultracentrifugation is used to study molecular interactions, and
define the properties of the analyte, such as molecular weights, sedimentation coefficient,
shape, and conformation, preparative ultracentrifugation is primarily used to isolate and
purify specific particles. There are three main types of preparative ultracentrifugation:
differential (also known as pelleting), rate-zonal, and density-equilibrium (also known as
isopycnic). Differential centrifugation separates based on size or molecular weight in a
process in which successive pelleting steps allows researchers to recover the particle of
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interest. Rate-zonal centrifugation again resolves particles by size and shape dependent on
run time but the particle of interest remains isolated in the gradient and is typically
fractionated and recovered. Equilibrium density centrifugation, however, separates entirely
on density, independent of run time. In the methods introduced in this chapter, equilibrium
density and rate zonal gradients are employed. Equilibrium density gradient
ultracentrifugation is used in the CsCl gradient purification of ssRNA oligomers and ratezonal is employed in the sucrose gradient purification of supramolecular RNA
nanoparticles.
Post in vitro transcription, RNA is separated from unincorporated nucleotides and
protein impurities by CsCl equilibrium density gradient ultracentrifugation (Fig 5.6).
Exploiting the differences in density between proteins, RNA nucleotides, and synthesized
RNA oligonucleotides enables the large-scale purification of ssRNA, which are then used
to form multi-strand supramolecular RNA nanoparticles.
RNA nanoparticles are then constructed from the purified ssRNA oligonucleotides.
The RNA nanoparticles are purified from misfolded and aggregated complexes and
unincorporated ssRNA by sucrose gradient rate-zonal ultracentrifugation (Fig 5.7). Post
centrifugation, fractions are collected and examined on non-denaturing AGE and stained
with ethidium bromide (EtBr) (Fig 5.8).
To demonstrate the expected results utilizing this procedure, synthesis and
purification of RNA nanoparticles utilizing the packaging RNA (pRNA) (306) from the
phi29 bacteriophage DNA packaging motor was performed. The native pRNA structure
has previously been engineered to assemble into many nanostructures including dimers,
trimers, tetramers, hexamers, and larger supramolecular complexes utilizing hand-in-hand
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and foot-to-foot interactions (12,50,104,105,200). As an example, we show here the
purification of pRNA monomer and dimer constructs from two distinct pRNA monomers,
Ab’ and Ba’ (151). Monomers were purified by CsCl equilibrium density gradient
ultracentrifugation and monomer and dimer constructs were purified by 5-20% sucrose
gradient rate-zonal ultracentrifugation. The Ab’ and Ba’ pRNA monomers assemble to
form dimer constructs, a size difference that can be confirmed by traditional native PAGE
analysis. Despite a size difference of only 120 nucleotides between monomer and dimer,
the two species can be resolved by sucrose gradient ultracentrifugation. Furthermore, the
recovered fractions exhibited comparable dimer assembly to RNA nanoparticles purified
by PAGE (Fig 5.9).
MATERIALS:
Prepare all solutions using Millipore water (prepared by purifying deionized water
to attain a sensitivity of 18.2 MΩ cm-1 at 25°C) that has been incubated at 37°C overnight
with diethylpyrocarbonate (DEPC) and then autoclaved. All reagents used should be
analytical grade and RNase and DNase free as RNA is extremely sensitive to RNase
degradation. All glassware, tubes, and pipette tips used in preparation of reagents and
buffers should be autoclaved to ensure sterilization. Gloves and lab coats should be worn
at all times. All waste disposal regulations should be carefully followed. Prepare and store
reagents at room temperature (RT) unless otherwise noted.
2.1. For Gradient Preparation
1) Diethylpyrocarbonate (DEPC) aqueous solution: 0.05% solution in millipore water
(v/v): Add 5 mL DEPC to 995 mL millipore water and shake the solution vigorously.
Incubate the solution overnight at 37°C and then autoclave to remove DEPC.
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2) CsCl Ultracentrifugation Buffer: 1X Tris-EDTA (TE) Buffer (10 mM Tris-HCl, 1 mM
ethylenediaminetetraacetate (EDTA)). Add about 100 mL water to a 1-L glass beaker
with a magnetic stir bar (see Note 1). Weigh 1.21 g Tris-HCl, and 0.000292 g EDTA
(see Note 2) and transfer to the glass beaker. Bring the volume to 900 mL with water
and then adjust the pH to 8.0 with HCl (see Note 4). Bring the final volume to 1 L and
autoclave.
3) Sucrose Ultracentrifugation Buffer: 1X Tris-magnesium saline (TMS) Buffer (50 mM
Tris-HCl, 100 mM NaCl, and 10 mM MgCl2). Add about 100 mL water to a 1-L glass
beaker with a magnetic stir bar. Weigh 6.05 g Tris base, 5.844 g sodium chloride, and
2.03 g MgCl2 hexahydrate and transfer to the glass beaker. Bring the volume to 900 mL
with water and then adjust the pH to 8.0 with HCl. Bring the final volume to 1 L and
autoclave.
4) CsCl Solutions: d=1.65 (0.790 g/mL). Dissolve 79.0 g molecular biology grade CsCl
in 50 mL of 1X TE buffer in a glass beaker and mix with a magnetic stir bar. Once
dissolved, dilute to 100 mL with 1X TE buffer in a graduated cylinder. D=1.95 (1.230
mg/mL). Follow same procedure as before with 116.73 grams of CsCl. Additional
1.745 g CsCl for sample preparation. (see Note 5)
5) Sucrose solution: 5%, 10%, 15%, 20% (w/v). To prepare sucrose solutions, dilute
respective amount of sucrose (e.g. 5 g for 5% w/v) to 100 mL final volume with 1X
TMS Buffer. Mix in glass beakers and stir with a magnetic beaker. (see Note 5)
6) Ultracentrifugation tubes: Beckman #326819, 5-mL.
7) Automated Gradient Maker: BioComp Gradient Master Model 106 (BioComp
Instruments) gradient maker.

146

8) Long Neck Pipette tips: Bio-Rad 223-9916. 1-200 µL pipette tip for gel loading.
9) Syringe and Needle: 5-mL BD Syringe, Fisher Scientific. Reusable non-sterile
hypodermic needle, 3.5 in, Fisher Scientific.
10) Mild detergent: Alconox Detergent, Fisher Scientific #NC9003111.
11) Pipette: 1000 µL and 200 µL pipette, Denville Scientific Inc.
12) Vortexer: VWR Analog Vortex Mixer.
2.2. For Ultracentrifugation
1) Analytical Balance: Mettler Toledo AB204-S Analytic Balance.
2) Ultracentrifuge: Beckman Coulter L-80 Ultracentrifuge (Beckman #392051) (see Note
6).
3) Ultracentrifuge Rotor: Beckman Coulter SW 55 Ti Rotor (Beckman #342194) (see
Note 7).
4) Ultracentrifugation Bucket: Swinging Bucket for SW 55 Ti Rotor (Beckman #342194)
(see Note 8).
5) Ultracentrifugation Bucket Rack: Bucket rack for swinging bucket SW 55 Ti Rotor
(Beckman #331313).
6) Ultracentrifugation Spinkote Lubricant: Lubricant for ultracentrifuge (Beckman
#306812) (see Note 9).
7) Ultracentrifugation Vacuum Grease: Vacuum seal grease (Beckman #335148) (see
Note 10).
2.3. For Fractionation and Sample Analysis
1) Tubes: Fisherbrand Premium Microcentrifuge tubes, 1.5 mL. Catalog No: 05-408-120.
Autoclaved.
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2) Pipette: 200 µL pipette, Denville Scientific Inc. and sterile pipette 200 µL pipette tips
3) Fraction Collector (Optional): Beckman Coulter Fraction Recovery System, No:
343890. (see Note 11)
4) Agarose: Low-melting, molecular biology grade. Fisher BioReagents. Catalog No:
BP165-25.
5) Agarose Gel Buffer/Running Buffer: 1X TAE (40 mM Tris-acetate, 1 mM EDTA) with
10 mM MgCl2. Add about 100 mL water to a 1-L glass beaker with a magnetic stir bar.
While stirring, add 0.00725 g Tris-acetate, 0.000292 g EDTA, and 2.03 g MgCl2
hexahydrate and transfer to the glass beaker. Bring the volume to 1-L.
6) Microwave
7) Imaging System: Typhoon FLA 7000 imaging system, GE Healthcare.
8) Agarose Gel Electrophoresis System, mini-sub cell GT system, Bio-Rad.
9) Ethidium Bromide: 1% Solution, Molecular Grade. Fisher BioReagents Catalogue No:
BP1302-10.
10) Sample Concentration: Amicron Ultra 0.5 mL Centrifugal Filters, Millipore.
METHODS:
Carry out all procedures at RT unless otherwise specified.
3.1: CsCl Equilibrium Density method RNA Purification
This method details the purification of RNA prepared by in vitro transcription using
T7 RNA polymerase as described in detail previously (105). CsCl centrifugation will
remove unincorporated nucleotides as well as proteins and other impurities from the
transcription reaction mixture based on differences in density. The sample being used for
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centrifugation in the following procedure can be used directly after in vitro transcription
without further modification (Figure 1).
3.1.1: Preparation of d=1.65-1.95 CsCl Gradient
1. Prepare two CsCl solutions with densities of 1.65 (0.790 g/mL) and 1.95 (1.23 g/mL)
as detailed previously. (see Note 5)
2. Prepare CsCl sample solution with density equal to 1.75 (1.164 g/mL). Dilute the
sample from RNA transcription to 1.0 mL (maximum sample volume for 5 mL
centrifuge tube is 1.0 mL) with 1X TE buffer. To the diluted sample add 1.7452 g CsCl
and mix thoroughly with a vortexer (see Note 5). Adjust the final volume to 1.5 mL.
3. Pipette the 1.5 mL sample in CsCl solution, d=1.75, into a 5.0 mL ultracentrifuge tube
(Beckman #326819).
4. Using a syringe and long needle, pipette the d=1.95 CsCl solution to the bottom of the
ultracentrifuge tube, below the sample CsCl solution
5. On top of the sample solution, pipette 1.5 mL of d=1.65 CsCl solution.
6. Cap the centrifuge tube. (see Note 12)
3.1.2: Ultracentrifugation Procedure
At all times, be gentle when handling the tubes with the prepared CsCl gradients.
Too rough of handling will disturb the gradient and affect the sample purification.
1) Place the ultracentrifuge tube into the centrifugation buckets.
2) Using an analytical balance, measure and record the weight of each bucket and
respective bucket top with the tube inside. It is extremely important to equilibrate
weights of buckets that will be across from each other when attached to the rotor (see
Note 13). To make the weights equal, use water to match weights between the pairs of
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buckets. For each 0.01 gram of difference, pipette 10 µL of water into the bucket with
less weight (see Note 14).
3) Once the buckets are balanced, tightly secure the tops of the buckets to prevent leaking.
Finally, secure the buckets onto the swinging-bucket rotor (Beckman SW Ti 55) (see
Note 15).
4) Holding onto the base and the top of the rotor, carefully place the rotor into the
ultracentrifuge (Beckman L-80 ultracentrifuge) (see Note 16).
5) Bring the temperature down to 4.0°C and turn on the vacuum to equilibrate the rotor
and sample. Wait until the final temperature and lowest pressure (<20 microns) are
reached before commencing rotation (see Note 17).
6) Spin the rotor (Beckman SW 55 Ti) at 45,000 RPM (246, 078 x g) for 16 hours. (see
Note 18).
7) After centrifugation, wait for the rotor to come to a complete stop and the RPM reading
on the ultracentrifuge reaches "0." Once the rotor has stopped, release the vacuum and
open the lid. Carefully grabbing the base and the top of the rotor, remove the rotor form
the ultracentrifuge and place it back on the rotor stand.
8) Remove the rotor buckets and place them back in the bucket holder rack. Remove the
tubes and place them in a sample rack. It is important to now thoroughly clean and dry
the buckets as excess moisture can cause damage to the buckets.
9) Proceed to section 3.3 for fractionation and sample analysis.
3.2: Rate-zonal sucrose gradient for Nanoparticle Separation or cushioned Rate-Zonal
Sucrose Gradient
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This method details the separation of the final nanoparticle assembly from incorrect
structures such as misformed aggregates and unincorporated strands. The RNA assemblies
should be annealed prior to purification by ultracentrifugation in 1X TMS buffer.
Maximum sample volume for ultracentrifugation is 500 µL.
3.2.1: Preparation of 5-20% (v/v) sucrose density gradient preparation
3.2.1.1: Gradient preparation by gradient maker
1) Prepare two sucrose solutions, 5% and 20% (w/v), in 1X TMS buffer by diluting 5 g
and 20 g, respectively, of sucrose to 100 mL volume in a graduated cylinder. Transfer
to a glass beaker and use a magnetic stir bar to thoroughly mix the solutions.
2) Into a 5.0 mL polypropylene (Beckman #326819) ultracentrifuge tube, cleaned with a
mild detergent and thoroughly dried, pipette 2.4 mL of 5% sucrose solution. In a 5-mL
syringe with a long tip needle, carefully syringe 2.4 mL of 20% (w/v) sucrose solution
to the bottom of the ultracentrifuge tube. Insert the cap of the centrifuge tube into the
top of the tube (see Note 12).
3) In this method, the gradient was made using the BioComp Gradient Master Model 106
(BioComp Instruments) gradient maker (see Note 19). For the specified gradient, 5%20% sucrose (w/v), set the gradient maker to spin for one minute and thirteen seconds
at an angle of 86° at 16 RPM. After the gradient maker is done, remove the
ultracentrifuge tube and place in a sample holder rack (see Note 20).
3.2.1.2: Gradient preparation by manual layering (if gradient maker not available)
This method details the procedure to make the 5%-20% (w/v) sucrose gradient if
there is no automated gradient maker available.
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1) By the same procedure previously detailed, make 5%, 10%, 15%, and 20% (w/v)
sucrose solutions.
2) Using the prepared solutions, layer from most dense (20%) to least dense (5%) with
1.2 mL of each solution. Carefully layer the solutions into a 5.0-mL (Beckman
#326819) ultracentrifuge tube using a long-tip hypodermic needle. (see Note 21)
3) Incubate the tube overnight at 4°C to form a continuous gradient, ideally in a cold room
(see Note 22).
3.2.2: Sample loading and ultracentrifugation procedure
At all times, be gentle when handling the tubes with the prepared sucrose gradients.
Too rough of handling will disturb the gradient and affect the sample purification.
1. Before being loaded, ensure the sample is in its native annealing buffer (see Note 23).
To load the sample, slowly pipette a maximum volume of 100 µL on top of the
previously prepared sucrose gradient (see Note 24).
2. Using an analytical balance, measure and record the weight of each bucket and
respective cap with the tube inside. It is extremely important to equilibrate weights of
buckets that will be across from each other when attached to the rotor (see Note 13).
Use water to equal bucket weights. For each 0.01 gram of difference, pipette 10 µL of
water into the bucket with less weight (see Note 14).
3. Once the buckets are balanced, tightly secure the tops of the buckets to prevent leaking.
Finally, secure the buckets onto the swinging-bucket rotor (Beckman SW Ti 55) (see
Note 15).
4. Holding onto the base and the top of the rotor, carefully place the rotor into the
ultracentrifuge (Beckman L-80 ultracentrifuge) (see Note 16).
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5. Bring the temperature down to 4.0°C and turn on the vacuum to equilibriate the rotor
and sample. Wait until the final temperature and lowest pressure (<20 microns) are
reached before commencing rotation (see Note 17).
6. Spin the rotor (Beckman SW 55 Ti) at 50,000 RPM (303, 800 x g) for 7 hours. (see
Note 18).
7. After centrifugation, wait for the rotor to come to a complete stop and the RPM reading
on the ultracentrifuge has reached "0." Once the rotor has stopped, release the vacuum
and open the lid. Carefully grabbing the base and the top of the rotor, remove the rotor
from the ultracentrifuge and place it back on the stand.
8. Remove the rotor buckets and place them back in the bucket holder rack. Remove the
tubes and place them in a sample rack. It is important to now thoroughly clean and dry
the buckets as excess moisture can cause damage to the buckets.
3.2.3 Preparation of Cushioned Sucrose Gradient for Rate-Zonal Purification of RNA
Nanoparticles
This method details the use of a high-density sucrose “cushion” at the bottom of
the gradient during the rate-zonal purification of RNA nanoparticles (Fig 5.9E). Utilizing
a cushion has multiple advantages. For low amounts of sample, the sample can be run to
the bottom of the gradient and then stopped at the cushion. This allows the samples to be
collected at a higher concentration (fewer fractions) while avoiding pelleting. Pelleting can
sometimes lead to damage of sensitive samples during resuspension. Additionally, using a
cushion enhances the collection of nanoparticles that display multiple conformations,
which would otherwise spread to multiple fractions. Importantly, when purifying
nanoparticles that contain small molecule therapeutics or reporter molecules, a cushion will
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help to purify the nanoparticle complex from free small molecules by allowing large
separation between the two species. The size of the complex can easily separate from free
drug due to the buoyancy of the small molecule, which will prevent the small molecule
from co-localizing in the denser (lower) portion of the gradient.
1. First prepare the 5-20% sucrose gradient as described earlier in section 3.2.1. However,
when using the BioComp gradient maker reduce the volume of each solution to 2.3 mL
and when manually layering each solution decrease the volume of each solution to 1.15
mL. This will account for the additional volume needed for the high-density sucrose
cushion.
2. After preparation of the 5-20% sucrose gradient, with decreased volume, use a pipette
to load .2 mL of 60% sucrose solution to the bottom of the gradient. Slowly pipette the
60% sucrose solution down the side of the ultracentrifuge tube, from the top of the
gradient. Because of the high density of the solution, it will fall to the bottom of the
tube forming a sucrose cushion.
3. Let the cushion settle for 5 minutes being careful not to disturb the solution in the tube.
4. For sample loading and fractionation follow the same procedures detailed for sucrose
gradient rate-zonal ultracentrifugation without use of the cushion.
3.3: Fractionation and sample analysis/recovery (Same for CsCl and Sucrose)
During this step it is important to keep track of each fraction when removing it from
the tubes. Pre-label autoclaved tubes to ensure accuracy of fractions.
1) To remove fractions, use a pipette to remove 200 µL from the very top of the CsCl or
sucrose gradient and place in a pre-labeled tube to ensure accuracy of fraction numbers
(see Note 25).
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2) Continue to remove 200 µL fractions from the very top of the tube until the tubes are
completely empty (see Note 26).
3) Prepare a 2.0% non-denaturing agarose gel containing 1X EtBr gel stain (2.0 grams
agarose, diluted to 100 mL in 1X TAE Buffer containing 10 mM-Mg) (see Note 27).
4) Into each well of the agarose gel load 10 µL aliquots of each fraction. Run for 30
minutes at 120 V at RT in 1 X TAE buffer with 10 mM MgCl2.
5) After the gel has finished running, scan on a Typhoon FLA 7000 laser scanner for EtBr
signal. Similar gel scanning devices can also be used. (see Note 28)
6) Combine the fractions containing the desired products and reconstitute into the native
folding buffer, 1X TMS, using Amicron Ultra 0.5 mL centrifugal filters (see Note 29).
EXPECTED RESULTS:
Synthesis and purification of RNA nanoparticles utilizing the pRNA from the phi29
bacteriophage was performed. In nature, the pRNA forms a hexameric ring that is used in
gearing the phi29 DNA packaging motor (12,306). Previously, the native pRNA structure
was engineered to assemble into diverse RNA nanoparticles including dimers, trimers,
tetramers, hexamers, and larger supramolecular complexes utilizing hand-in-hand and
foot-to-foot interactions (12,50,104,105,200). As demonstration of expected results, we
show here the purification of pRNA monomer and dimer constructs from two different
pRNA monomers, Ab’ and Ba’ (151). Monomers were purified by CsCl density gradient
ultracentrifugation and dimer constructs by 5-20% sucrose gradient rate-zonal
ultracentrifugation. The Ab’ and Ba’ pRNA monomers assemble via hand-in-hand kissing
loops to form dimer constructs (Fig 5.9A). CsCl density gradient ultracentrifugation was
used to purify RNA directly after in vitro transcription from the proteins and DNA template
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using the procedures detailed here. Post in vitro RNA transcription, the reaction mixture
contains proteins and DNA template, which are undesired products. The DNA template is
degraded by DNase enzyme and the proteins are easily separated from the RNA product
by the difference in their densities. The high density of RNA results in the products
migrating to the densest portion of the gradient. Despite a small size difference between
monomers and dimer, ~120 nucleotide monomer and ~240 nucleotide dimer, the monomer
and dimer can be separated by sucrose density gradient ultracentrifugation following the
procedures detailed here (Fig 5.9C). The recovered fractions demonstrated comparable
dimer assembly to RNA nanoparticles purified by PAGE (Fig 5.9D).
NOTES:
1) Adding reagents to already circulating water helps to dissolve them easily. If there is
trouble dissolving the reagents the glass beaker can be heated gently to 37°C. However,
pH must be adjusted at room temperature.
2) Use caution when handling EDTA. EDTA is a skin, eye, and respiratory tract irritant
3) MgCl2 will absorb moisture from the air. Be sure to handle as quickly as possible and
then recap the reagent bottle tightly to prevent moisture absorption.
4) Use caution when handling concentrated HCl. HCl is a strong acid and is very
corrosive. HCl is a strong eye, skin, and respiratory tract irritant. HCl can cause severe
burns, be sure to handle with gloves and wear splash goggles to prevent it from getting
in eyes.
5) Be sure to mix vigorously enough to have a homogeneous mixture of CsCl or sucrose
and 1X TE buffer.
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6) Be sure regular maintenance has been carried out on the ultracentrifuge to ensure proper
operation and safety for the user.
7) Before use, inspect rotor to make sure there are no cracks or disfigurements, use of
damaged buckets could result in danger to the user and damage to the ultracentrifuge.
8) Before use inspect buckets for cracks and/or disfigurements, use of damaged buckets
could result in danger to the user and damage to the ultracentrifuge.
9) Before using the ultracentrifuge, be sure the rotation bearings are properly lubricated.
10) Prior to ultracentrifugation ensure the vacuum seal is properly greased. A badly greased
vacuum seal will not allow the proper low-pressure environment to be reached and
ultracentrifugation will not be able to commence.
11) The Beckman Coulter Fraction Recovery System works by puncturing a whole in the
bottom of the ultracentrifugation tube and collection occurs from the bottom of the
tube. This system can be a viable alternative to the method described here, however
this equipment is optional.
12) When capping the ultracentrifuge tube make sure to cap at an angle to prevent air
bubbles from forming in the gradient. Keep air bubbles out while preparing the
gradient. When syringing higher density CsCl or sucrose do so slowly and with extreme
care to avoid mixing the high density with the low-density solutions. The gradient used
will not be identical for all complexes. In some cases the ideal gradient to use must be
experimentally determined.
13) Each bucket is labeled with a number 1-6, 1 is across from 4, 2 from 5, 3 from 6. It is
important that each pair be identical in weight and are placed across from each other
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on the rotor. Also, even if six samples are not being run, it is important that all buckets
be in place during centrifugation and run with equal weight.
14) Do not pipette into the ultracentrifuge tube, pipette into the space surrounding the tube
inside the bucket.
15) Before beginning ultracentrifugation, make sure each bucket is securely fixed to the
rotor. Do this by gently but firmly tugging down on each bucket once it is attached to
the rotor. However, while doing this do not disturb the gradient and sample in the tube.
16) The rotor must rotate freely to ensure proper function of the ultracentrifuge. Ensure
that the connection is sufficiently greased (Beckman #306812) and test by rotating the
rotor clockwise by hand. If it moves freely it is sufficiently lubricated.
17) A proper vacuum seal is required to hold the vacuum constant. Make sure the seal is
sufficient, if not apply grease to ensure a proper seal (Beckman #335148).
18) The optimal centrifugation time depends on the exact mass and shape of the RNA
complex. This should be experimentally determined. Avoid excessive centrifugation as
this may lead to sample pelleting at the bottom of the tube, which will negatively affect
the purification of the RNA assembly. Pelleting time, or k-factor, can be calculated
quickly by equation t=k/s, where t is run time in hours required to pellet a particle of
known sedimentation coefficient s (in Svedberg units, S). The k-factor is a function of
the maximum and minimum radius of a rotor and the run speed in RPM. The k-factor
for the SW-55 Ti rotor at 45,000 RPM is 72.4. After determining the sedimentation
coefficient of the particle of interest, the pelleting time can be calculated and a shorter
time should be used.
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19) This exact model of gradient maker is not required. Follow the gradient maker protocol
for correct angle, speed, and duration.
20) Always prepare gradients with location in mind. Try to move the formed gradients as
little as possible as moving the gradients can disturb the final density gradient.
21) Pipette as carefully as possible when stacking the different densities of CsCl or sucrose.
Taking care not to mix the different gradients will lead to a better quality gradient.
22) A cold room is preferred over a refrigerator. Repeated opening and closing of a
refrigerator door will disturb the gradient during its equilibration.
23) Sample should be in its native annealing buffer, 1X TMS.
24) When pipetting the sample onto the top of the gradient take great care to pipette slowly
and get as narrow a band as possible of the sample. This will lead to higher resolution
during ultracentrifugation.
25) 200 µL may not be an ideal volume for every purification situation. In a case where the
RNA complex is not as well separated a lower fraction volume may be ideal, in cases
where resolution is high larger fraction volumes may be ideal. This should be
experimentally determined.
26) Be sure to use a new pipette tip with each fraction to avoid contamination.
27) Be careful handling EtBr, it is thought to act as a mutagen because it intercalates with
dsDNA and dsRNA.
28) Be sure to include a molecular weight marker in the agarose gel to determine which
fractions are the correctly formed complexes.
29) Follow the manufacturer's protocol. The size of the RNA complex being purified will
determine the specific filter to be used. Centrifugal force less than 4500g should be
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used in order to minimize sample damage and loss. Typically this will result in 50-100
μL of purified RNA complex.
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Figure 5.1: Scheme for Circular dsDNA Assembly. ssDNA CircLigase is first used to
self-cyclize a phosphorylated ssDNA. Following hybridization of the complementary
strand, T4 DNA ligase is used to close the nick. T7 RNA polymerase transcribes the
sequence, which contains self-cleaving ribozymes to release the target RNA sequence. The
target RNA sequence can be a defined RNA oligomer or nanoparticle sequence.
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Figure 5.2: Transcription and Cleavage Confirmation. (A) Assembly of circular
dsDNA. This is a representative gel of the general assembly analysis. (B) Assembly of
circular dsDNA is confirmed by inactivating the ribozyme in the sequence. Inactive
ribozymes leads to concatamerized RNA, while cleavage results in short oligomers. (C)
Circular and linear transcription for dsDNA constructs encoding for release of the 3WJ
ssRNA oligomers. (D) Assembly of the 3WJ occurs co-transcriptionally by mixing
equimolar amounts of dsDNA encoding for the release of 3WJ-A, B, and C strands.
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Figure 5.3: One-Strand RNA Nanoparticle Assembly. (A) Schematic for modified
design of self-cleaving ribozyme. A portion of one ribozyme is positioned 5’ of the
nanoparticle sequence while the other portion is located 3’ of the nanoparticle sequence.
Self-cleavage occurs after transcription of the entirety of the dsDNA template. (B) Circular
dsDNA was assembled to code for the 3WJ and MG-3WJ nanoparticles assembled from
one long piece of RNA. (C) PAGE gels showing assembly of the one-stranded
nanoparticles. Gels were stained with both ethidium bromide (total RNA) and MG dye,
which shows correct folding and release of the nanoparticles.
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Figure 5.4: Transcription Kinetics. (A) Comparison of linear transcription and circular
transcription. MG-3WJ was used as fluorescence can be an indicator for the progression of
transcription. (B, C) Gel analysis of transcription. Bands were integrated and plotted. (D,
E) Monitoring of transcription using MG fluorescence (specific to nanoparticle folding,
panel D) and SYBR GreenII (RNA specific, panel E).
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Figure 5.5: Gel-electrophoresis Column Purification. (A) MG fluorescence and
absorbance at 260 nm were used to analyze fractions after purification. (B) PAGE gel
analysis determines the identity of the peaks from fluorescence and absorbance analysis.
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Figure 5.6. Mechanism for CsCl equilibrium density gradient. (A) Different densities
of CsCl salt solution are loaded into centrifuge tube with sample in medium density
solution. (B) Post centrifugation, when equilibrium is reached, a gradient is formed with
the migration of particles separating by their density (specific gravity).
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Figure

5.7.

Mechanism

of

separation

for

sucrose

gradient

rate-zonal

ultracentrifugation. (A) Before centrifugation, the sample is loaded on the top of the
gradient in a thin band. (B) After centrifugation, the particles separate based on shape and
mass. Higher mass particles migrate faster to the higher density portion of the gradient and
lower mass particles stay in the lower density portion at the top of the gradient.
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Figure 5.8. Gradient formation, sample loading and analysis scheme of sucrose
gradient rate-zonal ultracentrifugation and expected results. (A) Formation of gradient
by automated gradient maker. (B) Formation of gradient by manual layering. (c) Sample is
loaded in a thin band on top of the gradient. After centrifugation the particles are separated
by size. (D) Alternate method for the formation a cushioned sucrose rate-zonal density
gradient using 60 % sucrose solution pipetted to the bottom of a preformed sucrose
gradient. (E) Expected AGE analysis results. AGE analysis reveals the identity of each
fraction. After AGE analysis the target particle fractions are combined and concentrated.
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Figure 5.9. pRNA monomer and dimer purification. (A) Schematic Representation of
pRNA monomer (Ab′ and Ba′) and dimer complex (Ab′–Ba′). The pRNA dimer is formed
by two distinct pRNA monomers, termed Ab′ and Ba′ (B) The two pRNA monomers are
purified by CsCl density gradient ultracentrifugation and analyzed by agarose gel
electrophoresis. The monomer sedimented toward the bottom of the tube, an example of
differential centrifugation. (C) 5–20 % sucrose gradient was used to purify the pRNA
dimer complex (red ). As a reference, pRNA monomer was also examined under the same
conditions (black). (D) Post centrifugation, fraction 7 was recovered and native PAGE was
used to examine the assembly of pRNA dimers purified by ultracentrifugation (UC, Lane
3) compared to those purified by PAGE (Lane 6). Lanes 1 and 2 are pRNA monomers
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purified by CsCl ultracentrifugation, used as size controls in the gel; Lanes 4 and 5 were
purified by PAGE as a comparison to results obtained by purification using
ultracentrifugation. Comparable assembly of the pRNA dimer complex is observed
between each method

Copyright © Daniel L. Jasinski 2017
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Chapter 6: Summary of Thesis Achievements and Outlook

This chapter was reproduced (with some modification) with permission from
Jasinski, D; Haque, F; Binzel, DW; and Guo, P. “Advancement of the Emerging Field of
RNA Nanotechnology.” ACS Nano, 2017. DOI: 10.1021/acsnano.6b05737. Copyright
2017 American Chemical Society.

SUMMARY:
This thesis work describes the development of RNA nanoparticles with diverse and
controllable sizes, shapes, and physical properties. Before this work, RNA nanotechnology
was somewhat limited in its diversity of nanoparticles. As mentioned previously, size and
shape diversity are paramount for in vivo drug delivery systems, since these properties have
profound effects on biodistribution, circulation time, toxicity, and interactions with the in
vivo environment. Thermodynamically stable and serum resistant 2’F RNA triangles,
squares, and pentagons were constructed using a modular design approach with the pRNA3WJ as the base unit. The same angle of the 3WJ was used to construct the nanoparticles,
displaying diversity in shape from one RNA motif. Nanosquares were tuned in size by
modulating RNA duplex length between adjacent 3WJ modules. The nanosquares
displayed homogeneous size and narrow size distribution, as evidenced by DLS
measurements. Upon IV administration of the diverse size RNA nanosquares, differences
in biodistribution profiles were seen. A strong correlation between increased size of
nanosquares and increased circulation time is evident by time course fluorescent images of
mice whole body and organs. While triangle, square, and pentagon RNA nanoparticles
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demonstrated similar biodistribution after 24 h, different fluorescent intensities in organs
at 12 h suggest diverse elimination pathways. The tunable nature of RNA nanoparticles
lends this platform advantages when precise control over size, and therefore in vivo
properties, is desired. Additionally, 3D RNA nanoprisms were constructed and used for a
unique small molecule encapsulation technique. A fragile RNA aptamer enclosed within
the stable frame of the nanoprism protected the small molecule cargo from degradation and
prevented leaking of the small molecule drug. Finally, a method for the large scale in vitro
production of RNA nanoparticles was developed. Rolling circle transcription (RCT) was
used to transcribe fully double stranded circular DNA encoding for self-cleaving ribozymes
to release target RNA. The target RNA was either single stranded RNA oligomers, which
co-transcriptionally assembled into RNA nanoparticles, or one-stranded RNA
nanoparticles, which also folded co-transcriptionally and produced functional RNA
nanoparticles.
RNA NANOTECHNOLOGY OUTLOOK:
RNA nanotechnology for drug delivery has garnered much attention recently as it
has tremendous potential to help treat many diseases. Certainly, improvements are
necessary to push this innovative platform towards clinical trials and bring the product to
the market. Some of the challenges and possible solutions are discussed below.
Limited therapeutic payload
Currently, RNA nanoparticles have limited small molecule drug loading capacity.
Single drugs can be labeled onto the terminal ends of RNA strands and incorporated into
RNA nanoparticles. Whole chain labeling methods can increase chemical drug payload,
but can cause misfolding of RNA nanoparticles due to steric hindrance and compromise

172

the release of the drugs. Computational approaches can help to identify locations where
drugs can be introduced without disrupting the folding of the nanoparticle. Ensuring the
drugs are orientated out of plane from the RNA nanostructure can also minimize any
structural defects in the scaffold.
Intercalation is another viable approach to increase drug loading capacity, but drug
release profiles need to be closely evaluated as premature release of the drug leads to nonspecific side effects. For instance, if the pRNA-3WJ nanoparticle is used as a delivery
vector for targeting solid tumors, the projected half-life of the intercalated drug release
should be more than 4 h, as extensive biodistribution studies revealed that the vast majority
of the systemically administered pRNA-3WJ nanoparticles localize in the tumor site within
1-4 hrs.
RNAi is considered the next frontier of cancer therapy, and is thought by many to
have potential to “drug the undruggable.” However, like chemical drug conjugation, RNA
nanoparticles are limited in the number of RNAi molecules that can be delivered to cells.
However, this limitation may not be an issue as studies report that there are only about 103–
105 Dicer molecules per cell and oversaturation of therapeutic RNAs can lead to nonspecific binding and off-target gene knockdown (308). Too much shRNA delivered to cells
can cause cytotoxic effects (309), thus, a lower payload of RNAi may not be an issue in
the end. However, nanoparticle systems such as RNA microsponges have the potential for
delivering high payloads of siRNAs (38) and their utility in broader preclinical studies will
be improved if the particle size can be reduced to avoid organ accumulation.
Endosome escape to fulfill the promise of RNAi
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Like most nanoparticle platforms, RNA nanoparticles enter cells through receptormediated endocytosis. Thus, intracellular RNA nanoparticle trafficking becomes the next
challenge. Early endosomal vesicles are the first destination of RNA nanoparticles. Once
sorted, RNA nanoparticles are transferred to late endosomes and lysosomes, where they
are trapped without reaching their intended target. Fortunately, endosomal escape using
small 8-nt anti-miRNA LNA fragments in RNA nanoparticle delivery was successful and
cancer regression efficient (58), but the efficacy of endosomal escape of siRNA in RNA
nanoparticles is still unknown as cancer regression after siRNA delivery via receptor
mediated endocytosis is relatively low (56,310). To date, there is very limited knowledge
on different cellular endocytosis or internalization pathways that govern subsequent
intracellular processing and endosomal escape of RNA nanoparticles. Nevertheless, there
are well-characterized tools available to enhance endosome escape such as chemical
functional groups including acid-cleavable and pH sensitive (311). The pH-sensitive
materials undergo high amounts of protonation thereby inducing an influx of ions into the
endosome, resulting in osmosis and endosome rupture - referred to as 'proton-sponge'
effect.
Large-scale production and purification of RNA nanoparticles
One of the major bottlenecks for future clinical applications is the large-scale
production, large-scale purification, and cost of RNA nanoparticle production. Typically,
RNA nanoparticles are designed to be modular composed of multiple short strands that are
well within the limits of chemical synthesis (maximum of 80 nt). Over the years, the cost
of RNA oligo synthesis has progressively decreased due to improvements in chemical
synthesis efficiency. However, large-scale purification remains a challenge. HPLC and gel
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electrophoresis purification have limited capabilities with somewhat low yields. Due to the
special nature of RNA nanotechnology, the size of the assembled nanoparticle is
significantly different from its building blocks, thus, preparative ultracentrifugation has
recently been employed (312) and looks to be a promising approach for purification of
fully assembled RNA nanoparticles with high yield.
CONCLUSIONS:
RNA nanotechnology has come a long way since its inception in 1998 (12). Some
of the most exciting advancements happened only within the last five years. The design of
elegant nanostructures with precise arrangement of functional modules in 3D space and
self-assembly in a programmable 4D structure with controlled manner have greatly
advanced the field. Progress in the understanding of the principle for structure-based design
will enhance the capacity to make more intricate RNA nanoparticles with diverse function
that one day can mimic naturally occurring RNA nanomachines like the ribosome. RNA
nanoparticles display many advantages over other nanoparticle systems; however, the
development of RNA nanoparticles as drugs lags behind that of liposome and polymer
systems, which have been in clinical trials for years. To reach clinical applications, the
development of RNA nanoparticles should broaden beyond that of just their construction
and focus more on applying the advantages of RNA nanotechnology.
FUTURE STUDIES:
Chapter 2 details a novel modular design technique for constructing RNA
nanoparticles followed by a unique multi-strand assembly process that results in stable and
tunable nanoparticle scaffolds. This method has been well developed, and the construction
of RNA nanoparticles with tunable size, shape, and stabilities has been realized. This
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system allows a platform for studying how nanoparticle properties affect in vivo PK/PD
properties.
However, further development and optimization of this nanoparticle platform is
still preferable. For example, stretching of the 3WJ angle was shown to decrease stability,
despite increasing the number of base pairs and theoretical stability based on nearest
neighbor parameters. In-depth investigation of this phenomenon is desirable. It is apparent
that the stretching of the 3WJ angle is causing the decrease in stability, therefore,
modifying the 3WJ could be one possibility to retain stability despite angle stretching. One
possible way in which this could be accomplished is adding flexibility to the inner angles
of the 3WJ by addition of unpaired uracil bases, a common bulge seen in RNA structures
that imparts flexibility into their 3D conformations.
In addition to increasing flexibility of the 3WJ, and in turn increasing the stability
of the nanoparticles constructed from this 3WJ, nanoparticle rigidity has been shown to
influence interactions with the immune system. We believe these nanoparticles to be
relatively rigid and locked into their geometrical configurations. By imparting flexibility
into the 3WJ module, it is possible that flexibility could be introduced into the higher order
nanostructures, thus reducing interaction with the immune system and possible toxicity
caused by the nanoparticles in vivo.
Future work utilizing these nanoparticles also lies on the biological side. That is, a
systematic study utilizing this platform could results in a full set of size/shape/property
relationships with other factors such as biodistribution, cellular entry pathways, and drug
delivery efficacies. More work needs to be done studying how physical properties can
influence the way in which RNA nanoparticles enter cells, as cell entry pathways go a long
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way in determining therapeutic effect. By studying a property-efficacy relationship, it
could be possible to optimize the drug delivery pathways for numerous cell and cancer
types.
While the biodistribution studies in this thesis demonstrate a clear relationship
between increased size of RNA nanoparticles and their increased circulation time,
fluorescence is not a quantitative measure. Despite using near-infrared fluorophores, which
have shown potential penetration depths of up to 5-7 mm (307), quantitative labeling, such
as radiolabeling, could show statistical differences in nanoparticle accumulation in organs
and tumors among diverse nanoparticles. Additionally, more investigation to reveal a
molecular basis for different biodistributions of different size and shape RNA nanoparticles
would be extremely beneficial for our understanding of RNA nanoparticle interaction with
the in vivo environment.
The overall goal of nanotechnology is to increase delivery efficacy of the
administered dose of therapeutic, whether it be chemical drug, protein therapeutic, or
RNAi. However, as nanoparticles have significant size, the immune system recognizes
nanoparticles as foreign objects, thus engulfing them in macrophages, filtering them out
through the kidneys, or if they enter cells, sequestering them in organelles such as
endosomes and lysosomes, where they are eventually degraded. This drastically reduces
the amount of therapeutic that can be effective. To this point, the cellular trafficking
pathways of RNA nanoparticles is not known. Due to the fact that many RNA nanoparticles
use chemical ligands or RNA aptamers to enter cells, it is assumed that the particles enter
the cells via receptor mediated endocytosis, where they are most likely trafficked to
endosomes and degraded by the acidic environment. It is a necessary step to determine how
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RNA nanoparticles are trafficked. Once this step has been taken, it will be possible to
examine how nanoparticles with different sizes, shapes, and physical properties (ie
stability, hydrophobicity, solubility, charge, etc) enter cells, and which particles show the
largest advantages in regards to drug delivery efficacy. With all these factors taken into
consideration, it could be possible to optimize which particles to use to maximize cellular
entry and drug efficacy. According to literature on other nanoparticle systems, the smaller
particles will enter cells to a higher degree. However, as shown in this thesis, the smaller
particles appear to circulate out of the body faster. Thus, a balance should be struck
between circulation time, cellular entry and entrapment, and accumulation in healthy
organs such as the liver, spleen, and kidneys.
In this thesis was also demonstrated a novel method for the protection of a small
molecule model drug by binding to a fragile RNA aptamer inside a stable RNA
nanoparticle frame. This study is the first to show encapsulation of a small molecule within
an RNA nanocage. However, the increase in half-life needs to be extended to at least 4
hours, as this is the time it takes for RNA nanoparticles to circulate to tumors and
accumulate in an amount high enough to be therapeutically relevant. Other techniques,
such as developing more stable aptamers to hold their small molecule cargo more tightly,
or construction techniques to prevent breathing of the stable frame and invasion by
nucleases, could help to overcome this challenge. It is possible that this system could be
extremely helpful in the delivery of vaccines and other protein cargoes to specified targets.
Preventing off target effects of proteins is extremely important as some potent proteins can
cause high immune responses in vivo.
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Finally, this thesis demonstrated a method for large-scale in vitro synthesis and
purification of RNA oligomers and RNA nanoparticles. This method overcame the hurdle
of transcribing a ssDNA sequence with stable secondary structure by constructing circular
double stranded DNA. Despite this advancement, the resulting nanoparticles will be
susceptible to degradation in vivo, as they are not chemically modified after the RCT and
ribozyme cleavage process. Currently, there are no ribozymes available that are both 2’F
modified and can cleave 2’F RNA. It is conceivable that this type of ribozyme could be
made by in vitro selection (SELEX). Following the selection of a modified ribozyme, this
process would result in the production of a high yield of RNA nanoparticle that could be
used in nanomedicine and biomedical applications. Additionally, this method is currently
challenged by the cost of synthesizing long single stranded DNA oligoes. A new method
of double stranded circular DNA synthesis, such as the assembly of multiple short DNA
oligoes into circular double stranded DNA, would be beneficial to reduce cost of DNA
preparation.
It is possible that the increased production of RNA nanoparticles could decrease
their folding efficiency. Certain downstream steps of nanoparticle synthesis could be
necessary to produce the high-quality RNA nanoparticles constructed from traditional
methods. This could be achieved by thermal denaturation followed by a typical annealing
procedure. Thus, all mis-folding occurring from expedited transcription rates would be
avoided.
In addition to in vitro methods for RNA nanoparticle synthesis, the RCT method
developed in this thesis will also lend itself to in vivo production of stable RNA
nanoparticles. This would allow RNA nanoparticles to be produced by bacterial cells, thus
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drastically increasing production scale and drastically decreasing cost. However, to
produce 2’F modified nanoparticles for use in nanomedicine, bacterial cells would need to
be modified in order to produce and incorporate modified nucleotides. While the challenge
of this project is significant, it is not at all impossible due to the increased knowledge and
techniques of bacterial engineering and molecular engineering. If this bacterial engineering
project were to be achieved, the cost and scale-up challenges of RNA nanoparticle
production would be eliminated, thus allowing a clear path to clinical translation and
testing of RNA nanoparticles.

Copyright © Daniel L. Jasinski 2017
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Appendix 1: Supplemental Data for Chapter 2
Appendix 1 was reproduced (with some modification) with permission from:
Khisamutdinov, EF*; Li, H*; Jasinski, DL*; Chen, J; Fu, J; and Guo, P. “Enhancing
immunomodulation on innate immunity by shape transition among RNA triangle, square,
and pentagon nanovehicles.” Nucleic Acids Research, 2014. 42(15), 9996-20004. DOI:
10.1093/nar/gku516. Copyright 2014 Oxford Publishing; Jasinski, DL; Khisamutdinov,
EF; Lyubchenko, YL; and Guo P. “Physicochemically tunable polyfunctionalized RNA
square architecture with fluorogenic and ribozymatic properties.” ACS Nano. 2014. 8(8),
7620-7629. DOI: 10.1021/nn502160s. Copyright 2014 American Chemical Society.
Chemical Society. Special thanks to Dr. Emil F. Khisamutdinov for help in preparation of
data for figures A.1.3.
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Figure A.1.1. Sequences and secondary structures of RNA polygons. RNA polygons
and quantified assembly yields (a) triangle, (b) square and (c) pentagon.
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Figure A.1.2. RNA polygons dissociation constant determination. From left to right,
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polygons. Below, the gels is the plot used to determine the equilibrium concentration for
each polygon which were then used to calculate the apparent dissociation constant.
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Figure A.1.5. Total strand participation in square assembly. 7% native PAGE and
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assembly of the square nanoparticle. Each strand was individually end radiolabeled and
the radiolabeled strand was varied for each sample. The “*” denotes which strand is
labeled. The first four lanes show the stepwise assembly of the RNA square.
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staining. ImageJ software was used to integrate the intensities of the FITC bands and then
compared to untreated integration to calculate the percent degradation of each hybrid at
specified time points.

188

A

B

C

D

E

F

Figure A.1.8. Temperature gradient gel electrophoresis (TGGE) analysis of total
RNA square (A, D), 2’F RNA hybrid square (B, E), and DNA hybrid square (C,F). A,
B, and C were carried out under .2 mM Mg ion concentration conditions and D, E,
and F were carried out under 10 mM Mg ion conditions. A temperature gradient,
perpendicular to electric current, of 30°C - 75°C was used to determine the melting
temperature of the three square nanoparticles. ImageJ software was used to analyze the
gels and integrate the intensities of the bands. Melting temperatures were taken to be 50%
square formation compared to 100% formation in lane two. Lane one in each gel represents
a single short strand monomer RNA strand. 5’-[γ-32P]-ATP labeling was used with a total
RNA concentration of 80 nM. In D, E, and F no melting temperature is reached under 10
mM Mg ion conditions.
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Figure A.1.9. Secondary structure diagram with primary sequences of the multifunctional square. Including Luciferase siRNA, RNA Spinach aptamer, RNA Malachite
Green (MG) aptamer, and Hepatitis B Virus (HBV) ribozyme. Short strand B incorporates
the spinach aptamer at its 5' end, short strand C incorporates the MG aptamer at its 5' end,
and short strand D incorporates the HBV ribozyme at its 5' end and the luciferase siRNA
sense strand sticky end at its 3' end. Chemically synthesized RNA oligo is used for the
anti-sense luciferase siRNA strand.
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A

B

C

Figure A.1.10. Fluorescence signal testing in native PAGE. MG dye stain (A), Spinach
dye stain (B), and total RNA by ethidium bromide staining (C). 7% native PAGE was run
with stepwise assembly of the multifunctional square nanoparticle. The gel was then
simultaneously stained with MG and Spinach dyes and scanned for both signals separately.
The gel was then total RNA stained with ethidium bromide and scanned for ethidium
bromide signal.
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Appendix 2: Supplemental Data for Chapter 3
Appendix 2 was reproduced (with some modification) with permission from:
Jasinski, DL; Li, H; and Guo, P. “The Effect of Size and Shape of RNA Nanoparticles on
Biodistribution.” Molecular Therapy. Under Revision. Copyright 2017 Elsevier Inc.;
Jasinski, DL; Yin H; Li, Z; and Guo P. “The Hydrophobic Effect from Conjugated
Chemicals or Drugs on in Vivo Biodistribution of RNA Nanoparticles.” Human Gene
Therapy. Under Revision. Copyright 2017 Mary Ann Liebert Publishing.
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Figure A.2.1. HPLC Hydrophobicity Comparisons. %ACN elution for fluorophores
alone (A), Cy5.5 species (B), SulfoCy5.5 species (C), and AlexaFluor700 species (D).
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Figure A.2.2. Amino Acid Hydrophobicity Comparison Plots. Predicted ClogP values,
determined using ChemDraw Pro 16, were compared to four different previously
determined hydrophobicity scales of amino acids. Cornette scale (233) (A), Kyte-Doolittle
scale (236) (B), Eisengerg Scale (234) (C), and the Engelman GES scale (237) (D).
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Figure A.2.3. Chemical Structures of Fluorophores and Nucleic Acids. The chemical
structures of Cy5.5 and SulfoCy5.5 mono-, di-, and tri-nucleotide derivatives.
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Appendix 3: Supplemental Data for Chapter 4
Appendix 3 was reproduced (with some modification) with permission from
Khisamutdinov, EF*; Jasinski, DL*; Li, H; Zhang, K; Chiu, W; and Guo, P. “Fabrication
of RNA 3D Nanoprisms for Loading and Protection of Small RNAs and Model Drugs.”
Advanced Materials, 2016. 28(45), 9996-20004. DOI: 10.1002/adma.201603180.
Copyright 2016 Wiley Publishing. Special thanks to Dr. Emil F. Khisamutdinov for help
in preparation of data for these figures.
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Table A.3.1. Prism sequences and control construct sequences.
Supplementary Table S1. RNA nanoprism 2D structures and sequences utilized in this project.
A
RNA triangle prism
Nucleic Acid sequence 5’ → 3’
A GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC
B GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
A
B
D

C

C

2xD/d'
a'

a'

b'

b'
d'
c'

GUACCACGAGCGUACC
GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU
GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGC
GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG
GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC

c'

GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC

A

GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC
GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC
GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU
GGAAGACGGUCAUGUGUAUGGUAAUCGUAGGUCAUGUGUAUGCGUGGUAGGUG
UCAUGUGUAUGCUUUUUUCGAGGAUCCCGACUGGCAUAG
GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG
GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC
GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC
GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUCUAUGCCAGGUAACGAAUGGAUCCUCG

Prism with RNA MGA
A

B

B

C

D

D-MGA

C

a'

MGA

b'

b'

a'

c'

d'

d'-MGA

c'

Control open prism #1
A
A

B

B

C

D

D-MGA

C
MGA

B

a'
d'
c'

a'
B
c'
d'-MGA

Small prism with RNA MGA
A
B
A
B
D
C
C
D-MGA
a'
a'
b'
d'
b'
c'
c'
d'-MGA

GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC
GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC
GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU
GGAAGACGGUCAUGUGUAUGGUAAUCGUAGGUCAUGUGUAUGCGUGGUAGGUG
UCAUGUGUAUGCUUUUUUCGAGGAUCCCGACUGGCAUAG
GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG
GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC
GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC
GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUCUAUGCCAGGUAACGAAUGGAUCCUCG
GGCCAGCGAAUCCUACGACCUUUGUUAUCGCGUUUUGCGAGUUGUC
GGCGCGAUAAUCCGUCUUCCUUUGUUGAGACCUUUUGAGACGUACC
GGUCUCAAUCAUGGCCACUUUGUUCGCUGGUUUUCCCAGCUUGG
GACGGUGGUCGUAGGUGUGGUCAUGUGGAA UUUUUU GCGUCCGACAUCC
GGCGUCAAUCUGUCCGCCUUUGUUGAGCCCUUUUCCAAGCUGGG
GGAAUCAAUCUAUACACCUUUGUUGACGCCUUUUGACAACUCGC
GGGCUCAAUCGAUAGAGCUUUGUUGAUUCCUUUUGGUACGUCUC
GACAGUGGUGUAUAGUGCUCUAUCGUGGCG UUUUU
GGAUGGUAACGAAUGACGC
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Table A.3.2. Sequences of Prism Control Constructs
Control open prism #2

A

2xA

GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC

2xB

GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC

2xC

GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU

D-MGA

GGAAGACGGUCAUGUGUAUGGUAAUCGUAGGUCAUGUGUAUGCGUGGUAGGUG
UCAUGUGUAUGCUUUUUUCGAGGAUCCCGACUGGCAUAG

d'-MGA

GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUCUAUGCCAGGUAACGAAUGGAUCCUCG

B
D
C
MGA

B

A
d'
C

Control open prism #3 (dimer)
2xA
A

B
D
C

b'

a'
d'
c'

C

GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC

2xB

GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC

2xC

GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU

D-MGA

GGAAGACGGUCAUGUGUAUGGUAAUCGUAGGUCAUGUGUAUGCGUGGUAGGUG
UCAUGUGUAUGCUUUUUUCGAGGAUCCCGACUGGCAUAG

d'-MGA

GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUCUAUGCCAGGUAACGAAUGGAUCCUCG

2xD/d’

GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGC

2xa’

GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG

2xb’

GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC

2xc’

GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC

M GA

A

B
D
C

b'

a'
d'
c'
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Table A.3.3. Prism sequences and control construct sequences.
2’F-RNA frame + CoreB
2’f-A
A

2’f-B

B

2’f-C

D
C

D/d’-core
b'

a'
d'
c'

2’f-a'
2’f-b'
2’f-c'

2’F-RNA frame + DNA-FA

A

C

1DNA-FA
2DNA-FA
3DNA-FA
4DNA-FA
5DNA-FA
6DNA-FA
1xDNA-Cy5

B
C

2’f-A
b'

a'
c'

GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC
GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC
GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU
GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUUAAUCCCGCGGCCAUGGCGGCCGGGAGUUUUUUGG
ACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUGUC
AUGUGUAUGGC
GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG
GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC
GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC

2’f-B
2’f-C
2’f-a'
2’f-b'
2’f-c'

GTATGGTAATCGTAGGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG
GTATGCGTGTATATTGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG
GTATGCGTGGTAGGTGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG
GTATGCTCTATCGTTGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG
GTATGCTGGAAGACGGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG
GTATGGCGGACACTTGTCATGTTTTTATCCCGCCGCCATGGCGGCCGGGAG
GTATGCGTGGTAGGTGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG-Cy5
GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC
GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC
GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU
GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG
GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC
GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC

ssDNA conjugates complementary to the core
DNA-folate FA-TCCCGGCCGC CATGGCCGCG GGATT
DNA-cyclodextrin

TCCCGGCCGC CATGGCCGCG GGATT-CLDXT

DNA-biotin

TCCCGGCCGC CATGGCCGCG GGATT-biotin

DNA-taxol

TCCCGGCCGC CATGGCCGCG GGATT-TXL

DNA-Cy5

TCCCGGCCGC CATGGCCGCG GGATT-Cy5

Cy3-DNA-biotin

Cy3-TCCCGGCCGC CATGGCCGCG GGATT-biotin

A

Triangle prism can be formed using RNA as well as 2’F U/C modified RNA strands. The sequence for the
complementary linkers are underlined
B
The D/d’-core RNA sequence locating inside of the prism is underlined. This underlined sequence portion is
complementary to the ssDNA-drug conjugates.
C
The RNA complementary sequences for the 3’-end labeled DNA-FA is underlined
D
The bolded nucleotides correspond to CpG motif
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Figure A.3.1. Detailed sequence design and schematic for the assembly of 3D triangular
nanoprisms from previously designed flat RNA triangle nanoparticles.
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6% NATIVE PAGE
6% NATIVE PAGE

Figure A.3.2. (A)

Magnesium effect on assembly of triangular nanoprism. Higher

concentrations of magnesium ions dictate higher assembly efficiencies. (B) TGGE melting
gel analysis of 2’F prism frame. Melting temperature is taken to be 50% assembled
nanoparticle.
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1 2

3

E.B.
1 2

3

MG
Figure A.3.3. Control PAGE experiments excluding prism dimer and open prism
constructs from gel shift assembly experiments. Decrease in migration in lanes 2 and 3
indicate that the prism dimer and open prism, formed by sequence engineering, will migrate
much slower than the closed prism, as expected.
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DNA-Cy5
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0.5 µM
L
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Cy5 channel
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Figure A.3.4. Analysis of the 2’f-RNA frame hybridization with DNA-folate and DNACy5 strands. Experiments were conducted on 6% native PAGE. The same gel was first
scanned using Cy5 channel to detect signal from Cy5 fluorophore following staining in EB
for total nucleic acid visualization. Lane Cy5 contains the following complex: 0.5 M 2’fRNA frame, 2.5 M DNA-FA, and 0.5 M DNA-Cy5; L = DNA ladder Thermo Scientific
O’GeneRuler 1 kb
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Appendix 4: Supplemental Data for Chapter 5
Appendix 4 was reproduced (with some modification) from Jasinski, DL; and Guo,
P. “Co-Transcriptional Assembly of RNA Nanoparticles via Rolling Circle Transcription
of Fully Double Stranded Circular DNA.” Under Submission and Jasinski, DL; Schwartz,
CT; Haque, F; and Guo, P. “Large scale purification of RNA nanoparticles by preparative
ultracentrifugation.” Methods in Molecular Biology. 2015. 1297, 67-82. DOI:
10.1007/978-1-4939-2562-9_5.
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Table A.4.1. Sequence of constructs.
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Table A.4.2. Table summarizing the cleavage efficiencies of the ribozymes in each of the
sequences, broken down for 5’ and 3’ ribozyme of each sequence, as well as total cleavage
efficiency of the full-length constructs (those containing both 5’ and 3’ ribozymes)
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Table A.4.3. Summary of sequences used in publications with RCT reactions
(38,125,270,275,280,290-292). The DeltaG of most templates are close to 0 or positive,
indicating unstable secondary structure, which is suitable for transcription using bacterial
polymerases. Besides dumbbell sequences (denoted by a “*” before the reference), which
have previously been shown as suitable substrates for transcription. Templates from this
manuscript display a large negative DeltaG value, demonstrating the need for a fully double
stranded circular DNA template.
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Fig A.4.1. (A) PAGE analysis shows active RCT constructs along with size controls of
inactivated ribozyme constructs. Size controls allow confirmation of ribozyme cleavage
and release of target RNA oligomers. (B) Typical experiment run to determine cleavage
efficiency of self-cleaving ribozymes. The target sequence (green box) intensity was added
with the cleaved ribozyme (blue box) intensity and then divided by the total band intensity
(red + blue + green box) per well. A plot on the right shows the ribozyme cleavage
efficiency over time, comparing first generation design (RCT-1.0) to the second generation
design (RCT-1.1). The construct containing 3WJ-B sequence is shown here. While a better
curve was desired for ribozyme cleavage kinetics, ribozymes self-cleave as they are being
208

transcribed, making it difficult to obtain time points of low percent cleavage. (C) An
increase in ribozyme efficiency is attributed to increasing the length of the duplex in the
“closing” region of the ribozyme sequence, shown in red boxes.
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Figure A.4.2. PAGE analyzing the assembly of circular dsDNA constructs containing the
T7 promoter used for transcription reactions.
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Figure A.4.3. (A) Ribozyme cleaved 3WJ ssRNA oligomers were compared to chemically
synthesized sequences identical to those of the target sequence. Evidenced by identical
migration rate, we can conclude that the cleaved RNA oligomers are the same size as
chemically synthesized controls. (B) RCT cleaved 3WJ ssRNA oligomers were purified by
PAGE band isolation. After elution from gel pieces assembly was tested on native PAGE.
A stepwise assembly from monomer to dimer and finally trimer complex demonstrate the
ssRNA from RCT reactions are indeed the correct sequences.
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Figure A.4.4. (A/B) Plots and linear fitting of DNA template concentration, x-axis, versus
RNA output, as monitored by SYBR GreenII fluorescence. (C) Values of slope and
intercept, along with their standard errors and R-Squared values of the fits.
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Figure A.4.5. (A) Ribozyme cleavage with native sequences was attempted with modified
nucleotides, fluorine substitution on the 2’ hydroxyl of the ribose sugar (2’F) of C and U
bases, the pyrimidines. As evidenced by no short RNA fragments after gel analysis, the 2’F
modifications abolish ribozyme activity. (B) Because hammerhead ribozymes proceed by
a hydrolysis mechanism, we hypothesized that removal of the 2’OH hindered ribozyme
activity. Therefore, the C at the cleavage site was replaced with an A, thus the 2’OH would
still be present, as only pyrimidines are modified with 2’F. However, cleavage activity was
still zero. It is apparent that modification to the duplex structure by the 2’F modification
stops ribozyme activity.
Copyright © Daniel L. Jasinski 2017
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